1	BACKGROUND	O
2	:	O
3	Ischemic	O
4	heart	O
5	disease	O
6	is	O
7	the	O
8	primary	O
9	cause	O
10	of	O
11	morbidity	O
12	and	O
13	mortality	O
14	among	O
15	diabetics	O
16	,	O
17	especially	O
18	those	O
19	who	O
20	became	O
21	ill	O
22	at	O
23	a	O
24	young	O
25	age	O
26	.	O

1	More	O
2	importantly	O
3	,	O
4	this	O
5	fusion	O
6	converted	O
7	a	O
8	less	O
9	effective	O
10	vaccine	O
11	into	O
12	one	O
13	with	O
14	significant	O
15	potency	O
16	against	O
17	established	O
18	E7	B
19	-	O
20	expressing	O
21	metastatic	O
22	tumors	O
23	.	O

1	Reverse	O
2	transcription	O
3	-	O
4	PCR	O
5	analysis	O
6	of	O
7	mRNA	O
8	from	O
9	patients	O
10	shows	O
11	that	O
12	each	O
13	of	O
14	these	O
15	five	O
16	mutations	O
17	results	O
18	in	O
19	aberrant	O
20	splicing	O
21	.	O

1	Using	O
2	the	O
3	postural	O
4	and	O
5	force	O
6	data	O
7	as	O
8	input	O
9	to	O
10	a	O
11	3	O
12	-	O
13	D	O
14	biomechanical	O
15	model	O
16	,	O
17	the	O
18	lumbosacral	O
19	spinal	O
20	compression	O
21	was	O
22	calculated	O
23	.	O

1	Sequence	O
2	analysis	O
3	revealed	O
4	significant	O
5	differences	O
6	between	O
7	the	O
8	5	O
9	'	O
10	region	O
11	of	O
12	the	O
13	beta	B
14	subunit	I
15	gene	I
16	and	O
17	the	O
18	corresponding	O
19	regions	O
20	of	O
21	the	O
22	homologous	O
23	GlyR	B
24	alpha	I
25	subunit	I
26	genes	I
27	;	O
28	it	O
29	also	O
30	identified	O
31	a	O
32	novel	O
33	exon	O
34	(	O
35	exon	O
36	0	O
37	)	O
38	that	O
39	encodes	O
40	most	O
41	of	O
42	the	O
43	5	O
44	'-	O
45	untranslated	O
46	portion	O
47	of	O
48	the	O
49	GlyR	B
50	beta	I
51	mRNA	I
52	.	O

1	Therefore	O
2	,	O
3	we	O
4	suggested	O
5	that	O
6	both	O
7	proteins	O
8	might	O
9	belong	O
10	to	O
11	the	O
12	PLTP	B
13	family	I
14	.	O

1	Influence	O
2	of	O
3	compression	O
4	therapy	O
5	on	O
6	symptoms	O
7	following	O
8	soft	O
9	tissue	O
10	injury	O
11	from	O
12	maximal	O
13	eccentric	O
14	exercise	O
15	.	O

1	STAT5A	B
2	mutations	O
3	in	O
4	the	O
5	Src	B
6	homology	I
7	2	I
8	(	O
9	SH2	B
10	)	O
11	and	O
12	SH3	B
13	domains	I
14	did	O
15	not	O
16	alter	O
17	the	O
18	BTK	B
19	-	O
20	mediated	O
21	tyrosine	O
22	phosphorylation	O
23	.	O

1	In	O
2	the	O
3	present	O
4	work	O
5	,	O
6	the	O
7	complete	O
8	genome	O
9	sequences	O
10	of	O
11	Pyrococcus	O
12	horikoshii	O
13	and	O
14	Pyrococcus	O
15	abyssi	O
16	,	O
17	two	O
18	species	O
19	in	O
20	a	O
21	genus	O
22	of	O
23	hyperthermophilic	O
24	archaeon	O
25	(	O
26	archaebacterium	O
27	),	O
28	were	O
29	compared	O
30	to	O
31	detect	O
32	large	O
33	genome	O
34	polymorphisms	O
35	linked	O
36	with	O
37	restriction	O
38	-	O
39	modification	O
40	gene	O
41	homologs	O
42	.	O

1	In	O
2	addition	O
3	,	O
4	these	O
5	patients	O
6	show	O
7	both	O
8	quantitative	O
9	and	O
10	qualitative	O
11	differences	O
12	in	O
13	their	O
14	infectious	O
15	microbiological	O
16	spectrum	O
17	,	O
18	mainly	O
19	in	O
20	clean	O
21	-	O
22	contaminated	O
23	,	O
24	contaminated	O
25	and	O
26	dirty	O
27	surgical	O
28	procedures	O
29	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	PKC	B
6	and	O
7	p44	B
8	/	O
9	p42MAPK	B
10	signalings	O
11	are	O
12	required	O
13	for	O
14	the	O
15	HBx	O
16	-	O
17	induced	O
18	Sp1	B
19	-	O
20	mediated	O
21	IGF	O
22	-	O
23	II	O
24	P4	O
25	transcriptional	O
26	activity	O
27	since	O
28	(	O
29	i	O
30	)	O
31	PKC	B
32	activation	O
33	by	O
34	PMA	O
35	or	O
36	PKC	B
37	expression	O
38	vector	O
39	increases	O
40	Sp1	B
41	phosphorylation	O
42	and	O
43	P4	B
44	activity	O
45	in	O
46	HBx	O
47	-	O
48	transfected	O
49	HepG2	O
50	cells	O
51	;	O
52	(	O
53	ii	O
54	)	O
55	PKC	B
56	inhibition	O
57	by	O
58	PKC	B
59	inhibitor	O
60	Go6976	O
61	reduces	O
62	Sp1	B
63	phosphorylation	O
64	,	O
65	P4	B
66	activity	O
67	,	O
68	and	O
69	IGF	B
70	-	I
71	II	I
72	mRNA	I
73	in	O
74	HBx	O
75	-	O
76	transfected	O
77	HepG2	O
78	cells	O
79	;	O
80	and	O
81	(	O
82	iii	O
83	)	O
84	the	O
85	inhibition	O
86	of	O
87	MEK	B
88	activation	O
89	by	O
90	U0126	O
91	reduces	O
92	Sp1	B
93	phosphorylation	O
94	,	O
95	P4	B
96	activity	O
97	and	O
98	IGF	B
99	-	I
100	II	I
101	mRNA	I
102	in	O
103	HBx	O
104	-	O
105	transfected	O
106	HepG2	O
107	cells	O
108	.	O

1	We	O
2	show	O
3	that	O
4	p73	B
5	can	O
6	transcriptionally	O
7	inhibit	O
8	a	O
9	number	O
10	of	O
11	cellular	O
12	and	O
13	viral	O
14	promoters	O
15	.	O

1	Similarly	O
2	,	O
3	curcumin	O
4	(	O
5	diferuloylmethane	O
6	),	O
7	an	O
8	anti	O
9	-	O
10	inflammatory	O
11	agent	O
12	,	O
13	suppressed	O
14	OSM	O
15	-	O
16	stimulated	O
17	STAT1	B
18	phosphorylation	O
19	,	O
20	DNA	O
21	-	O
22	binding	O
23	activity	O
24	of	O
25	STAT1	B
26	,	O
27	and	O
28	c	B
29	-	I
30	Jun	I
31	N	I
32	-	I
33	terminal	I
34	kinase	I
35	activation	O
36	without	O
37	affecting	O
38	JAK1	B
39	,	O
40	JAK2	B
41	,	O
42	JAK3	B
43	,	O
44	ERK1	B
45	/	I
46	2	I
47	,	O
48	and	O
49	p38	B
50	phosphorylation	O
51	.	O

1	The	O
2	effects	O
3	of	O
4	the	O
5	transfected	O
6	receptors	O
7	were	O
8	associated	O
9	with	O
10	antagonism	B
11	of	I
12	activator	I
13	protein	I
14	1	I
15	(	O
16	AP	B
17	-	I
18	1	I
19	)	O
20	activity	O
21	.	O

1	Furthermore	O
2	,	O
3	the	O
4	soluble	O
5	forms	O
6	of	O
7	ATF6	B
8	and	O
9	the	O
10	G13	B
11	gene	I
12	product	I
13	are	O
14	unable	O
15	to	O
16	bind	O
17	to	O
18	several	O
19	point	O
20	mutants	O
21	of	O
22	the	O
23	cis	O
24	-	O
25	acting	O
26	ER	O
27	stress	O
28	response	O
29	element	O
30	in	O
31	vitro	O
32	that	O
33	hardly	O
34	respond	O
35	to	O
36	ER	O
37	stress	O
38	in	O
39	vivo	O
40	.	O

1	PURPOSE	O
2	:	O
3	The	O
4	objective	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	assess	O
11	first	O
12	embryo	O
13	cleavage	O
14	(	O
15	FEC	O
16	)	O
17	25	O
18	-	O
19	27	O
20	h	O
21	after	O
22	intracytoplasmic	O
23	sperm	O
24	injection	O
25	(	O
26	ICSI	O
27	)	O
28	as	O
29	a	O
30	parameter	O
31	for	O
32	the	O
33	embryo	O
34	selection	O
35	process	O
36	.	O

1	RESULTS	O
2	:	O
3	A	O
4	significant	O
5	correlation	O
6	(	O
7	p	O
8	<	O
9	0	O
10	.	O
11	001	O
12	)	O
13	was	O
14	observed	O
15	for	O
16	mean	O
17	wall	O
18	thickness	O
19	and	O
20	vessel	O
21	wall	O
22	area	O
23	between	O
24	MRI	O
25	and	O
26	histopathology	O
27	(	O
28	r	O
29	=	O
30	0	O
31	.	O
32	87	O
33	and	O
34	r	O
35	=	O
36	0	O
37	.	O
38	85	O
39	,	O
40	respectively	O
41	).	O

1	Molecular	O
2	cloning	O
3	,	O
4	genomic	O
5	mapping	O
6	,	O
7	and	O
8	expression	O
9	of	O
10	two	O
11	secretor	O
12	blood	O
13	group	O
14	alpha	O
15	(	O
16	1	O
17	,	O
18	2	O
19	)	O
20	fucosyltransferase	O
21	genes	O
22	differentially	O
23	regulated	O
24	in	O
25	mouse	O
26	uterine	O
27	epithelium	O
28	and	O
29	gastrointestinal	O
30	tract	O
31	.	O

1	We	O
2	show	O
3	that	O
4	several	O
5	heme	O
6	-	O
7	responsive	O
8	mechanisms	O
9	combine	O
10	to	O
11	regulate	O
12	DAN	O
13	/	O
14	TIR	B
15	gene	O
16	expression	O
17	.	O

1	No	O
2	'	O
3	TATA	O
4	'	O
5	motif	O
6	was	O
7	identified	O
8	near	O
9	either	O
10	the	O
11	GABPalpha	O
12	or	O
13	ATPsynCF6	O
14	transcription	O
15	start	O
16	sites	O
17	.	O

1	These	O
2	results	O
3	indicate	O
4	the	O
5	presence	O
6	of	O
7	TATA	O
8	-	O
9	unified	O
10	transcription	O
11	systems	O
12	in	O
13	contemporary	O
14	eukaryotes	O
15	and	O
16	provide	O
17	insight	O
18	into	O
19	the	O
20	residual	O
21	need	O
22	for	O
23	TBP	B
24	by	O
25	all	O
26	three	O
27	Pols	O
28	in	O
29	other	O
30	eukaryotes	O
31	despite	O
32	a	O
33	lack	O
34	of	O
35	TATA	O
36	elements	O
37	in	O
38	their	O
39	promoters	O
40	.	O

1	Different	O
2	thermoluminescent	O
3	detectors	O
4	(	O
5	TLD	O
6	)	O
7	have	O
8	been	O
9	used	O
10	to	O
11	measure	O
12	the	O
13	contribution	O
14	of	O
15	the	O
16	low	O
17	linear	O
18	energy	O
19	transfer	O
20	component	O
21	(	O
22	LET	O
23	<	O
24	10	O
25	keV	O
26	/	O
27	micrometer	O
28	)	O
29	and	O
30	plastic	O
31	nuclear	O
32	track	O
33	detectors	O
34	(	O
35	PNTD	O
36	)	O
37	for	O
38	the	O
39	high	O
40	linear	O
41	energy	O
42	tranfer	O
43	(	O
44	LET	O
45	)	O
46	component	O
47	.	O

1	However	O
2	,	O
3	the	O
4	beta5L	O
5	splice	O
6	variant	O
7	was	O
8	found	O
9	only	O
10	in	O
11	the	O
12	retina	O
13	.	O

1	This	O
2	analysis	O
3	supports	O
4	the	O
5	use	O
6	of	O
7	fluticasone	O
8	propionate	O
9	88	O
10	microg	O
11	twice	O
12	daily	O
13	as	O
14	first	O
15	-	O
16	line	O
17	treatment	O
18	in	O
19	patients	O
20	with	O
21	persistent	O
22	asthma	O
23	previously	O
24	treated	O
25	with	O
26	short	O
27	-	O
28	acting	O
29	beta2	O
30	-	O
31	agonist	O
32	alone	O
33	.	O

1	The	O
2	mice	O
3	are	O
4	phenotypically	O
5	normal	O
6	and	O
7	do	O
8	not	O
9	develop	O
10	spontaneous	O
11	tumors	O
12	at	O
13	an	O
14	early	O
15	age	O
16	,	O
17	in	O
18	contrast	O
19	to	O
20	knock	O
21	-	O
22	out	O
23	(	O
24	p53	B
25	(-/-))	O
26	strains	O
27	with	O
28	a	O
29	defective	O
30	p53	B
31	gene	I
32	.	O

1	Furthermore	O
2	,	O
3	stable	O
4	expression	O
5	of	O
6	a	O
7	constitutively	O
8	active	O
9	form	O
10	of	O
11	chicken	B
12	Notch1	I
13	or	O
14	Notch2	B
15	in	O
16	a	O
17	B	O
18	cell	O
19	line	O
20	results	O
21	in	O
22	a	O
23	down	O
24	-	O
25	regulation	O
26	of	O
27	surface	B
28	IgM	I
29	expression	O
30	,	O
31	which	O
32	is	O
33	accompanied	O
34	by	O
35	the	O
36	reduction	O
37	of	O
38	IgH	B
39	gene	I
40	transcripts	I
41	.	O

1	On	O
2	Cox	O
3	proportional	O
4	hazards	O
5	regression	O
6	adenocarcinoma	O
7	(	O
8	P	O
9	=	O
10	0	O
11	.	O
12	006	O
13	),	O
14	the	O
15	development	O
16	of	O
17	BPF	O
18	(	O
19	P	O
20	=	O
21	0	O
22	.	O
23	003	O
24	),	O
25	older	O
26	age	O
27	(	O
28	P	O
29	=	O
30	0	O
31	.	O
32	03	O
33	)	O
34	and	O
35	higher	O
36	pathological	O
37	stage	O
38	(	O
39	P	O
40	=	O
41	0	O
42	.	O
43	02	O
44	)	O
45	were	O
46	independent	O
47	adverse	O
48	predictors	O
49	of	O
50	survival	O
51	.	O

1	We	O
2	found	O
3	that	O
4	RhoA	B
5	can	O
6	initiate	O
7	a	O
8	linear	O
9	kinase	O
10	cascade	O
11	leading	O
12	to	O
13	the	O
14	activation	O
15	of	O
16	ERK6	B
17	(	O
18	p38	B
19	gamma	I
20	),	O
21	a	O
22	recently	O
23	identified	O
24	member	O
25	of	O
26	the	O
27	p38	B
28	family	O
29	of	O
30	MAPKs	O
31	.	O

1	Twenty	O
2	-	O
3	six	O
4	(	O
5	55	O
6	%)	O
7	(	O
8	95	O
9	%	O
10	CI	O
11	,	O
12	41	O
13	-	O
14	69	O
15	%)	O
16	patients	O
17	experienced	O
18	>	O
19	or	O
20	=	O
21	grade	O
22	3	O
23	acute	O
24	toxicity	O
25	(	O
26	RTOG	O
27	).	O

1	We	O
2	hypothesize	O
3	that	O
4	proprioception	O
5	may	O
6	be	O
7	used	O
8	to	O
9	calibrate	O
10	the	O
11	efference	O
12	copy	O
13	during	O
14	development	O
15	and	O
16	in	O
17	response	O
18	to	O
19	perturbations	O
20	by	O
21	signaling	O
22	potential	O
23	mismatches	O
24	between	O
25	eye	O
26	movement	O
27	information	O
28	derived	O
29	from	O
30	the	O
31	efferent	O
32	command	O
33	and	O
34	the	O
35	actual	O
36	motion	O
37	of	O
38	the	O
39	eye	O
40	transduced	O
41	by	O
42	the	O
43	proprioceptive	O
44	organs	O
45	.	O

1	Thus	O
2	,	O
3	BALB	O
4	/	O
5	c	O
6	mice	O
7	appear	O
8	to	O
9	be	O
10	the	O
11	most	O
12	appropriate	O
13	strain	O
14	of	O
15	mice	O
16	to	O
17	perform	O
18	studies	O
19	on	O
20	the	O
21	possible	O
22	connection	O
23	between	O
24	infection	O
25	with	O
26	T	O
27	.	O
28	canis	O
29	and	O
30	allergic	O
31	asthma	O
32	.	O

1	They	O
2	correspond	O
3	to	O
4	nucleotides	O
5	equivalent	O
6	to	O
7	base	O
8	-	O
9	pair	O
10	C1	O
11	-	O
12	G72	O
13	and	O
14	discriminator	O
15	base	O
16	A73	O
17	in	O
18	the	O
19	amino	O
20	acid	O
21	-	O
22	acceptor	O
23	branch	O
24	of	O
25	the	O
26	molecule	O
27	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	central	O
7	role	O
8	of	O
9	the	O
10	Notch	B
11	-	O
12	CBF1	B
13	/	O
14	RBP	B
15	-	O
16	Jkappa	B
17	signaling	O
18	pathway	O
19	in	O
20	cell	O
21	fate	O
22	decisions	O
23	renders	O
24	it	O
25	susceptible	O
26	to	O
27	pathways	O
28	of	O
29	viral	O
30	replication	O
31	and	O
32	oncogenic	O
33	conversion	O
34	.	O

1	High	O
2	-	O
3	affinity	O
4	binding	O
5	of	O
6	NF	B
7	-	I
8	1	I
9	to	O
10	PSE	O
11	-	O
12	B	O
13	,	O
14	but	O
15	not	O
16	to	O
17	PSE	O
18	-	O
19	A	O
20	,	O
21	was	O
22	confirmed	O
23	by	O
24	competition	O
25	of	O
26	DNA	O
27	-	O
28	protein	O
29	interactions	O
30	by	O
31	using	O
32	NF	B
33	-	I
34	1	I
35	DNA	I
36	elements	I
37	and	O
38	antibodies	O
39	.	O

1	The	O
2	first	O
3	case	O
4	of	O
5	HCV	O
6	seroconversion	O
7	in	O
8	Portugal	O
9	after	O
10	the	O
11	introduction	O
12	of	O
13	HCV	O
14	NAT	O
15	screening	O
16	.	O

1	Substitutions	O
2	in	O
3	the	O
4	YFV	B
5	Ag	I
6	-	I
7	binding	I
8	region	I
9	(	O
10	ABR	O
11	)	O
12	occur	O
13	at	O
14	four	O
15	of	O
16	the	O
17	eight	O
18	highly	O
19	conserved	O
20	residues	O
21	that	O
22	are	O
23	essential	O
24	for	O
25	binding	O
26	of	O
27	peptide	B
28	-	I
29	Ag	I
30	in	O
31	the	O
32	class	O
33	Ia	O
34	molecules	O
35	.	O

1	The	O
2	Novacor	O
3	Left	O
4	Ventricular	O
5	Assist	O
6	System	O
7	(	O
8	LVAS	O
9	)	O
10	(	O
11	Novacor	O
12	Corp	O
13	,	O
14	Oakland	O
15	,	O
16	CA	O
17	)	O
18	was	O
19	initially	O
20	console	O
21	-	O
22	based	O
23	and	O
24	has	O
25	been	O
26	available	O
27	since	O
28	1993	O
29	in	O
30	a	O
31	wearable	O
32	configuration	O
33	.	O

1	Ileal	O
2	digestibilities	O
3	of	O
4	DM	O
5	,	O
6	OM	O
7	,	O
8	CP	O
9	,	O
10	total	O
11	dietary	O
12	fiber	O
13	(	O
14	TDF	O
15	),	O
16	fat	O
17	and	O
18	gross	O
19	energy	O
20	(	O
21	GE	O
22	)	O
23	were	O
24	lower	O
25	(	O
26	P	O
27	<	O
28	0	O
29	.	O
30	05	O
31	)	O
32	for	O
33	dogs	O
34	fed	O
35	diets	O
36	containing	O
37	supplemental	O
38	fiber	O
39	compared	O
40	with	O
41	dogs	O
42	fed	O
43	the	O
44	control	O
45	diet	O
46	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	consensus	O
6	amino	O
7	acid	O
8	motif	O
9	for	O
10	serine	B
11	threonine	I
12	receptor	I
13	kinases	I
14	was	O
15	also	O
16	present	O
17	.	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	the	O
7	phorbol	O
8	ester	O
9	PMA	O
10	decreases	O
11	both	O
12	basal	O
13	and	O
14	dexamethasone	O
15	/	O
16	cAMP	O
17	-	O
18	induced	O
19	expression	O
20	of	O
21	a	O
22	luciferase	B
23	gene	I
24	under	O
25	the	O
26	control	O
27	of	O
28	the	O
29	G6Pase	B
30	promoter	I
31	in	O
32	transiently	O
33	transfected	O
34	H4IIE	O
35	hepatoma	O
36	cells	O
37	.	O

1	The	O
2	difference	O
3	between	O
4	the	O
5	patients	O
6	and	O
7	the	O
8	controls	O
9	was	O
10	statistically	O
11	significant	O
12	(	O
13	p	O
14	=	O
15	0	O
16	.	O
17	03	O
18	).	O

1	Altogether	O
2	,	O
3	we	O
4	confirm	O
5	that	O
6	all	O
7	genes	O
8	of	O
9	the	O
10	Rad52	O
11	recombinational	O
12	repair	O
13	pathway	O
14	are	O
15	required	O
16	for	O
17	the	O
18	survival	O
19	of	O
20	rad27	B
21	Delta	I
22	strains	O
23	at	O
24	both	O
25	permissive	O
26	(	O
27	23	O
28	degrees	O
29	C	O
30	)	O
31	and	O
32	semipermissive	O
33	(	O
34	30	O
35	degrees	O
36	C	O
37	)	O
38	temperatures	O
39	for	O
40	growth	O
41	.	O

1	Neuron	O
2	-	O
3	specific	O
4	Bcl	B
5	-	I
6	2	I
7	homology	I
8	3	I
9	domain	I
10	-	O
11	only	O
12	splice	O
13	variant	O
14	of	O
15	Bak	O
16	is	O
17	anti	O
18	-	O
19	apoptotic	O
20	in	O
21	neurons	O
22	,	O
23	but	O
24	pro	O
25	-	O
26	apoptotic	O
27	in	O
28	non	O
29	-	O
30	neuronal	O
31	cells	O
32	.	O

1	The	O
2	mechanism	O
3	of	O
4	the	O
5	induction	O
6	of	O
7	3beta	B
8	-	I
9	HSD	I
10	type	I
11	1	I
12	gene	I
13	expression	O
14	was	O
15	further	O
16	characterized	O
17	in	O
18	ZR	O
19	-	O
20	75	O
21	-	O
22	1	O
23	human	O
24	breast	O
25	cancer	O
26	cells	O
27	.	O

1	Contagious	O
2	bovine	O
3	pleuropneumonia	O
4	is	O
5	a	O
6	major	O
7	threat	O
8	for	O
9	cattle	O
10	in	O
11	Africa	O
12	.	O

1	Treatment	O
2	includes	O
3	both	O
4	medical	O
5	and	O
6	surgical	O
7	options	O
8	,	O
9	with	O
10	medical	O
11	therapy	O
12	further	O
13	subclassified	O
14	into	O
15	pharmacologic	O
16	and	O
17	pneumatic	O
18	dilation	O
19	.	O

1	Since	O
2	the	O
3	latter	O
4	is	O
5	very	O
6	small	O
7	for	O
8	physiological	O
9	flows	O
10	,	O
11	the	O
12	result	O
13	is	O
14	that	O
15	alpha	O
16	<	O
17	1	O
18	even	O
19	at	O
20	relatively	O
21	high	O
22	values	O
23	of	O
24	the	O
25	Reynolds	O
26	number	O
27	(	O
28	i	O
29	.	O
30	e	O
31	.,	O
32	for	O
33	non	O
34	-	O
35	negligible	O
36	inertia	O
37	)	O
38	and	O
39	we	O
40	validate	O
41	our	O
42	perturbation	O
43	theory	O
44	results	O
45	by	O
46	comparison	O
47	with	O
48	a	O
49	numerical	O
50	integration	O
51	of	O
52	the	O
53	full	O
54	model	O
55	.	O

1	This	O
2	plus	O
3	the	O
4	reduced	O
5	phosphorylation	O
6	of	O
7	p27	B
8	by	O
9	MAPK	O
10	enhanced	O
11	the	O
12	stability	O
13	of	O
14	p27	O
15	that	O
16	associated	O
17	with	O
18	nuclear	O
19	Cdk2	O
20	at	O
21	high	O
22	stoichiometry	O
23	and	O
24	inhibited	O
25	its	O
26	kinase	O
27	activity	O
28	.	O

1	Similar	O
2	data	O
3	were	O
4	also	O
5	obtained	O
6	when	O
7	either	O
8	dominant	O
9	negative	O
10	EGFR	O
11	-	O
12	CD533	O
13	or	O
14	dominant	B
15	negative	I
16	Ras	I
17	N17	I
18	were	O
19	used	O
20	to	O
21	block	O
22	MAPK	O
23	activation	O
24	.	O

1	The	O
2	assay	O
3	herein	O
4	described	O
5	allows	O
6	the	O
7	comparison	O
8	of	O
9	relative	O
10	FGFR	O
11	expression	O
12	levels	O
13	,	O
14	both	O
15	within	O
16	a	O
17	single	O
18	RNA	O
19	pool	O
20	and	O
21	among	O
22	multiple	O
23	RNA	O
24	pool	O
25	samples	O
26	.	O

1	This	O
2	was	O
3	most	O
4	pronounced	O
5	during	O
6	the	O
7	initial	O
8	phase	O
9	of	O
10	Erk	B
11	activation	O
12	.	O

1	DESIGN	O
2	:	O
3	Prospective	O
4	cohort	O
5	study	O
6	with	O
7	a	O
8	20	O
9	y	O
10	follow	O
11	-	O
12	up	O
13	period	O
14	,	O
15	the	O
16	First	O
17	National	O
18	Health	O
19	and	O
20	Examination	O
21	Survey	O
22	(	O
23	NHANES	O
24	1	O
25	)	O
26	Epidemiologic	O
27	Follow	O
28	-	O
29	up	O
30	Study	O
31	(	O
32	NHEFS	O
33	).	O

1	To	O
2	assess	O
3	the	O
4	maximum	O
5	oxygen	O
6	uptake	O
7	(	O
8	V	O
9	'	O
10	O2	O
11	max	O
12	)	O
13	of	O
14	Hong	O
15	Kong	O
16	Chinese	O
17	children	O
18	and	O
19	to	O
20	explore	O
21	its	O
22	association	O
23	with	O
24	respiratory	O
25	illnesses	O
26	,	O
27	we	O
28	conducted	O
29	the	O
30	Multistage	O
31	Fitness	O
32	Test	O
33	(	O
34	MFT	O
35	),	O
36	a	O
37	20	O
38	-	O
39	m	O
40	shuttle	O
41	run	O
42	test	O
43	,	O
44	in	O
45	1	O
46	,	O
47	427	O
48	schoolchildren	O
49	aged	O
50	between	O
51	8	O
52	-	O
53	12	O
54	years	O
55	.	O

1	After	O
2	all	O
3	doses	O
4	of	O
5	d	O
6	-	O
7	amphetamine	O
8	,	O
9	responding	O
10	occurred	O
11	largely	O
12	on	O
13	the	O
14	saline	O
15	key	O
16	under	O
17	both	O
18	schedules	O
19	.	O

1	A	O
2	novel	O
3	myeloid	O
4	-	O
5	restricted	O
6	zebrafish	O
7	CCAAT	B
8	/	I
9	enhancer	I
10	-	I
11	binding	I
12	protein	I
13	with	O
14	a	O
15	potent	O
16	transcriptional	O
17	activation	O
18	domain	O
19	.	O

1	METHODS	O
2	:	O
3	Humphrey	O
4	Field	O
5	Analyzer	O
6	model	O
7	630	O
8	(	O
9	HFA	O
10	I	O
11	,	O
12	program	O
13	30	O
14	-	O
15	2	O
16	with	O
17	a	O
18	rectangular	O
19	6	O
20	degrees	O
21	x	O
22	6	O
23	degrees	O
24	grid	O
25	)	O
26	was	O
27	used	O
28	as	O
29	the	O
30	conventional	O
31	perimetric	O
32	method	O
33	.	O

1	These	O
2	data	O
3	reveal	O
4	a	O
5	complex	O
6	network	O
7	of	O
8	interactions	O
9	between	O
10	GTPases	O
11	in	O
12	the	O
13	ARF	B
14	family	I
15	and	O
16	their	O
17	effectors	O
18	and	O
19	reveal	O
20	a	O
21	potential	O
22	for	O
23	cross	O
24	-	O
25	talk	O
26	not	O
27	demonstrated	O
28	previously	O
29	.	O

1	Net	O
2	lift	O
3	and	O
4	combined	O
5	drag	O
6	from	O
7	all	O
8	8	O
9	bearings	O
10	of	O
11	the	O
12	4	O
13	-	O
14	bladed	O
15	impeller	O
16	are	O
17	compared	O
18	with	O
19	predictions	O
20	based	O
21	on	O
22	2	O
23	-	O
24	D	O
25	theory	O
26	.	O

1	In	O
2	the	O
3	course	O
4	of	O
5	screening	O
6	for	O
7	transcription	O
8	factors	O
9	which	O
10	interact	O
11	with	O
12	the	O
13	human	B
14	myeloperoxidase	I
15	(	O
16	MPO	B
17	)	O
18	promoter	O
19	we	O
20	,	O
21	for	O
22	the	O
23	first	O
24	time	O
25	,	O
26	identified	O
27	and	O
28	cloned	O
29	the	O
30	cDNA	O
31	and	O
32	genomic	O
33	DNA	O
34	for	O
35	human	O
36	HBP1	O
37	(	O
38	HMG	B
39	-	I
40	Box	I
41	containing	I
42	protein	I
43	1	I
44	),	O
45	a	O
46	member	O
47	of	O
48	the	O
49	high	O
50	mobility	O
51	group	O
52	of	O
53	non	O
54	-	O
55	histone	B
56	chromosomal	I
57	proteins	I
58	.	O

1	Therefore	O
2	,	O
3	vitamin	O
4	D3	O
5	analogues	O
6	have	O
7	a	O
8	substantial	O
9	antipsoriatic	O
10	effect	O
11	.	O

1	Methylation	O
2	at	O
3	both	O
4	cytosine	O
5	residues	O
6	in	O
7	the	O
8	E2F	B
9	element	I
10	((	I
11	m	I
12	)	O
13	CG	O
14	(	O
15	m	O
16	)	O
17	CG	O
18	)	O
19	generated	O
20	a	O
21	new	O
22	methylcytosine	O
23	-	O
24	specific	O
25	DNA	O
26	-	O
27	protein	O
28	complex	O
29	.	O

1	Hepatitis	O
2	A	O
3	infected	O
4	food	O
5	handler	O
6	at	O
7	an	O
8	Edmonton	O
9	,	O
10	Alberta	O
11	retail	O
12	food	O
13	facility	O
14	:	O
15	public	O
16	health	O
17	protection	O
18	strategies	O
19	.	O

1	The	O
2	co	O
3	-	O
4	existence	O
5	of	O
6	TE	O
7	domains	O
8	within	O
9	modular	O
10	PKSs	O
11	along	O
12	with	O
13	physically	O
14	separated	O
15	,	O
16	monofunctional	O
17	TEs	O
18	(	O
19	TE	O
20	IIs	O
21	)	O
22	has	O
23	been	O
24	reported	O
25	for	O
26	a	O
27	number	O
28	of	O
29	modular	O
30	polyketide	O
31	and	O
32	non	O
33	-	O
34	ribosomal	O
35	peptide	O
36	synthases	O
37	(	O
38	NRPS	O
39	).	O

1	Two	O
2	independent	O
3	transgenic	O
4	lines	O
5	were	O
6	produced	O
7	,	O
8	and	O
9	both	O
10	showed	O
11	expression	O
12	of	O
13	the	O
14	Gus	B
15	gene	I
16	specifically	O
17	in	O
18	the	O
19	endosperm	O
20	during	O
21	mid	O
22	-	O
23	development	O
24	(	O
25	first	O
26	detected	O
27	10	O
28	-	O
29	12	O
30	d	O
31	after	O
32	anthesis	O
33	).	O

1	Treadmill	O
2	training	O
3	at	O
4	least	O
5	for	O
6	2	O
7	weeks	O
8	can	O
9	reduce	O
10	the	O
11	infarction	O
12	size	O
13	and	O
14	edema	O
15	caused	O
16	by	O
17	MCA	O
18	occlusion	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	01	O
25	).	O

1	Mechanism	O
2	in	O
3	the	O
4	sequential	O
5	control	O
6	of	O
7	cell	O
8	morphology	O
9	and	O
10	S	O
11	phase	O
12	entry	O
13	by	O
14	epidermal	B
15	growth	I
16	factor	I
17	involves	O
18	distinct	O
19	MEK	B
20	/	O
21	ERK	B
22	activations	O
23	.	O

1	We	O
2	randomly	O
3	assigned	O
4	1	O
5	,	O
6	219	O
7	subjects	O
8	to	O
9	receive	O
10	either	O
11	the	O
12	standard	O
13	three	O
14	-	O
15	times	O
16	-	O
17	weekly	O
18	(	O
19	TIW	O
20	)	O
21	interferon	B
22	alfa	I
23	-	I
24	2b	I
25	dose	O
26	(	O
27	3	O
28	MIU	O
29	)	O
30	or	O
31	the	O
32	once	O
33	-	O
34	weekly	O
35	(	O
36	QW	O
37	)	O
38	peginterferon	O
39	alfa	O
40	-	O
41	2b	O
42	(	O
43	0	O
44	.	O
45	5	O
46	,	O
47	1	O
48	.	O
49	0	O
50	,	O
51	or	O
52	1	O
53	.	O
54	5	O
55	microg	O
56	/	O
57	kg	O
58	).	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	proper	O
6	direct	O
7	binding	O
8	of	O
9	Nhp2p	O
10	to	O
11	H	O
12	/	O
13	ACA	O
14	snoRNAs	O
15	is	O
16	required	O
17	for	O
18	the	O
19	assembly	O
20	of	O
21	H	O
22	/	O
23	ACA	O
24	snoRNPs	O
25	and	O
26	hence	O
27	for	O
28	the	O
29	stability	O
30	of	O
31	some	O
32	of	O
33	their	O
34	components	O
35	.	O

1	The	O
2	decrements	O
3	in	O
4	cerebrovascular	O
5	resistance	O
6	induced	O
7	by	O
8	hexamethonium	O
9	,	O
10	in	O
11	mm	O
12	Hg	O
13	ml	O
14	(-	O
15	1	O
16	).	O
17	min	O
18	(-	O
19	1	O
20	),	O
21	were	O
22	:	O
23	under	O
24	control	O
25	.	O

1	Here	O
2	we	O
3	provide	O
4	the	O
5	first	O
6	evidence	O
7	for	O
8	the	O
9	involvement	O
10	of	O
11	GCN1	B
12	-	O
13	GCN2	B
14	interaction	O
15	in	O
16	activation	O
17	of	O
18	GCN2	B
19	per	O
20	se	O
21	.	O

1	As	O
2	a	O
3	reflection	O
4	of	O
5	uncertainties	O
6	in	O
7	the	O
8	estimates	O
9	for	O
10	individual	O
11	sources	O
12	,	O
13	the	O
14	90th	O
15	percentiles	O
16	of	O
17	PCDD	B
18	/	O
19	F	O
20	releases	O
21	for	O
22	1999	O
23	ranged	O
24	up	O
25	to	O
26	4	O
27	.	O
28	1	O
29	g	O
30	I	O
31	-	O
32	TEQ	O
33	/	O
34	y	O
35	.	O

1	To	O
2	test	O
3	the	O
4	hypothesis	O
5	that	O
6	these	O
7	elements	O
8	are	O
9	required	O
10	for	O
11	promoter	O
12	activity	O
13	,	O
14	we	O
15	compared	O
16	the	O
17	reporter	O
18	expression	O
19	activity	O
20	of	O
21	segments	O
22	containing	O
23	mutations	O
24	of	O
25	these	O
26	elements	O
27	with	O
28	activity	O
29	of	O
30	the	O
31	parent	O
32	Hlx	O
33	promoter	O
34	sequence	O
35	.	O

1	Using	O
2	RACE	O
3	techniques	O
4	we	O
5	have	O
6	cloned	O
7	and	O
8	sequenced	O
9	one	O
10	of	O
11	the	O
12	hamster	O
13	liver	O
14	3	O
15	-	O
16	hydroxy	O
17	-	O
18	hexobarbital	O
19	dehydrogenases	O
20	which	O
21	catalyze	O
22	not	O
23	only	O
24	cyclic	O
25	alcohols	O
26	but	O
27	also	O
28	17beta	O
29	-	O
30	hydroxy	O
31	-	O
32	steroids	O
33	and	O
34	3alpha	O
35	-	O
36	hydroxysteroids	O
37	.	O

1	Concerted	O
2	transcriptional	O
3	activation	O
4	of	O
5	the	O
6	low	B
7	density	I
8	lipoprotein	I
9	receptor	I
10	gene	I
11	by	O
12	insulin	B
13	and	O
14	luteinizing	B
15	hormone	I
16	in	O
17	cultured	O
18	porcine	O
19	granulosa	O
20	-	O
21	luteal	O
22	cells	O
23	:	O
24	possible	O
25	convergence	O
26	of	O
27	protein	B
28	kinase	I
29	a	I
30	,	O
31	phosphatidylinositol	B
32	3	I
33	-	I
34	kinase	I
35	,	O
36	and	O
37	mitogen	B
38	-	I
39	activated	I
40	protein	I
41	kinase	I
42	signaling	O
43	pathways	O
44	.	O

1	Human	O
2	T	O
3	-	O
4	cell	O
5	leukemia	O
6	virus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	Tax	B
15	is	O
16	a	O
17	potent	O
18	transcriptional	O
19	regulator	O
20	that	O
21	can	O
22	activate	O
23	or	O
24	repress	O
25	specific	O
26	cellular	O
27	genes	O
28	and	O
29	that	O
30	has	O
31	been	O
32	proposed	O
33	to	O
34	contribute	O
35	to	O
36	leukemogenesis	O
37	in	O
38	adult	O
39	T	O
40	-	O
41	cell	O
42	leukemia	O
43	.	O

1	Also	O
2	,	O
3	small	O
4	,	O
5	sense	O
6	and	O
7	antisense	O
8	approximately	O
9	22	O
10	nt	O
11	RNAs	O
12	,	O
13	derived	O
14	from	O
15	the	O
16	satRNA	O
17	,	O
18	were	O
19	associated	O
20	with	O
21	the	O
22	replicating	O
23	satellite	O
24	.	O

1	Deletional	O
2	analyses	O
3	of	O
4	VDR	B
5	indicated	O
6	that	O
7	GRIP1	B
8	and	O
9	RAC3	B
10	required	O
11	an	O
12	intact	O
13	VDR	B
14	activation	O
15	function	O
16	(	O
17	AF	O
18	-	O
19	2	O
20	)	O
21	domain	O
22	for	O
23	efficient	O
24	interaction	O
25	as	O
26	well	O
27	as	O
28	additional	O
29	but	O
30	distinct	O
31	regions	O
32	of	O
33	the	O
34	VDR	B
35	.	O

1	RESULTS	O
2	:	O
3	During	O
4	the	O
5	stabilization	O
6	period	O
7	,	O
8	PaCO2	O
9	(	O
10	mean	O
11	+/-	O
12	SD	O
13	)	O
14	was	O
15	33	O
16	+/-	O
17	5	O
18	mm	O
19	Hg	O
20	,	O
21	and	O
22	arrhythmias	O
23	were	O
24	not	O
25	detected	O
26	.	O

1	TT	O
2	cells	O
3	,	O
4	a	O
5	human	O
6	MTC	O
7	cell	O
8	line	O
9	expressing	O
10	MEN	O
11	2A	O
12	type	O
13	RET	O
14	,	O
15	display	O
16	transcriptionally	O
17	active	O
18	RelA	B
19	(	O
20	p65	O
21	)	O
22	in	O
23	the	O
24	nucleus	O
25	.	O

1	The	O
2	human	B
3	protein	I
4	sequence	I
5	exhibits	O
6	a	O
7	putative	O
8	DNA	O
9	-	O
10	binding	O
11	domain	O
12	similar	O
13	to	O
14	that	O
15	seen	O
16	in	O
17	rat	O
18	HBP1	O
19	and	O
20	shows	O
21	homology	O
22	with	O
23	the	O
24	activation	O
25	and	O
26	repressor	O
27	domains	O
28	previously	O
29	demonstrated	O
30	in	O
31	the	O
32	rat	O
33	protein	O
34	.	O

1	In	O
2	contrast	O
3	the	O
4	human	O
5	and	O
6	mouse	O
7	BCNT	O
8	proteins	O
9	contain	O
10	one	O
11	repeat	O
12	unit	O
13	and	O
14	lack	O
15	the	O
16	RTE	O
17	-	O
18	1	O
19	-	O
20	derived	O
21	portion	O
22	.	O

1	Direct	O
2	superoxide	O
3	scavenging	O
4	activity	O
5	of	O
6	nonsteroidal	O
7	anti	O
8	-	O
9	inflammatory	O
10	drugs	O
11	:	O
12	determination	O
13	by	O
14	electron	O
15	spin	O
16	resonance	O
17	using	O
18	the	O
19	spin	O
20	trap	O
21	method	O
22	.	O

1	A	O
2	single	O
3	nucleotide	O
4	polymorphism	O
5	(	O
6	SNP	O
7	)	O
8	in	O
9	exon	O
10	2	O
11	,	O
12	which	O
13	is	O
14	tightly	O
15	liked	O
16	to	O
17	another	O
18	SNP	O
19	(	O
20	GTG83	B
21	/	O
22	ATG83	B
23	),	O
24	creates	O
25	an	O
26	additional	O
27	alternative	O
28	in	O
29	-	O
30	frame	O
31	AUG	O
32	in	O
33	B	O
34	-	O
35	type	O
36	MTH1	O
37	mRNAs	O
38	yielding	O
39	the	O
40	fourth	B
41	MTH1	I
42	polypeptide	I
43	,	O
44	p26	O
45	that	O
46	possesses	O
47	an	O
48	additional	O
49	mitochondrial	O
50	targeting	O
51	signal	O
52	.	O

1	Six	O
2	of	O
3	the	O
4	gstC	O
5	'	O
6	mutants	O
7	,	O
8	primarily	O
9	in	O
10	the	O
11	C	O
12	-	O
13	terminal	O
14	half	O
15	of	O
16	C	O
17	',	O
18	exhibited	O
19	a	O
20	defect	O
21	in	O
22	the	O
23	ability	O
24	to	O
25	bind	O
26	L	O
27	protein	O
28	.	O

1	We	O
2	developed	O
3	a	O
4	system	O
5	for	O
6	domain	O
7	shuffling	O
8	to	O
9	establish	O
10	the	O
11	function	O
12	of	O
13	C1	O
14	domains	O
15	from	O
16	human	B
17	Raf	I
18	kinase	I
19	and	O
20	rat	B
21	PKC	I
22	eta	I
23	in	O
24	yeast	O
25	.	O

1	Expression	O
2	of	O
3	herpes	O
4	simplex	O
5	virus	O
6	type	O
7	2	O
8	US3	O
9	affects	O
10	the	O
11	Cdc42	B
12	/	O
13	Rac	B
14	pathway	O
15	and	O
16	attenuates	O
17	c	B
18	-	I
19	Jun	I
20	N	I
21	-	I
22	terminal	I
23	kinase	I
24	activation	O
25	.	O

1	Inhibition	O
2	of	O
3	constitutive	O
4	NF	B
5	-	I
6	kappaB	I
7	activity	O
8	results	O
9	in	O
10	cell	O
11	death	O
12	of	O
13	TT	O
14	cells	O
15	and	O
16	blocks	O
17	focus	O
18	formation	O
19	induced	O
20	by	O
21	oncogenic	O
22	forms	O
23	of	O
24	RET	B
25	in	O
26	NIH	O
27	3T3	O
28	cells	O
29	.	O

1	Corneal	O
2	scrapping	O
3	and	O
4	deep	O
5	stromal	O
6	biopsy	O
7	were	O
8	obtained	O
9	and	O
10	stained	O
11	for	O
12	microscopic	O
13	evaluation	O
14	with	O
15	periodic	O
16	acid	O
17	-	O
18	Schiff	O
19	,	O
20	Giemsa	O
21	,	O
22	and	O
23	Gomori	O
24	'	O
25	s	O
26	methenamine	O
27	silver	O
28	stains	O
29	.	O

1	ICAM	B
2	-	I
3	1	I
4	has	O
5	been	O
6	suggested	O
7	a	O
8	predictor	O
9	of	O
10	the	O
11	onset	O
12	of	O
13	GO	O
14	.	O

1	Once	O
2	ICP	O
3	reaches	O
4	critical	O
5	values	O
6	(>	O
7	30	O
8	mm	O
9	Hg	O
10	)	O
11	herniation	O
12	occurs	O
13	,	O
14	usually	O
15	within	O
16	2	O
17	to	O
18	5	O
19	days	O
20	.	O

1	The	O
2	present	O
3	data	O
4	also	O
5	demonstrate	O
6	that	O
7	ectopic	O
8	expression	O
9	of	O
10	blr1	O
11	increased	O
12	JNK	B
13	/	O
14	SAPK	B
15	activity	O
16	,	O
17	but	O
18	JNK	B
19	/	O
20	SAPK	B
21	activation	O
22	was	O
23	not	O
24	needed	O
25	for	O
26	accelerated	O
27	RA	O
28	-	O
29	induced	O
30	differentiation	O
31	and	O
32	growth	O
33	arrest	O
34	.	O

1	Here	O
2	,	O
3	we	O
4	identify	O
5	Rsc3	O
6	and	O
7	Rsc30	O
8	as	O
9	novel	O
10	components	O
11	of	O
12	the	O
13	essential	O
14	yeast	O
15	remodeler	O
16	RSC	O
17	complex	O
18	.	O

1	The	O
2	pharmacokinetic	O
3	profiles	O
4	of	O
5	digoxin	O
6	and	O
7	warfarin	O
8	were	O
9	not	O
10	altered	O
11	by	O
12	the	O
13	simultaneous	O
14	and	O
15	continued	O
16	administration	O
17	of	O
18	sevelamer	O
19	.	O

1	Forskolin	O
2	treatment	O
3	(	O
4	10	O
5	microM	O
6	)	O
7	of	O
8	the	O
9	transfected	O
10	cells	O
11	for	O
12	3	O
13	--	O
14	6	O
15	h	O
16	maximally	O
17	induced	O
18	luciferase	B
19	threefold	O
20	.	O

1	E2F1	B
2	-	O
3	mediated	O
4	transcriptional	O
5	inhibition	O
6	of	O
7	the	O
8	plasminogen	B
9	activator	I
10	inhibitor	I
11	type	I
12	1	I
13	gene	I
14	.	O

1	In	O
2	this	O
3	report	O
4	this	O
5	technique	O
6	was	O
7	applied	O
8	to	O
9	human	O
10	breast	O
11	carcinoma	O
12	MDA	O
13	-	O
14	MB231	O
15	cells	O
16	overexpressing	O
17	human	B
18	MPG	I
19	in	O
20	order	O
21	to	O
22	assess	O
23	whether	O
24	up	O
25	-	O
26	regulation	O
27	of	O
28	the	O
29	initial	O
30	step	O
31	in	O
32	BER	O
33	alters	O
34	the	O
35	activity	O
36	of	O
37	selected	O
38	other	O
39	BER	O
40	(	O
41	hOGG1	O
42	and	O
43	APE	B
44	/	O
45	ref	B
46	-	I
47	1	I
48	)	O
49	or	O
50	direct	O
51	reversal	O
52	(	O
53	MGMT	O
54	)	O
55	repair	O
56	activities	O
57	.	O

1	Chlamydia	O
2	and	O
3	cervical	O
4	cancer	O
5	:	O
6	a	O
7	real	O
8	association	O
9	?	O

1	In	O
2	children	O
3	unable	O
4	to	O
5	perform	O
6	forced	O
7	expiratory	O
8	maneuvers	O
9	(	O
10	n	O
11	=	O
12	25	O
13	),	O
14	FOT	O
15	,	O
16	contrary	O
17	to	O
18	the	O
19	interrupter	O
20	technique	O
21	,	O
22	clearly	O
23	identified	O
24	a	O
25	subgroup	O
26	of	O
27	young	O
28	children	O
29	with	O
30	high	O
31	resistance	O
32	values	O
33	at	O
34	baseline	O
35	,	O
36	which	O
37	returned	O
38	to	O
39	normal	O
40	after	O
41	bronchodilation	O
42	.	O

1	Together	O
2	,	O
3	these	O
4	results	O
5	identify	O
6	HPK1	O
7	as	O
8	a	O
9	new	O
10	component	O
11	of	O
12	TCR	B
13	signaling	O
14	.	O

1	Pro	O
2	-	O
3	inflammatory	O
4	cytokine	O
5	,	O
6	tumor	B
7	necrosis	I
8	factor	I
9	-	I
10	alpha	I
11	(	O
12	TNF	B
13	-	I
14	alpha	I
15	),	O
16	produced	O
17	from	O
18	adipose	O
19	tissues	O
20	in	O
21	obese	O
22	subjects	O
23	,	O
24	is	O
25	known	O
26	to	O
27	play	O
28	a	O
29	predominant	O
30	role	O
31	in	O
32	inducing	O
33	insulin	B
34	resistance	O
35	.	O

1	The	O
2	Schistosoma	O
3	mansoni	O
4	homologue	O
5	(	O
6	SmSmad2	O
7	)	O
8	was	O
9	overexpressed	O
10	in	O
11	bacteria	O
12	as	O
13	a	O
14	Sj26	O
15	-	O
16	GST	B
17	fusion	O
18	protein	O
19	and	O
20	used	O
21	to	O
22	raise	O
23	specific	O
24	antibodies	O
25	.	O

1	To	O
2	study	O
3	the	O
4	in	O
5	vivo	O
6	role	O
7	of	O
8	p16	O
9	.	O
10	7	O
11	,	O
12	a	O
13	phi29	O
14	mutant	O
15	containing	O
16	a	O
17	suppressible	O
18	mutation	O
19	in	O
20	gene	O
21	16	O
22	.	O
23	7	O
24	was	O
25	constructed	O
26	.	O

1	The	O
2	differences	O
3	in	O
4	the	O
5	CPIgG	O
6	,	O
7	CRP	B
8	,	O
9	and	O
10	fibrinogen	B
11	levels	O
12	in	O
13	patients	O
14	who	O
15	were	O
16	diagnosed	O
17	with	O
18	ACS	O
19	versus	O
20	those	O
21	who	O
22	were	O
23	not	O
24	(	O
25	non	O
26	-	O
27	ACS	O
28	)	O
29	were	O
30	evaluated	O
31	.	O

1	There	O
2	are	O
3	many	O
4	different	O
5	proposals	O
6	for	O
7	the	O
8	statistical	O
9	analysis	O
10	of	O
11	data	O
12	to	O
13	determine	O
14	early	O
15	onset	O
16	of	O
17	action	O
18	.	O

1	Coexpression	O
2	of	O
3	the	O
4	p120	O
5	(	O
6	ctn	O
7	)	O
8	protein	O
9	with	O
10	an	O
11	N	O
12	-	O
13	terminal	O
14	deletion	O
15	,	O
16	which	O
17	eliminates	O
18	some	O
19	potential	O
20	tyrosine	O
21	phosphorylation	O
22	sites	O
23	,	O
24	or	O
25	the	O
26	protein	O
27	with	O
28	a	O
29	single	O
30	amino	O
31	acid	O
32	substitution	O
33	(	O
34	tyrosine	O
35	at	O
36	217	O
37	to	O
38	phenylalanine	O
39	)	O
40	resulted	O
41	in	O
42	an	O
43	increase	O
44	in	O
45	the	O
46	aggregation	O
47	of	O
48	v	B
49	-	I
50	Src	I
51	-	O
52	transformed	O
53	EL	O
54	and	O
55	EalphaCL	O
56	cells	O
57	.	O

1	We	O
2	find	O
3	that	O
4	our	O
5	response	O
6	function	O
7	is	O
8	well	O
9	approximated	O
10	by	O
11	the	O
12	GSER	O
13	only	O
14	within	O
15	a	O
16	particular	O
17	frequency	O
18	range	O
19	determined	O
20	by	O
21	the	O
22	material	O
23	parameters	O
24	of	O
25	both	O
26	the	O
27	bead	O
28	and	O
29	the	O
30	network	O
31	.	O

1	The	O
2	novel	O
3	approach	O
4	to	O
5	insulin	B
6	administration	O
7	known	O
8	as	O
9	chronic	O
10	intermittent	O
11	intravenous	O
12	insulin	B
13	therapy	O
14	(	O
15	CIIIT	O
16	)	O
17	delivers	O
18	insulin	B
19	in	O
20	a	O
21	pulsatile	O
22	fashion	O
23	and	O
24	achieves	O
25	physiological	O
26	insulin	B
27	concentration	O
28	in	O
29	the	O
30	portal	O
31	vein	O
32	.	O

1	This	O
2	article	O
3	comparatively	O
4	evaluates	O
5	five	O
6	Generic	O
7	Systems	O
8	that	O
9	describe	O
10	the	O
11	basic	O
12	alternatives	O
13	to	O
14	composting	O
15	facility	O
16	design	O
17	and	O
18	control	O
19	.	O

1	With	O
2	a	O
3	GC	O
4	content	O
5	of	O
6	45	O
7	%	O
8	the	O
9	one	O
10	segment	O
11	would	O
12	correspond	O
13	to	O
14	"	O
15	isochore	O
16	H1	O
17	"	O
18	and	O
19	the	O
20	other	O
21	segment	O
22	(	O
23	39	O
24	%	O
25	GC	O
26	in	O
27	human	O
28	,	O
29	40	O
30	%	O
31	GC	O
32	in	O
33	mouse	O
34	)	O
35	to	O
36	"	O
37	isochore	O
38	L1	O
39	/	O
40	L2	O
41	".	O

1	A	O
2	review	O
3	of	O
4	the	O
5	literature	O
6	identified	O
7	8	O
8	comprehensive	O
9	clinical	O
10	studies	O
11	,	O
12	all	O
13	of	O
14	which	O
15	failed	O
16	to	O
17	document	O
18	any	O
19	relationship	O
20	between	O
21	NF1	O
22	and	O
23	intracranial	O
24	aneurysms	O
25	.	O

1	Serial	O
2	US	O
3	images	O
4	were	O
5	obtained	O
6	before	O
7	and	O
8	20	O
9	,	O
10	30	O
11	,	O
12	40	O
13	,	O
14	50	O
15	,	O
16	60	O
17	,	O
18	90	O
19	,	O
20	120	O
21	,	O
22	150	O
23	,	O
24	180	O
25	,	O
26	240	O
27	,	O
28	and	O
29	300	O
30	s	O
31	after	O
32	intravenous	O
33	injection	O
34	of	O
35	2	O
36	g	O
37	of	O
38	contrast	O
39	agent	O
40	using	O
41	conventional	O
42	and	O
43	harmonic	O
44	PD	O
45	US	O
46	.	O

1	Eight	O
2	CAD	O
3	patients	O
4	who	O
5	were	O
6	matched	O
7	to	O
8	the	O
9	treated	O
10	patients	O
11	for	O
12	age	O
13	(+/-	O
14	3	O
15	years	O
16	),	O
17	baseline	O
18	low	O
19	density	O
20	lipoprotein	O
21	(+/-	O
22	5	O
23	mg	O
24	/	O
25	dL	O
26	),	O
27	and	O
28	triglycerides	O
29	(+/-	O
30	50	O
31	mg	O
32	/	O
33	dL	O
34	)	O
35	but	O
36	who	O
37	had	O
38	never	O
39	been	O
40	treated	O
41	with	O
42	lipid	O
43	-	O
44	lowering	O
45	drugs	O
46	were	O
47	selected	O
48	as	O
49	controls	O
50	.	O

1	Here	O
2	we	O
3	present	O
4	evidence	O
5	that	O
6	the	O
7	distal	O
8	half	O
9	(	O
10	Stem	O
11	2	O
12	)	O
13	of	O
14	the	O
15	conserved	O
16	base	O
17	-	O
18	paired	O
19	stem	O
20	structure	O
21	found	O
22	in	O
23	all	O
24	hY	O
25	RNAs	O
26	also	O
27	plays	O
28	a	O
29	critical	O
30	role	O
31	in	O
32	the	O
33	export	O
34	process	O
35	.	O

1	The	O
2	contrasting	O
3	effects	O
4	of	O
5	dopaminergic	O
6	stimulation	O
7	on	O
8	the	O
9	motor	O
10	performance	O
11	and	O
12	on	O
13	some	O
14	aspects	O
15	of	O
16	cognitive	O
17	processing	O
18	suggest	O
19	the	O
20	existence	O
21	of	O
22	complex	O
23	interactions	O
24	within	O
25	pre	O
26	-	O
27	and	O
28	postsynaptic	O
29	brain	O
30	dopamine	O
31	receptors	O
32	,	O
33	and	O
34	an	O
35	intervention	O
36	of	O
37	segregated	O
38	basal	O
39	ganglia	O
40	-	O
41	prefrontal	O
42	cortex	O
43	loops	O
44	in	O
45	motor	O
46	and	O
47	cognitive	O
48	behaviour	O
49	.	O

1	The	O
2	size	O
3	of	O
4	the	O
5	infarct	O
6	was	O
7	determined	O
8	using	O
9	the	O
10	creatine	B
11	kinase	I
12	integral	O
13	method	O
14	.	O

1	These	O
2	corrections	O
3	do	O
4	not	O
5	involve	O
6	sequences	O
7	predicted	O
8	to	O
9	function	O
10	as	O
11	transcription	B
12	factor	I
13	binding	I
14	sites	I
15	.	O

1	A	O
2	comprehensive	O
3	neuropsychological	O
4	battery	O
5	was	O
6	administered	O
7	to	O
8	48	O
9	veterans	O
10	with	O
11	Gulf	O
12	War	O
13	Illness	O
14	(	O
15	GWI	O
16	)	O
17	characterized	O
18	by	O
19	severe	O
20	fatigue	O
21	(	O
22	GV	O
23	-	O
24	F	O
25	)	O
26	and	O
27	39	O
28	healthy	O
29	veterans	O
30	(	O
31	GV	O
32	-	O
33	H	O
34	).	O

1	Quantitative	O
2	PCR	O
3	studies	O
4	indicated	O
5	that	O
6	synthesis	O
7	and	O
8	transport	O
9	of	O
10	vector	O
11	DNA	O
12	into	O
13	the	O
14	nucleus	O
15	were	O
16	similar	O
17	for	O
18	macrophages	O
19	infected	O
20	with	O
21	the	O
22	clone	O
23	239	O
24	and	O
25	316	O
26	pseudotypes	O
27	,	O
28	suggesting	O
29	that	O
30	the	O
31	restriction	O
32	for	O
33	SIVmac239	O
34	infection	O
35	is	O
36	after	O
37	reverse	O
38	transcription	O
39	and	O
40	nuclear	O
41	import	O
42	of	O
43	viral	O
44	DNA	O
45	.	O

1	EXAFS	O
2	measurements	O
3	around	O
4	the	O
5	Ge	O
6	-	O
7	K	O
8	edge	O
9	have	O
10	been	O
11	carried	O
12	out	O
13	for	O
14	liquid	O
15	Ge	O
16	-	O
17	Si	O
18	alloys	O
19	for	O
20	the	O
21	first	O
22	time	O
23	to	O
24	investigate	O
25	the	O
26	local	O
27	structure	O
28	around	O
29	a	O
30	Ge	O
31	atom	O
32	.	O

1	Hp	O
2	positive	O
3	relatives	O
4	of	O
5	gastric	O
6	cancer	O
7	had	O
8	a	O
9	markedly	O
10	higher	O
11	prevalence	O
12	of	O
13	atrophy	O
14	than	O
15	those	O
16	with	O
17	Hp	O
18	negativity	O
19	without	O
20	cancer	O
21	relatives	O
22	(	O
23	29	O
24	vs	O
25	.	O

1	Thus	O
2	,	O
3	replication	O
4	fork	O
5	movement	O
6	near	O
7	HML	O
8	pauses	O
9	at	O
10	a	O
11	silent	O
12	origin	O
13	which	O
14	is	O
15	competent	O
16	for	O
17	replication	O
18	initiation	O
19	but	O
20	kept	O
21	silent	O
22	through	O
23	Orc2p	O
24	,	O
25	a	O
26	component	O
27	of	O
28	the	O
29	replication	O
30	initiator	O
31	.	O

1	Cardiac	O
2	markers	O
3	troponin	O
4	T	O
5	,	O
6	CK	O
7	-	O
8	MB	O
9	mass	O
10	and	O
11	myoglobin	O
12	were	O
13	helpful	O
14	in	O
15	the	O
16	differential	O
17	diagnosis	O
18	of	O
19	chest	O
20	pain	O
21	,	O
22	even	O
23	when	O
24	the	O
25	ECG	O
26	was	O
27	unremarkable	O
28	or	O
29	nonspecific	O
30	.	O

1	RESULTS	O
2	:	O
3	A	O
4	novel	O
5	gene	O
6	was	O
7	cloned	O
8	.	O

1	Both	O
2	pancreatic	O
3	and	O
4	intestinal	O
5	cell	O
6	lines	O
7	were	O
8	found	O
9	to	O
10	express	O
11	a	O
12	number	O
13	of	O
14	POU	B
15	(	O
16	OCT	B
17	binding	I
18	)	I
19	homeodomain	I
20	proteins	I
21	examined	O
22	by	O
23	electrophoretic	O
24	mobility	O
25	shift	O
26	assay	O
27	.	O

1	In	O
2	conclusion	O
3	,	O
4	USPIO	O
5	-	O
6	enhanced	O
7	MRI	O
8	data	O
9	were	O
10	capable	O
11	to	O
12	characterize	O
13	tumor	O
14	microvessel	O
15	properties	O
16	in	O
17	this	O
18	breast	O
19	cancer	O
20	model	O
21	:	O
22	microvascular	O
23	permeability	O
24	(	O
25	determined	O
26	using	O
27	USPIO	O
28	)	O
29	correlated	O
30	significantly	O
31	with	O
32	tumor	O
33	grade	O
34	.	O

1	Radiolabeled	O
2	biantennary	O
3	N	O
4	-	O
5	glycans	O
6	synthesized	O
7	by	O
8	Pro	O
9	(-)	O
10	5Lec20	O
11	were	O
12	proportionately	O
13	less	O
14	ricin	O
15	-	O
16	bound	O
17	than	O
18	similar	O
19	species	O
20	from	O
21	parental	O
22	CHO	O
23	cells	O
24	,	O
25	and	O
26	Lec20	O
27	cell	O
28	extracts	O
29	had	O
30	a	O
31	markedly	O
32	reduced	O
33	ability	O
34	to	O
35	transfer	O
36	Gal	O
37	to	O
38	GlcNAc	O
39	-	O
40	terminating	O
41	acceptors	O
42	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	training	O
5	of	O
6	novices	O
7	using	O
8	MIST	O
9	-	O
10	VR	O
11	yields	O
12	quantifiable	O
13	changes	O
14	in	O
15	skill	O
16	that	O
17	are	O
18	transferable	O
19	to	O
20	a	O
21	simple	O
22	real	O
23	task	O
24	and	O
25	are	O
26	similar	O
27	to	O
28	the	O
29	results	O
30	achieved	O
31	with	O
32	conventional	O
33	training	O
34	.	O

1	To	O
2	investigate	O
3	the	O
4	convergent	O
5	role	O
6	of	O
7	the	O
8	insulin	B
9	/	O
10	IGF	B
11	-	I
12	I	I
13	effector	O
14	pathway	O
15	mediating	O
16	bihormonal	O
17	stimulation	O
18	of	O
19	LDL	B
20	receptor	I
21	promoter	I
22	expression	O
23	,	O
24	transfected	O
25	granulosa	O
26	-	O
27	luteal	O
28	cells	O
29	were	O
30	pretreated	O
31	for	O
32	30	O
33	min	O
34	with	O
35	two	O
36	specific	O
37	inhibitors	O
38	of	O
39	phophatidylinositol	B
40	3	I
41	-	I
42	kinase	I
43	,	O
44	wortmannin	O
45	(	O
46	100	O
47	nM	O
48	)	O
49	and	O
50	LY	O
51	294002	O
52	(	O
53	10	O
54	microM	O
55	),	O
56	or	O
57	of	O
58	mitogen	B
59	-	I
60	activated	I
61	protein	I
62	kinase	I
63	kinase	I
64	,	O
65	PD	O
66	98059	O
67	(	O
68	50	O
69	microM	O
70	),	O
71	U0126	O
72	(	O
73	10	O
74	microM	O
75	),	O
76	or	O
77	the	O
78	latter	O
79	'	O
80	s	O
81	inactive	O
82	derivative	O
83	,	O
84	U0124	O
85	(	O
86	10	O
87	microM	O
88	).	O

1	Instead	O
2	,	O
3	affective	O
4	flattening	O
5	was	O
6	associated	O
7	with	O
8	both	O
9	dopamine	B
10	receptor	I
11	sensitivity	O
12	and	O
13	psychomotor	O
14	slowing	O
15	.	O

1	Other	O
2	therapies	O
3	are	O
4	also	O
5	available	O
6	,	O
7	including	O
8	hypertonic	O
9	saline	O
10	solution	O
11	,	O
12	THAM	O
13	(	O
14	Tris	O
15	-	O
16	hydroxy	O
17	-	O
18	methyl	O
19	-	O
20	aminomethane	O
21	)	O
22	buffer	O
23	,	O
24	and	O
25	high	O
26	-	O
27	dose	O
28	barbiturates	O
29	.	O

1	CONCLUSION	O
2	:	O
3	There	O
4	are	O
5	no	O
6	differences	O
7	in	O
8	the	O
9	measurement	O
10	data	O
11	derived	O
12	from	O
13	this	O
14	method	O
15	and	O
16	actual	O
17	measurement	O
18	data	O
19	from	O
20	an	O
21	object	O
22	created	O
23	by	O
24	the	O
25	computer	O
26	-	O
27	aided	O
28	dental	O
29	design	O
30	program	O
31	.	O

1	NF	B
2	-	I
3	kappaB	I
4	pathway	O
5	activation	O
6	occurs	O
7	during	O
8	transformation	O
9	induced	O
10	by	O
11	a	O
12	number	O
13	of	O
14	classical	O
15	oncogenes	O
16	,	O
17	including	O
18	Bcr	B
19	/	O
20	Abl	B
21	,	O
22	Ras	B
23	and	O
24	Rac	B
25	,	O
26	and	O
27	is	O
28	necessary	O
29	for	O
30	full	O
31	transforming	O
32	potential	O
33	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	Gab1	B
6	is	O
7	involved	O
8	in	O
9	the	O
10	control	O
11	of	O
12	egr	B
13	-	I
14	1	I
15	expression	O
16	regulated	O
17	by	O
18	insulin	B
19	.	O

1	The	O
2	human	O
3	cytomegalovirus	O
4	(	O
5	HCMV	O
6	)	O
7	major	O
8	immediate	B
9	-	I
10	early	I
11	protein	I
12	IE2	I
13	is	O
14	a	O
15	nuclear	O
16	phosphoprotein	O
17	that	O
18	is	O
19	believed	O
20	to	O
21	be	O
22	a	O
23	key	O
24	regulator	O
25	in	O
26	both	O
27	lytic	O
28	and	O
29	latent	O
30	infections	O
31	.	O

1	Unexpectedly	O
2	,	O
3	Arg1	B
4	-	O
5	expressing	O
6	COS1	O
7	cells	O
8	showed	O
9	no	O
10	significant	O
11	proteinase	O
12	activity	O
13	to	O
14	various	O
15	synthesized	O
16	substrates	O
17	under	O
18	neutral	O
19	or	O
20	acidic	O
21	conditions	O
22	in	O
23	this	O
24	study	O
25	.	O

1	METHODS	O
2	:	O
3	126	O
4	patients	O
5	with	O
6	histologically	O
7	confirmed	O
8	MFH	O
9	were	O
10	analyzed	O
11	.	O

1	Regression	O
2	analyses	O
3	showed	O
4	that	O
5	SOREMP	O
6	dream	O
7	occurrences	O
8	were	O
9	significantly	O
10	related	O
11	to	O
12	the	O
13	amount	O
14	of	O
15	REM	O
16	sleep	O
17	,	O
18	while	O
19	NREMP	O
20	dream	O
21	occurrences	O
22	were	O
23	related	O
24	to	O
25	arousals	O
26	from	O
27	NREM	O
28	sleep	O
29	.	O

1	[	O
2	Diabetologia	O
3	(	O
4	2001	O
5	)	O
6	44	O
7	[	O
8	Suppl	O
9	3	O
10	]:	O
11	B37	O
12	-	O
13	B44	O
14	]	O

1	RESULTS	O
2	:	O
3	In	O
4	vivo	O
5	,	O
6	there	O
7	was	O
8	a	O
9	wide	O
10	distribution	O
11	with	O
12	the	O
13	coefficient	O
14	of	O
15	variation	O
16	(	O
17	SD	O
18	/	O
19	mean	O
20	x	O
21	100	O
22	%)	O
23	for	O
24	different	O
25	valve	O
26	sizes	O
27	ranging	O
28	from	O
29	21	O
30	%	O
31	to	O
32	39	O
33	%	O
34	in	O
35	the	O
36	St	O
37	Jude	O
38	Medical	O
39	valve	O
40	and	O
41	from	O
42	25	O
43	%	O
44	to	O
45	33	O
46	%	O
47	in	O
48	the	O
49	Omnicarbon	O
50	valve	O
51	.	O

1	A	O
2	microsporidian	O
3	,	O
4	Nosema	O
5	algerae	O
6	Vavra	O
7	and	O
8	undeen	O
9	,	O
10	was	O
11	found	O
12	parasitizing	O
13	larvae	O
14	and	O
15	adults	O
16	of	O
17	a	O
18	laboratory	O
19	colony	O
20	of	O
21	Culex	O
22	pipiens	O
23	L	O
24	.	O
25	originated	O
26	from	O
27	Gharbia	O
28	Governorate	O
29	.	O

1	Nearly	O
2	all	O
3	isolates	O
4	of	O
5	S	O
6	.	O
7	intermedius	O
8	and	O
9	most	O
10	isolates	O
11	of	O
12	S	O
13	.	O
14	constellatus	O
15	,	O
16	but	O
17	only	O
18	19	O
19	%	O
20	of	O
21	those	O
22	of	O
23	S	O
24	.	O
25	anginosus	O
26	,	O
27	were	O
28	associated	O
29	with	O
30	abscess	O
31	.	O

1	One	O
2	of	O
3	the	O
4	conserved	O
5	RNA	O
6	subdomains	O
7	,	O
8	designated	O
9	P3	B
10	,	O
11	has	O
12	previously	O
13	been	O
14	shown	O
15	to	O
16	be	O
17	required	O
18	for	O
19	nucleolar	O
20	localization	O
21	.	O

1	A	O
2	total	O
3	of	O
4	25	O
5	patients	O
6	with	O
7	malignant	O
8	brain	O
9	tumours	O
10	were	O
11	investigated	O
12	.	O

1	Interventions	O
2	aimed	O
3	at	O
4	these	O
5	specific	O
6	mediators	O
7	and	O
8	processes	O
9	may	O
10	be	O
11	successful	O
12	in	O
13	reducing	O
14	the	O
15	very	O
16	significant	O
17	human	O
18	and	O
19	economic	O
20	costs	O
21	of	O
22	vascular	O
23	access	O
24	dysfunction	O
25	.	O

1	We	O
2	used	O
3	stored	O
4	plasma	O
5	samples	O
6	from	O
7	409	O
8	patients	O
9	in	O
10	the	O
11	National	O
12	Institute	O
13	of	O
14	Neurological	O
15	Diseases	O
16	and	O
17	Stroke	O
18	(	O
19	NINDS	O
20	)	O
21	tissue	B
22	plasminogen	I
23	activator	I
24	(	O
25	t	O
26	-	O
27	PA	O
28	)	O
29	Stroke	O
30	Trial	O
31	to	O
32	examine	O
33	the	O
34	relationship	O
35	between	O
36	an	O
37	apolipoprotein	O
38	(	O
39	Apo	B
40	)	O
41	E2	O
42	or	O
43	an	O
44	Apo	B
45	E4	I
46	phenotype	I
47	and	O
48	a	O
49	favorable	O
50	outcome	O
51	3	O
52	months	O
53	after	O
54	stroke	O
55	,	O
56	the	O
57	risk	O
58	of	O
59	intracerebral	O
60	hemorrhage	O
61	,	O
62	and	O
63	the	O
64	response	O
65	to	O
66	intravenous	O
67	t	O
68	-	O
69	PA	O
70	therapy	O
71	.	O

1	These	O
2	results	O
3	were	O
4	robust	O
5	to	O
6	changes	O
7	in	O
8	the	O
9	baseline	O
10	assumptions	O
11	of	O
12	the	O
13	model	O
14	.	O

1	Cis	O
2	-	O
3	acting	O
4	CCAAT	O
5	elements	O
6	are	O
7	frequently	O
8	found	O
9	in	O
10	eukaryotic	O
11	promoter	O
12	regions	O
13	.	O

1	The	O
2	binary	O
3	and	O
4	tertiary	O
5	combinations	O
6	of	O
7	plant	O
8	-	O
9	derived	O
10	molluscicides	O
11	Azadirachta	O
12	indica	O
13	and	O
14	Cedrus	O
15	deodara	O
16	oil	O
17	with	O
18	synergists	O
19	MGK	O
20	-	O
21	264	O
22	,	O
23	piperonyl	O
24	butoxide	O
25	(	O
26	PB	O
27	)	O
28	and	O
29	fruit	O
30	powder	O
31	of	O
32	Embelia	O
33	ribes	O
34	were	O
35	used	O
36	against	O
37	the	O
38	Lymnaea	O
39	acuminata	O
40	.	O

1	This	O
2	article	O
3	reports	O
4	the	O
5	design	O
6	and	O
7	development	O
8	of	O
9	an	O
10	ECG	O
11	simulator	O
12	intended	O
13	for	O
14	use	O
15	in	O
16	the	O
17	testing	O
18	,	O
19	calibration	O
20	and	O
21	maintenance	O
22	of	O
23	electrocardiographic	O
24	equipment	O
25	.	O

1	Exchanging	O
2	the	O
3	human	O
4	propeptide	O
5	in	O
6	this	O
7	chimera	O
8	with	O
9	either	O
10	the	O
11	murine	B
12	MIC	I
13	-	I
14	1	I
15	or	O
16	TGF	B
17	-	I
18	beta1	I
19	propeptide	I
20	resulted	O
21	in	O
22	secretion	O
23	of	O
24	the	O
25	unprocessed	O
26	,	O
27	monomeric	O
28	chimera	O
29	,	O
30	suggesting	O
31	a	O
32	specific	O
33	interaction	O
34	between	O
35	the	O
36	human	O
37	MIC	O
38	-	O
39	1	O
40	propeptide	O
41	and	O
42	mature	O
43	peptide	O
44	.	O

1	RESULTS	O
2	:	O
3	The	O
4	analyzed	O
5	fragment	O
6	has	O
7	significant	O
8	activity	O
9	in	O
10	EpCAM	O
11	positive	O
12	cells	O
13	,	O
14	and	O
15	it	O
16	is	O
17	regulated	O
18	negatively	O
19	by	O
20	tumor	B
21	necrosis	I
22	factor	I
23	alpha	I
24	(	O
25	TNFalpha	O
26	).	O

1	The	O
2	mutant	O
3	receptors	O
4	,	O
5	as	O
6	well	O
7	as	O
8	sBMPR	O
9	-	O
10	IA	O
11	,	O
12	were	O
13	expressed	O
14	as	O
15	fusion	O
16	proteins	O
17	with	O
18	thioredoxin	B
19	in	O
20	Escherichia	O
21	coli	O
22	,	O
23	and	O
24	purified	O
25	using	O
26	reverse	O
27	phase	O
28	high	O
29	performance	O
30	liquid	O
31	chromatography	O
32	(	O
33	RP	O
34	-	O
35	HPLC	O
36	)	O
37	after	O
38	digestion	O
39	with	O
40	enterokinase	O
41	.	O

1	The	O
2	dual	O
3	specificity	B
4	kinases	I
5	mitogen	I
6	-	I
7	activated	I
8	protein	I
9	kinase	I
10	(	O
11	MAPK	B
12	)	O
13	kinase	O
14	(	O
15	MKK	O
16	)	O
17	7	O
18	and	O
19	MKK4	O
20	are	O
21	the	O
22	only	O
23	molecules	O
24	known	O
25	to	O
26	directly	O
27	activate	O
28	the	O
29	stress	B
30	kinases	I
31	stress	I
32	-	I
33	activated	I
34	protein	I
35	kinases	I
36	(	O
37	SAPKs	O
38	)/	O
39	c	B
40	-	I
41	Jun	I
42	N	I
43	-	I
44	terminal	I
45	kinases	I
46	(	O
47	JNKs	O
48	)	O
49	in	O
50	response	O
51	to	O
52	environmental	O
53	or	O
54	mitogenic	O
55	stimuli	O
56	.	O

1	This	O
2	unique	O
3	work	O
4	needs	O
5	to	O
6	be	O
7	edited	O
8	critically	O
9	and	O
10	afterwards	O
11	translated	O
12	into	O
13	Urdu	O
14	and	O
15	other	O
16	languages	O
17	for	O
18	the	O
19	benefit	O
20	of	O
21	the	O
22	present	O
23	day	O
24	students	O
25	and	O
26	scholars	O
27	.	O

1	RANTES	O
2	(	O
3	regulated	O
4	upon	O
5	activation	O
6	,	O
7	normally	O
8	T	O
9	-	O
10	cell	O
11	expressed	O
12	and	O
13	presumably	O
14	secreted	O
15	)	O
16	is	O
17	a	O
18	CC	O
19	chemokine	O
20	which	O
21	recruits	O
22	and	O
23	activates	O
24	monocytes	O
25	,	O
26	lymphocytes	O
27	,	O
28	and	O
29	eosinophils	O
30	,	O
31	all	O
32	cell	O
33	types	O
34	present	O
35	in	O
36	the	O
37	lung	O
38	inflammatory	O
39	infiltrate	O
40	induced	O
41	by	O
42	RSV	O
43	infection	O
44	.	O

1	Gabapentin	O
2	for	O
3	opiod	O
4	-	O
5	related	O
6	myoclonus	O
7	in	O
8	cancer	O
9	patients	O
10	.	O

1	Recently	O
2	,	O
3	it	O
4	was	O
5	shown	O
6	that	O
7	purified	O
8	RAG1	B
9	/	I
10	2	I
11	proteins	I
12	can	O
13	cleave	O
14	DNA	O
15	hairpins	O
16	in	O
17	vitro	O
18	,	O
19	but	O
20	the	O
21	same	O
22	activity	O
23	was	O
24	also	O
25	described	O
26	for	O
27	a	O
28	protein	O
29	complex	O
30	of	O
31	the	O
32	DNA	B
33	repair	I
34	proteins	I
35	Nbs1	I
36	/	O
37	Mre11	B
38	/	O
39	Rad50	O
40	.	O

1	APC	O
2	-	O
3	resistance	O
4	was	O
5	determined	O
6	with	O
7	a	O
8	functional	O
9	method	O
10	with	O
11	high	O
12	sensitivity	O
13	and	O
14	specificity	O
15	for	O
16	the	O
17	factor	O
18	V	O
19	Leiden	O
20	mutation	O
21	.	O

1	A	O
2	picture	O
3	is	O
4	emerging	O
5	showing	O
6	a	O
7	gradient	O
8	of	O
9	function	O
10	among	O
11	p53	B
12	,	O
13	p73	O
14	,	O
15	p63	O
16	ranging	O
17	from	O
18	tumor	O
19	suppression	O
20	to	O
21	development	O
22	.	O

1	High	O
2	plasma	O
3	AVP	B
4	levels	O
5	observed	O
6	in	O
7	the	O
8	two	O
9	cases	O
10	suggest	O
11	that	O
12	SSRIs	O
13	stimulate	O
14	AVP	B
15	secretion	O
16	,	O
17	thereby	O
18	causing	O
19	SIADH	O
20	.	O

1	Mutation	O
2	of	O
3	the	O
4	octamer	O
5	element	O
6	also	O
7	significantly	O
8	reduced	O
9	the	O
10	ability	O
11	of	O
12	HDAC1	O
13	to	O
14	confer	O
15	repression	O
16	of	O
17	inducible	O
18	HLA	B
19	-	I
20	DRA	I
21	promoter	I
22	activation	O
23	.	O

1	Requirements	O
2	for	O
3	the	O
4	nuclear	O
5	-	O
6	cytoplasmic	O
7	translocation	O
8	of	O
9	infected	O
10	-	O
11	cell	O
12	protein	O
13	0	O
14	of	O
15	herpes	O
16	simplex	O
17	virus	O
18	1	O
19	.	O

1	The	O
2	system	O
3	,	O
4	designed	O
5	to	O
6	exploit	O
7	the	O
8	relatively	O
9	constant	O
10	small	O
11	intestine	O
12	transit	O
13	time	O
14	,	O
15	consists	O
16	of	O
17	a	O
18	drug	O
19	-	O
20	containing	O
21	core	O
22	coated	O
23	with	O
24	a	O
25	polymeric	O
26	matrix	O
27	formed	O
28	by	O
29	a	O
30	channeling	O
31	agent	O
32	(	O
33	NaCl	O
34	,	O
35	mannitol	O
36	,	O
37	and	O
38	Emdex	O
39	)	O
40	and	O
41	an	O
42	inert	O
43	polymer	O
44	(	O
45	Eudragit	O
46	RS100	O
47	).	O

1	The	O
2	activity	O
3	of	O
4	Rac1	O
5	leads	O
6	to	O
7	STAT3	B
8	translocation	O
9	to	O
10	the	O
11	nucleus	O
12	coincident	O
13	with	O
14	STAT3	B
15	-	O
16	dependent	O
17	gene	O
18	expression	O
19	.	O

1	Treatment	O
2	of	O
3	ischemic	O
4	heart	O
5	disease	O
6	in	O
7	the	O
8	elderly	O

1	To	O
2	avoid	O
3	misinterpretations	O
4	,	O
5	special	O
6	reference	O
7	values	O
8	should	O
9	be	O
10	applied	O
11	for	O
12	preadolescents	O
13	,	O
14	at	O
15	least	O
16	with	O
17	regard	O
18	to	O
19	FVC	O
20	and	O
21	FEV1	O
22	.	O

1	STUDY	O
2	OBJECTIVE	O
3	:	O
4	This	O
5	study	O
6	assessed	O
7	several	O
8	methodological	O
9	aspects	O
10	related	O
11	to	O
12	the	O
13	quality	O
14	of	O
15	published	O
16	controlled	O
17	clinical	O
18	trials	O
19	(	O
20	CCTs	O
21	)	O
22	in	O
23	relation	O
24	to	O
25	the	O
26	participation	O
27	of	O
28	an	O
29	epidemiologist	O
30	/	O
31	biostatistician	O
32	(	O
33	E	O
34	/	O
35	B	O
36	).	O

1	To	O
2	the	O
3	best	O
4	of	O
5	our	O
6	knowledge	O
7	,	O
8	SNTCS	O
9	is	O
10	highly	O
11	malignant	O
12	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	with	O
5	one	O
6	of	O
7	the	O
8	PARNAs	O
9	revealed	O
10	a	O
11	highly	O
12	abundant	O
13	signal	O
14	of	O
15	approximately	O
16	2	O
17	.	O
18	0	O
19	kilobases	O
20	(	O
21	kb	O
22	)	O
23	present	O
24	in	O
25	all	O
26	cell	O
27	lines	O
28	tested	O
29	.	O

1	The	O
2	effect	O
3	of	O
4	crude	O
5	oil	O
6	spillage	O
7	on	O
8	growth	O
9	,	O
10	productivity	O
11	and	O
12	nutrient	O
13	uptake	O
14	of	O
15	maize	O
16	(	O
17	Zea	O
18	mays	O
19	L	O
20	.)	O
21	was	O
22	assessed	O
23	in	O
24	a	O
25	pot	O
26	experiment	O
27	using	O
28	an	O
29	Evwreni	O
30	manifold	O
31	sample	O
32	of	O
33	a	O
34	petroleum	O
35	development	O
36	company	O
37	,	O
38	which	O
39	had	O
40	a	O
41	specific	O
42	gravity	O
43	of	O
44	0	O
45	.	O
46	8778	O
47	.	O

1	10	O
2	.	O
3	0	O
4	+/-	O
5	2	O
6	.	O
7	0	O
8	pmol	O
9	/	O
10	24	O
11	h	O
12	,	O
13	P	O
14	<	O
15	0	O
16	.	O
17	01	O
18	)	O
19	and	O
20	remained	O
21	elevated	O
22	.	O

1	Pitx2	O
2	rescues	O
3	the	O
4	GABAergic	O
5	differentiation	O
6	defect	O
7	and	O
8	partially	O
9	rescues	O
10	the	O
11	axon	O
12	guidance	O
13	and	O
14	behavioral	O
15	phenotypes	O
16	of	O
17	unc	O
18	-	O
19	30	O
20	mutants	O
21	,	O
22	indicating	O
23	a	O
24	high	O
25	degree	O
26	of	O
27	functional	O
28	conservation	O
29	between	O
30	these	O
31	evolutionarily	O
32	related	O
33	genes	O
34	.	O

1	Phosphatidylinositol	B
2	3	I
3	-	I
4	kinase	I
5	potentiates	I
6	,	O
7	but	O
8	does	O
9	not	O
10	trigger	O
11	,	O
12	T	O
13	cell	O
14	proliferation	O
15	mediated	O
16	by	O
17	the	O
18	IL	B
19	-	I
20	2	I
21	receptor	I
22	.	O

1	In	O
2	addition	O
3	,	O
4	stonin	B
5	2	I
6	binds	O
7	to	O
8	the	O
9	C2B	O
10	domains	O
11	of	O
12	synaptotagmins	O
13	I	O
14	and	O
15	II	O
16	.	O

1	Sequence	O
2	comparison	O
3	and	O
4	binding	O
5	studies	O
6	of	O
7	the	O
8	18	O
9	-	O
10	bp	O
11	MOK2	O
12	-	O
13	binding	O
14	sites	O
15	present	O
16	in	O
17	intron	O
18	2	O
19	of	O
20	human	O
21	,	O
22	bovine	O
23	,	O
24	and	O
25	mouse	B
26	IRBP	I
27	genes	I
28	show	O
29	that	O
30	the	O
31	3	O
32	'-	O
33	half	O
34	sequence	O
35	is	O
36	the	O
37	essential	O
38	core	O
39	element	O
40	for	O
41	MOK2	O
42	binding	O
43	.	O

1	Measurements	O
2	were	O
3	obtained	O
4	:	O
5	(	O
6	i	O
7	)	O
8	just	O
9	after	O
10	the	O
11	traumatic	O
12	exposure	O
13	(	O
14	D0	O
15	);	O
16	(	O
17	ii	O
18	)	O
19	3	O
20	days	O
21	after	O
22	this	O
23	first	O
24	measurement	O
25	(	O
26	D3	O
27	);	O
28	and	O
29	(	O
30	iii	O
31	)	O
32	30	O
33	days	O
34	after	O
35	(	O
36	D30	O
37	).	O

1	Long	O
2	-	O
3	term	O
4	results	O
5	with	O
6	MACOP	O
7	-	O
8	B	O
9	and	O
10	radiation	O
11	therapy	O
12	for	O
13	aggressive	O
14	lymphomas	O
15	]	O
16	BACKGROUND	O
17	:	O
18	Long	O
19	-	O
20	term	O
21	results	O
22	are	O
23	needed	O
24	to	O
25	evaluate	O
26	chemotherapy	O
27	regimens	O
28	and	O
29	prognostic	O
30	factors	O
31	in	O
32	non	O
33	-	O
34	Hodgkin	O
35	'	O
36	s	O
37	lymphomas	O
38	(	O
39	NHL	O
40	).	O

1	From	O
2	the	O
3	above	O
4	results	O
5	,	O
6	we	O
7	might	O
8	infer	O
9	that	O
10	the	O
11	seizure	O
12	type	O
13	of	O
14	TLE	O
15	and	O
16	a	O
17	high	O
18	frequency	O
19	of	O
20	seizure	O
21	are	O
22	two	O
23	major	O
24	independent	O
25	precipitate	O
26	factors	O
27	for	O
28	abnormal	O
29	latencies	O
30	of	O
31	P300	B
32	in	O
33	the	O
34	epileptic	O
35	patients	O
36	.	O

1	Rapamycin	O
2	(	O
3	FRAP	B
4	/	O
5	mTOR	B
6	inhibitor	O
7	)	O
8	blocked	O
9	4E	B
10	-	I
11	BP1	I
12	phosphorylation	O
13	causing	O
14	a	O
15	predominance	O
16	of	O
17	the	O
18	alpha	O
19	(	O
20	hypophosphorylated	O
21	)	O
22	band	O
23	.	O

1	We	O
2	investigate	O
3	the	O
4	reaction	O
5	kinetics	O
6	of	O
7	small	O
8	spherical	O
9	particles	O
10	with	O
11	inertia	O
12	,	O
13	obeying	O
14	coalescence	O
15	type	O
16	of	O
17	reaction	O
18	,	O
19	B	O
20	+	O
21	B	O
22	-->	O
23	B	O
24	,	O
25	and	O
26	being	O
27	advected	O
28	by	O
29	hydrodynamical	O
30	flows	O
31	with	O
32	time	O
33	-	O
34	periodic	O
35	forcing	O
36	.	O

1	Corticosteroid	O
2	-	O
3	mediated	O
4	transcriptional	O
5	inhibition	O
6	was	O
7	greater	O
8	for	O
9	MR	O
10	/	O
11	GR	B
12	in	O
13	combination	O
14	than	O
15	for	O
16	MR	O
17	or	O
18	GR	O
19	alone	O
20	.	O

1	These	O
2	data	O
3	define	O
4	a	O
5	conserved	O
6	pathway	O
7	wherein	O
8	sequential	O
9	histone	O
10	modifications	O
11	establish	O
12	a	O
13	"	O
14	histone	O
15	code	O
16	"	O
17	essential	O
18	for	O
19	the	O
20	epigenetic	O
21	inheritance	O
22	of	O
23	heterochromatin	O
24	assembly	O
25	.	O

1	The	O
2	bovine	B
3	PGHS	I
4	-	I
5	2	I
6	cDNA	I
7	was	O
8	cloned	O
9	by	O
10	a	O
11	combination	O
12	of	O
13	reverse	O
14	transcription	O
15	-	O
16	polymerase	O
17	chain	O
18	reaction	O
19	and	O
20	cDNA	O
21	library	O
22	screening	O
23	.	O

1	Telomerase	O
2	is	O
3	a	O
4	ribonucleoprotein	O
5	complex	O
6	that	O
7	synthesizes	O
8	telomeric	O
9	DNA	O
10	onto	O
11	chromosomes	O
12	using	O
13	its	O
14	RNA	O
15	component	O
16	as	O
17	template	O
18	.	O

1	The	O
2	iterative	O
3	method	O
4	proposed	O
5	by	O
6	Bengtsson	O
7	[	O
8	Appl	O
9	.	O

1	Several	O
2	distinct	O
3	apoptotic	O
4	stimuli	O
5	induce	O
6	the	O
7	expression	O
8	and	O
9	caspase	O
10	-	O
11	dependent	O
12	cleavage	O
13	of	O
14	hTAF	B
15	(	I
16	II	I
17	)	O
18	80	O
19	delta	O
20	.	O
21	hTAF	O
22	(	O
23	II	O
24	)	O
25	80	O
26	delta	O
27	,	O
28	unlike	O
29	hTAF	O
30	(	O
31	II	O
32	)	O
33	80	O
34	,	O
35	forms	O
36	a	O
37	TFIID	B
38	-	O
39	like	O
40	complex	O
41	lacking	O
42	hTAF	B
43	(	I
44	II	I
45	)	I
46	31	I
47	.	O

1	With	O
2	NEU	B
3	overexpression	O
4	,	O
5	nodal	B
6	control	O
7	decreased	O
8	from	O
9	72	O
10	%	O
11	to	O
12	34	O
13	%	O
14	(	O
15	p	O
16	=	O
17	.	O
18	008	O
19	).	O

1	The	O
2	mouse	B
3	platelet	I
4	-	I
5	derived	I
6	growth	I
7	factor	I
8	(	I
9	PDGF	I
10	)	I
11	beta	I
12	-	I
13	receptor	I
14	promoter	I
15	contains	O
16	a	O
17	CCAAT	O
18	motif	O
19	,	O
20	and	O
21	NF	B
22	-	I
23	Y	I
24	plays	O
25	an	O
26	essential	O
27	role	O
28	in	O
29	its	O
30	transcription	O
31	.	O

1	Biol	O
2	.	O

1	The	O
2	loop	O
3	domain	O
4	of	O
5	heat	B
6	shock	I
7	transcription	I
8	factor	I
9	1	I
10	dictates	O
11	DNA	O
12	-	O
13	binding	O
14	specificity	O
15	and	O
16	responses	O
17	to	O
18	heat	O
19	stress	O
20	.	O

1	This	O
2	activation	O
3	was	O
4	then	O
5	blocked	O
6	by	O
7	CGS	O
8	12066A	O
9	.	O

1	Among	O
2	the	O
3	transcription	O
4	factors	O
5	known	O
6	to	O
7	interact	O
8	with	O
9	Groucho	B
10	-	I
11	related	I
12	protein	I
13	,	O
14	only	O
15	RUNX1	O
16	was	O
17	appreciably	O
18	downregulated	O
19	by	O
20	E2A	B
21	-	O
22	HLF	O
23	.	O

1	A	O
2	new	O
3	intron	O
4	of	O
5	476	O
6	base	O
7	pairs	O
8	was	O
9	found	O
10	in	O
11	the	O
12	middle	O
13	of	O
14	the	O
15	5	O
16	'-	O
17	untranslated	O
18	leader	O
19	sequence	O
20	and	O
21	was	O
22	shown	O
23	to	O
24	robustly	O
25	enhance	O
26	the	O
27	promoter	O
28	activity	O
29	.	O

1	Our	O
2	findings	O
3	further	O
4	our	O
5	understanding	O
6	of	O
7	how	O
8	ZBP	O
9	-	O
10	89	O
11	modulates	O
12	cell	O
13	proliferation	O
14	and	O
15	reveals	O
16	a	O
17	novel	O
18	mechanism	O
19	by	O
20	which	O
21	the	O
22	p53	B
23	protein	I
24	is	O
25	stabilized	O
26	.	O

1	In	O
2	the	O
3	free	O
4	-	O
5	swimming	O
6	rotatory	O
7	test	O
8	mice	O
9	spend	O
10	most	O
11	of	O
12	the	O
13	time	O
14	swimming	O
15	close	O
16	to	O
17	the	O
18	wall	O
19	of	O
20	the	O
21	container	O
22	attempting	O
23	to	O
24	escape	O
25	from	O
26	an	O
27	aversive	O
28	test	O
29	situation	O
30	.	O

1	As	O
2	well	O
3	,	O
4	mixtures	O
5	of	O
6	(	O
7	LA	O
8	)(	O
9	12	O
10	)	O
11	with	O
12	the	O
13	longer	O
14	chain	O
15	PEs	O
16	exhibit	O
17	unusual	O
18	biomodal	O
19	enthalpy	O
20	variations	O
21	,	O
22	suggesting	O
23	peptide	O
24	immiscibility	O
25	in	O
26	thicker	O
27	gel	O
28	state	O
29	bilayers	O
30	.	O

1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	blind	O
7	therapeutic	O
8	doses	O
9	,	O
10	Tg	O
11	-	O
12	off	O
13	values	O
14	ranged	O
15	from	O
16	8	O
17	to	O
18	608	O
19	microg	O
20	/	O
21	l	O
22	.	O

1	Nephrotoxicity	O
2	after	O
3	orthotopic	O
4	liver	O
5	transplantation	O
6	in	O
7	cyclosporin	O
8	A	O
9	and	O
10	FK	O
11	506	O
12	-	O
13	treated	O
14	patients	O
15	.	O

1	In	O
2	contrast	O
3	to	O
4	MPc3	B
5	,	O
6	data	O
7	indicate	O
8	that	O
9	the	O
10	Pc	B
11	protein	I
12	M33	I
13	does	O
14	not	O
15	interact	O
16	with	O
17	AF9	O
18	.	O

1	Hydrocoele	O
2	is	O
3	common	O
4	in	O
5	men	O
6	in	O
7	Wuchereria	O
8	bancrofti	O
9	-	O
10	endemic	O
11	areas	O
12	,	O
13	the	O
14	treatment	O
15	for	O
16	which	O
17	is	O
18	currently	O
19	surgical	O
20	intervention	O
21	.	O

1	Of	O
2	the	O
3	patients	O
4	in	O
5	each	O
6	regimen	O
7	who	O
8	reached	O
9	study	O
10	end	O
11	points	O
12	,	O
13	17	O
14	of	O
15	29	O
16	(	O
17	59	O
18	%)	O
19	were	O
20	in	O
21	regimen	O
22	A	O
23	,	O
24	11	O
25	of	O
26	20	O
27	(	O
28	55	O
29	%)	O
30	were	O
31	in	O
32	regimen	O
33	B	O
34	,	O
35	and	O
36	28	O
37	of	O
38	43	O
39	(	O
40	65	O
41	%)	O
42	were	O
43	in	O
44	regimen	O
45	C	O
46	met	O
47	the	O
48	treatment	O
49	success	O
50	criterion	O
51	.	O

1	One	O
2	maternal	O
3	death	O
4	,	O
5	reduced	O
6	body	O
7	weight	O
8	,	O
9	and	O
10	reduced	O
11	weight	O
12	gain	O
13	were	O
14	noted	O
15	at	O
16	the	O
17	high	O
18	dose	O
19	;	O
20	confirmed	O
21	pregnancy	O
22	rates	O
23	were	O
24	84	O
25	to	O
26	100	O
27	%	O
28	for	O
29	each	O
30	group	O
31	.	O

1	Karger	O
2	AG	O
3	,	O
4	Basel	O

1	In	O
2	regards	O
3	to	O
4	the	O
5	latter	O
6	activity	O
7	,	O
8	it	O
9	has	O
10	been	O
11	shown	O
12	that	O
13	S3	O
14	contains	O
15	vigorous	O
16	N	O
17	-	O
18	glycosylase	O
19	activity	O
20	for	O
21	the	O
22	removal	O
23	of	O
24	8	O
25	-	O
26	oxoguanine	O
27	residues	O
28	in	O
29	DNA	O
30	that	O
31	leaves	O
32	baseless	O
33	sites	O
34	in	O
35	their	O
36	places	O
37	.	O

1	We	O
2	describe	O
3	a	O
4	total	O
5	of	O
6	39	O
7	DEAH	O
8	helicases	O
9	in	O
10	these	O
11	four	O
12	species	O
13	.	O

1	A	O
2	prospective	O
3	trial	O
4	was	O
5	undertaken	O
6	to	O
7	determine	O
8	(	O
9	1	O
10	)	O
11	clinical	O
12	characteristics	O
13	of	O
14	patients	O
15	with	O
16	chest	O
17	pain	O
18	;	O
19	(	O
20	2	O
21	)	O
22	value	O
23	of	O
24	cardiac	O
25	markers	O
26	troponin	O
27	T	O
28	,	O
29	myoglobin	O
30	and	O
31	CK	O
32	-	O
33	MB	O
34	mass	O
35	in	O
36	differentiating	O
37	cardiac	O
38	and	O
39	noncardiac	O
40	chest	O
41	pain	O
42	;	O
43	(	O
44	3	O
45	)	O
46	the	O
47	proportion	O
48	of	O
49	patients	O
50	with	O
51	ACS	O
52	in	O
53	whom	O
54	these	O
55	markers	O
56	provided	O
57	helpful	O
58	additional	O
59	information	O
60	on	O
61	admission	O
62	and	O
63	afterwards	O
64	.	O

1	Inactivity	O
2	of	O
3	the	O
4	human	O
5	cytomegalovirus	O
6	(	O
7	HCMV	O
8	)	O
9	major	O
10	immediate	O
11	-	O
12	early	O
13	regulatory	O
14	region	O
15	(	O
16	MIERR	O
17	),	O
18	which	O
19	is	O
20	composed	O
21	of	O
22	promoter	O
23	,	O
24	enhancer	O
25	,	O
26	unique	O
27	region	O
28	,	O
29	and	O
30	modulator	O
31	,	O
32	is	O
33	linked	O
34	to	O
35	lack	O
36	of	O
37	HCMV	O
38	replication	O
39	in	O
40	latently	O
41	infected	O
42	cells	O
43	and	O
44	in	O
45	other	O
46	nonpermissive	O
47	cell	O
48	types	O
49	,	O
50	including	O
51	human	O
52	embryonal	O
53	NTera2	O
54	carcinoma	O
55	(	O
56	NT2	O
57	)	O
58	cells	O
59	.	O

1	The	O
2	observed	O
3	triplexes	O
4	depend	O
5	on	O
6	the	O
7	length	O
8	of	O
9	the	O
10	repeat	O
11	.	O

1	Statistical	O
2	Analysis	O
3	included	O
4	ANOVA	O
5	,	O
6	the	O
7	Pearson	O
8	Product	O
9	Moment	O
10	Correlation	O
11	Coefficient	O
12	,	O
13	Principal	O
14	Components	O
15	Analysis	O
16	and	O
17	Discriminant	O
18	Function	O
19	Analysis	O
20	and	O
21	the	O
22	calculation	O
23	of	O
24	Cronbach	O
25	'	O
26	s	O
27	alpha	O
28	(	O
29	alpha	O
30	)	O
31	RESULTS	O
32	:	O
33	Both	O
34	Sensitivity	O
35	and	O
36	specificity	O
37	exceed	O
38	90	O
39	.	O
40	00	O
41	at	O
42	23	O
43	/	O
44	24	O
45	,	O
46	Chronbach	O
47	'	O
48	s	O
49	alpha	O
50	for	O
51	the	O
52	total	O
53	scale	O
54	was	O
55	equal	O
56	to	O
57	0	O
58	.	O
59	95	O
60	.	O

1	BACKGROUND	O
2	:	O
3	Previous	O
4	studies	O
5	have	O
6	indicated	O
7	that	O
8	the	O
9	60	O
10	-,	O
11	30	O
12	-,	O
13	28	O
14	-	O
15	and	O
16	12	O
17	-	O
18	item	O
19	versions	O
20	of	O
21	the	O
22	General	O
23	Health	O
24	Questionnaire	O
25	(	O
26	GHQ	O
27	)	O
28	are	O
29	liable	O
30	to	O
31	retest	O
32	effects	O
33	,	O
34	especially	O
35	when	O
36	administered	O
37	multiple	O
38	times	O
39	with	O
40	short	O
41	intervals	O
42	.	O

1	Cross	O
2	-	O
3	linking	O
4	FcalphaR	O
5	on	O
6	wt	O
7	-	O
8	ITAM	O
9	or	O
10	IIA	O
11	-	O
12	ITAM	O
13	cells	O
14	triggered	O
15	equivalent	O
16	PI	B
17	3	I
18	-	I
19	kinase	I
20	-	O
21	dependent	O
22	activation	O
23	of	O
24	PKBalpha	O
25	.	O

1	An	O
2	F222W	O
3	:	O
4	W21F	B
5	rGST	I
6	A1	I
7	-	I
8	1	I
9	double	O
10	mutant	O
11	provides	O
12	a	O
13	direct	O
14	fluorescence	O
15	probe	O
16	of	O
17	changes	O
18	in	O
19	the	O
20	environment	O
21	of	O
22	the	O
23	C	O
24	-	O
25	terminal	O
26	residue	O
27	.	O

1	Binding	O
2	of	O
3	serum	B
4	response	I
5	factor	I
6	to	O
7	CArG	O
8	box	O
9	sequences	O
10	is	O
11	necessary	O
12	but	O
13	not	O
14	sufficient	O
15	to	O
16	restrict	B
17	gene	I
18	expression	O
19	to	O
20	arterial	O
21	smooth	O
22	muscle	O
23	cells	O
24	.	O

1	They	O
2	consist	O
3	of	O
4	at	O
5	least	O
6	two	O
7	separable	O
8	components	O
9	,	O
10	one	O
11	heat	O
12	stable	O
13	and	O
14	the	O
15	other	O
16	heat	O
17	labile	O
18	.	O

1	No	O
2	preferential	O
3	VH	O
4	/	O
5	VL	O
6	-	O
7	chains	O
8	correlated	O
9	with	O
10	any	O
11	of	O
12	the	O
13	12	O
14	different	O
15	antigen	O
16	reactivities	O
17	,	O
18	even	O
19	for	O
20	mAbs	O
21	with	O
22	nearly	O
23	identical	O
24	cross	O
25	-	O
26	reactivities	O
27	.	O

1	These	O
2	results	O
3	were	O
4	compared	O
5	with	O
6	the	O
7	estimates	O
8	of	O
9	penetration	O
10	from	O
11	steady	O
12	-	O
13	state	O
14	calculations	O
15	,	O
16	square	O
17	root	O
18	of	O
19	time	O
20	calculations	O
21	,	O
22	and	O
23	a	O
24	biologically	O
25	based	O
26	mathematical	O
27	model	O
28	.	O

1	Based	O
2	on	O
3	this	O
4	analysis	O
5	,	O
6	we	O
7	propose	O
8	that	O
9	the	O
10	interactions	O
11	of	O
12	Sos	O
13	with	O
14	the	O
15	switch	O
16	1	O
17	and	O
18	switch	O
19	2	O
20	regions	O
21	of	O
22	Ras	B
23	have	O
24	distinct	O
25	functional	O
26	consequences	O
27	:	O
28	the	O
29	interaction	O
30	with	O
31	switch	B
32	2	I
33	mediates	O
34	the	O
35	anchoring	O
36	of	O
37	Ras	B
38	to	O
39	Sos	O
40	,	O
41	whereas	O
42	the	O
43	interaction	O
44	with	O
45	switch	O
46	1	O
47	leads	O
48	to	O
49	disruption	O
50	of	O
51	the	O
52	nucleotide	O
53	-	O
54	binding	O
55	site	O
56	and	O
57	GDP	O
58	dissociation	O
59	.	O

1	Thus	O
2	,	O
3	the	O
4	interaction	O
5	of	O
6	Tat	B
7	with	O
8	the	O
9	components	O
10	of	O
11	this	O
12	rel	B
13	/	O
14	AP1	B
15	cooperative	O
16	complex	O
17	seems	O
18	to	O
19	induce	O
20	quantitative	O
21	and	O
22	qualitative	O
23	alterations	O
24	of	O
25	this	O
26	complex	O
27	as	O
28	activation	O
29	progresses	O
30	,	O
31	resulting	O
32	in	O
33	a	O
34	decrease	O
35	of	O
36	IL	B
37	-	I
38	2	I
39	gene	I
40	transcription	O
41	.	O

1	SIT	O
2	(	O
3	SHP2	B
4	-	O
5	interacting	O
6	transmembrane	O
7	adaptor	O
8	protein	O
9	)	O
10	is	O
11	a	O
12	recently	O
13	identified	O
14	transmembrane	O
15	adaptor	O
16	protein	O
17	,	O
18	which	O
19	is	O
20	expressed	O
21	in	O
22	lymphocytes	O
23	.	O

1	In	O
2	this	O
3	manuscript	O
4	we	O
5	demonstrate	O
6	that	O
7	two	O
8	tandem	O
9	Ets	B
10	sites	I
11	in	O
12	the	O
13	mouse	B
14	GL	I
15	alpha	I
16	promoter	I
17	bind	O
18	the	O
19	transcription	O
20	factors	O
21	Elf	O
22	-	O
23	1	O
24	and	O
25	PU	B
26	.	I
27	1	I
28	,	O
29	and	O
30	that	O
31	the	O
32	3	O
33	'	O
34	site	O
35	is	O
36	essential	O
37	for	O
38	expression	O
39	of	O
40	a	O
41	luciferase	B
42	reporter	O
43	gene	O
44	driven	O
45	by	O
46	the	O
47	GL	B
48	alpha	I
49	promoter	I
50	.	O

1	ICA	O
2	in	O
3	the	O
4	reference	O
5	solution	O
6	was	O
7	characterised	O
8	by	O
9	LC	O
10	and	O
11	time	O
12	-	O
13	of	O
14	-	O
15	flight	O
16	(	O
17	TOF	O
18	)	O
19	MS	O
20	and	O
21	quantified	O
22	by	O
23	LC	O
24	chemiluminescent	O
25	nitrogen	O
26	detection	O
27	(	O
28	LC	O
29	-	O
30	CLND	O
31	).	O

1	These	O
2	disorders	O
3	include	O
4	low	O
5	-	O
6	back	O
7	pain	O
8	,	O
9	saddle	O
10	anesthesia	O
11	,	O
12	bilateral	O
13	sciatica	O
14	,	O
15	then	O
16	motor	O
17	weakness	O
18	of	O
19	the	O
20	lower	O
21	extremities	O
22	or	O
23	chronic	O
24	paraplegia	O
25	and	O
26	,	O
27	bladder	O
28	dysfunction	O
29	.	O

1	C	O
2	.	O
3	elegans	O
4	embryogenesis	O
5	begins	O
6	with	O
7	a	O
8	stereotyped	O
9	sequence	O
10	of	O
11	asymmetric	O
12	cell	O
13	divisions	O
14	that	O
15	are	O
16	largely	O
17	responsible	O
18	for	O
19	establishing	O
20	the	O
21	nematode	O
22	body	O
23	plan	O
24	.	O

1	Additionally	O
2	,	O
3	a	O
4	CaCO3	O
5	-	O
6	CO2	O
7	/	O
8	N2	O
9	buffered	O
10	solution	O
11	was	O
12	necessary	O
13	to	O
14	maintain	O
15	a	O
16	pH	O
17	of	O
18	8	O
19	.	O

1	Mss4	B
2	also	O
3	acts	O
4	as	O
5	a	O
6	relatively	O
7	inefficient	O
8	guanine	B
9	nucleotide	I
10	exchange	I
11	factor	I
12	(	O
13	GEF	B
14	).	O

1	Effects	O
2	of	O
3	3	O
4	'	O
5	terminus	O
6	modifications	O
7	on	O
8	mRNA	O
9	functional	O
10	decay	O
11	during	O
12	in	O
13	vitro	O
14	protein	O
15	synthesis	O
16	.	O

1	Disciplinary	O
2	action	O
3	for	O
4	DNA	O
5	violation	O
6	.	O

1	This	O
2	is	O
3	necessary	O
4	if	O
5	psychiatric	O
6	diagnoses	O
7	are	O
8	ultimately	O
9	going	O
10	to	O
11	be	O
12	refined	O
13	and	O
14	validated	O
15	against	O
16	biological	O
17	criteria	O
18	.	O

1	We	O
2	also	O
3	demonstrate	O
4	that	O
5	the	O
6	spo20	B
7	(+)	I
8	gene	I
9	product	I
10	is	O
11	structurally	O
12	homologous	O
13	to	O
14	Saccharomyces	O
15	cerevisiae	O
16	Sec14	O
17	,	O
18	the	O
19	major	O
20	phosphatidylinositol	O
21	transfer	O
22	protein	O
23	of	O
24	budding	O
25	yeast	O
26	.	O

1	In	O
2	addition	O
3	,	O
4	another	O
5	derivative	O
6	of	O
7	pCMVJS21	O
8	(	O
9	pCMVJS21DeltaGP	O
10	)	O
11	in	O
12	which	O
13	the	O
14	gag	B
15	,	O
16	pol	B
17	(	O
18	and	O
19	orf	O
20	-	O
21	x	O
22	)	O
23	coding	O
24	sequences	O
25	were	O
26	deleted	O
27	also	O
28	gave	O
29	transformed	O
30	foci	O
31	.	O

1	It	O
2	is	O
3	shown	O
4	that	O
5	,	O
6	for	O
7	any	O
8	periodic	O
9	input	O
10	,	O
11	the	O
12	map	O
13	representing	O
14	the	O
15	relation	O
16	between	O
17	input	O
18	phases	O
19	at	O
20	consecutive	O
21	discharge	O
22	times	O
23	can	O
24	be	O
25	restricted	O
26	to	O
27	a	O
28	piecewise	O
29	continuous	O
30	,	O
31	orientation	O
32	preserving	O
33	circle	O
34	map	O
35	.	O

1	Decreased	O
2	serum	O
3	ceruloplasmin	O
4	and	O
5	copper	O
6	levels	O
7	in	O
8	cervical	O
9	dystonia	O
10	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	of	O
5	RNAs	O
6	from	O
7	a	O
8	number	O
9	of	O
10	mouse	O
11	tissues	O
12	reveals	O
13	that	O
14	Atp6i	B
15	is	O
16	expressed	O
17	predominantly	O
18	in	O
19	osteoclasts	O
20	,	O
21	and	O
22	this	O
23	predominant	O
24	expression	O
25	was	O
26	confirmed	O
27	by	O
28	reverse	O
29	-	O
30	transcription	O
31	polymerase	O
32	chain	O
33	reaction	O
34	(	O
35	RT	O
36	-	O
37	PCR	O
38	)	O
39	assay	O
40	and	O
41	immunohistochemical	O
42	analysis	O
43	.	O

1	Behavioural	O
2	tests	O
3	with	O
4	192	O
5	specimen	O
6	of	O
7	the	O
8	roman	O
9	garden	O
10	snail	O
11	Helix	O
12	pomatia	O
13	L	O
14	.	O
15	were	O
16	performed	O
17	in	O
18	order	O
19	to	O
20	clarify	O
21	whether	O
22	the	O
23	thermopreferendum	O
24	of	O
25	this	O
26	pulmonate	O
27	is	O
28	influenced	O
29	not	O
30	only	O
31	by	O
32	the	O
33	temperature	O
34	of	O
35	the	O
36	substratum	O
37	but	O
38	also	O
39	by	O
40	air	O
41	temperature	O
42	.	O

1	As	O
2	well	O
3	,	O
4	IFN	B
5	-	I
6	gamma	I
7	-	O
8	induced	O
9	expression	O
10	of	O
11	IRF	B
12	-	I
13	1	I
14	and	O
15	its	O
16	binding	O
17	to	O
18	the	O
19	IRF	B
20	element	I
21	is	O
22	inhibited	O
23	.	O

1	Baseline	O
2	BMD	O
3	values	O
4	were	O
5	significantly	O
6	lower	O
7	in	O
8	the	O
9	oligo	O
10	-	O
11	amenorrheic	O
12	group	O
13	than	O
14	in	O
15	the	O
16	two	O
17	others	O
18	at	O
19	the	O
20	level	O
21	of	O
22	lumbar	O
23	spine	O
24	(	O
25	anteroposterior	O
26	view	O
27	:	O
28	0	O
29	.	O
30	941	O
31	+/-	O
32	0	O
33	.	O
34	039	O
35	in	O
36	oligo	O
37	-	O
38	amenorrheic	O
39	vs	O
40	1	O
41	.	O
42	077	O
43	+/-	O
44	0	O
45	.	O
46	029	O
47	or	O
48	1	O
49	.	O
50	051	O
51	+/-	O
52	0	O
53	.	O
54	017	O
55	g	O
56	x	O
57	cm	O
58	(-	O
59	2	O
60	),	O
61	P	O
62	<	O
63	0	O
64	.	O
65	005	O
66	,	O
67	in	O
68	the	O
69	eumenorrheic	O
70	and	O
71	contraceptive	O
72	user	O
73	groups	O
74	,	O
75	respectively	O
76	)	O
77	but	O
78	not	O
79	in	O
80	weight	O
81	-	O
82	bearing	O
83	bone	O
84	such	O
85	as	O
86	proximal	O
87	and	O
88	midshaft	O
89	femur	O
90	.	O

1	The	O
2	glucose	O
3	/	O
4	insulin	B
5	stimulation	O
6	was	O
7	inhibited	O
8	by	O
9	the	O
10	addition	O
11	of	O
12	polyunsaturated	O
13	fatty	O
14	acids	O
15	.	O

1	We	O
2	report	O
3	the	O
4	results	O
5	of	O
6	a	O
7	detailed	O
8	policy	O
9	analysis	O
10	comparing	O
11	2	O
12	CJD	O
13	-	O
14	related	O
15	decisions	O
16	:	O
17	a	O
18	1995	O
19	recall	O
20	of	O
21	blood	O
22	from	O
23	a	O
24	donor	O
25	with	O
26	classic	O
27	CJD	O
28	and	O
29	the	O
30	1999	O
31	decision	O
32	to	O
33	defer	O
34	donations	O
35	from	O
36	individuals	O
37	with	O
38	a	O
39	6	O
40	-	O
41	month	O
42	travel	O
43	history	O
44	to	O
45	the	O
46	UK	O
47	between	O
48	1980	O
49	and	O
50	1996	O
51	due	O
52	to	O
53	concerns	O
54	related	O
55	to	O
56	variant	O
57	CJD	O
58	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	sequence	O
6	of	O
7	the	O
8	3B	B
9	gene	I
10	is	O
11	extremely	O
12	A	O
13	+	O
14	T	O
15	rich	O
16	but	O
17	contains	O
18	five	O
19	G	O
20	/	O
21	C	O
22	rich	O
23	stretches	O
24	,	O
25	each	O
26	approximately	O
27	7bp	O
28	long	O
29	,	O
30	which	O
31	have	O
32	strong	O
33	sequence	O
34	similarity	O
35	to	O
36	the	O
37	G	O
38	boxes	O
39	found	O
40	upstream	O
41	of	O
42	other	O
43	developmentally	O
44	regulated	O
45	Dictyostelium	O
46	genes	O
47	.	O

1	PACAP	O
2	mRNA	O
3	was	O
4	widely	O
5	expressed	O
6	in	O
7	most	O
8	human	O
9	tissues	O
10	;	O
11	in	O
12	transfected	O
13	cells	O
14	,	O
15	PACAP	O
16	was	O
17	diffusely	O
18	expressed	O
19	in	O
20	the	O
21	cytoplasm	O
22	.	O

1	The	O
2	proportion	O
3	of	O
4	the	O
5	biopsies	O
6	found	O
7	to	O
8	be	O
9	seropositive	O
10	for	O
11	HBs	B
12	antigen	I
13	was	O
14	27	O
15	.	O
16	9	O
17	%,	O
18	and	O
19	these	O
20	showed	O
21	either	O
22	MGN	O
23	or	O
24	MPGN	O
25	pattern	O
26	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	have	O
8	determined	O
9	the	O
10	ICBP90	O
11	gene	O
12	structure	O
13	by	O
14	screening	O
15	of	O
16	a	O
17	human	O
18	placenta	O
19	genomic	O
20	library	O
21	and	O
22	PCR	O
23	analysis	O
24	.	O

1	In	O
2	the	O
3	stable	O
4	transfectants	O
5	(	O
6	BM3	O
7	cells	O
8	)	O
9	expressing	O
10	a	O
11	mutant	O
12	bacterial	O
13	P450	O
14	AA	O
15	epoxygenase	O
16	,	O
17	F87V	B
18	BM3	I
19	,	O
20	which	O
21	was	O
22	genetically	O
23	engineered	O
24	to	O
25	metabolize	O
26	arachidonic	O
27	acid	O
28	only	O
29	to	O
30	14	O
31	,	O
32	15	O
33	-	O
34	EET	O
35	,	O
36	AA	O
37	did	O
38	not	O
39	induce	O
40	apoptosis	O
41	and	O
42	protected	O
43	against	O
44	agonist	O
45	-	O
46	induced	O
47	apoptosis	O
48	.	O

1	The	O
2	revitalization	O
3	of	O
4	surgery	O
5	for	O
6	Parkinson	O
7	'	O
8	s	O
9	disease	O
10	(	O
11	PD	O
12	)	O
13	has	O
14	fueled	O
15	discussion	O
16	about	O
17	the	O
18	best	O
19	methodology	O
20	to	O
21	define	O
22	the	O
23	target	O
24	.	O

1	Foreigners	O
2	return	O
3	.	O

1	She	O
2	drank	O
3	alcohol	O
4	once	O
5	or	O
6	twice	O
7	a	O
8	week	O
9	and	O
10	regularly	O
11	took	O
12	an	O
13	analgesic	O
14	preparation	O
15	,	O
16	containing	O
17	aspirin	O
18	and	O
19	acetaminophen	O
20	,	O
21	for	O
22	alleviation	O
23	of	O
24	headaches	O
25	.	O

1	The	O
2	authors	O
3	did	O
4	not	O
5	detect	O
6	any	O
7	significant	O
8	correlations	O
9	between	O
10	parameters	O
11	of	O
12	the	O
13	lipids	O
14	of	O
15	bone	O
16	marrow	O
17	and	O
18	leptin	B
19	levels	O
20	in	O
21	serum	O
22	and	O
23	bone	O
24	marrow	O
25	.	O

1	When	O
2	the	O
3	blood	O
4	clot	O
5	is	O
6	formed	O
7	in	O
8	the	O
9	vitreous	O
10	cavity	O
11	,	O
12	intravitreal	O
13	injection	O
14	of	O
15	t	O
16	-	O
17	PA	O
18	can	O
19	convert	O
20	plasminogen	O
21	to	O
22	plasmin	O
23	and	O
24	remove	O
25	the	O
26	clot	O
27	.	O

1	When	O
2	this	O
3	CCAAT	O
4	box	O
5	was	O
6	inserted	O
7	into	O
8	a	O
9	heterologous	O
10	promoter	O
11	construct	O
12	,	O
13	OA	O
14	induction	O
15	was	O
16	dependent	O
17	on	O
18	an	O
19	intact	O
20	CCAAT	O
21	box	O
22	.	O

1	Encouraged	O
2	by	O
3	a	O
4	Dutch	O
5	study	O
6	using	O
7	etidronate	O
8	/	O
9	fluoride	O
10	in	O
11	corticoid	O
12	-	O
13	induced	O
14	osteoporosis	O
15	,	O
16	we	O
17	performed	O
18	a	O
19	pilot	O
20	study	O
21	in	O
22	33	O
23	men	O
24	with	O
25	severe	O
26	established	O
27	primary	O
28	osteoporosis	O
29	giving	O
30	cyclically	O
31	etidronate	O
32	for	O
33	14	O
34	days	O
35	followed	O
36	by	O
37	fluoride	O
38	plus	O
39	calcium	O
40	/	O
41	vitamin	O
42	D	O
43	for	O
44	76	O
45	days	O
46	.	O

1	Far	O
2	Western	O
3	blot	O
4	analysis	O
5	suggested	O
6	that	O
7	the	O
8	tandem	O
9	SH2	O
10	domains	O
11	of	O
12	SHP2	B
13	bind	O
14	to	O
15	Gab1	O
16	in	O
17	a	O
18	specific	O
19	orientation	O
20	,	O
21	in	O
22	which	O
23	the	O
24	N	O
25	-	O
26	SH2	B
27	domain	I
28	binds	O
29	to	O
30	phosphotyrosine	O
31	(	O
32	Tyr	O
33	(	O
34	P	O
35	))-	O
36	627	O
37	and	O
38	the	O
39	C	B
40	-	I
41	SH2	I
42	domain	I
43	binds	O
44	to	O
45	Tyr	O
46	(	O
47	P	O
48	)-	O
49	659	O
50	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	and	O
6	coimmunoprecipitation	O
7	studies	O
8	suggest	O
9	that	O
10	homo	O
11	-	O
12	and	O
13	heterodimerization	O
14	occurs	O
15	between	O
16	cKrox	O
17	family	O
18	members	O
19	.	O

1	Expression	O
2	of	O
3	human	B
4	RACK1	I
5	efficiently	I
6	relieves	O
7	E1A	B
8	-	O
9	mediated	O
10	growth	O
11	inhibition	O
12	in	O
13	HF7c	O
14	and	O
15	protects	O
16	human	O
17	tumor	O
18	cells	O
19	from	O
20	E1A	B
21	-	O
22	induced	O
23	apoptosis	O
24	.	O

1	By	O
2	using	O
3	space	O
4	-	O
5	discrete	O
6	/	O
7	continuous	O
8	metapopulation	O
9	dynamic	O
10	models	O
11	and	O
12	computer	O
13	simulations	O
14	,	O
15	we	O
16	show	O
17	that	O
18	there	O
19	can	O
20	be	O
21	two	O
22	principally	O
23	different	O
24	regimes	O
25	of	O
26	metapopulation	O
27	dynamics	O
28	.	O

1	Arterial	O
2	blood	O
3	gas	O
4	tensions	O
5	were	O
6	similar	O
7	across	O
8	all	O
9	ventilation	O
10	modes	O
11	.	O

1	Four	O
2	casein	B
3	kinase	I
4	I	I
5	isoforms	I
6	are	O
7	differentially	O
8	partitioned	O
9	between	O
10	nucleus	O
11	and	O
12	cytoplasm	O
13	.	O

1	CONCLUSION	O
2	:	O
3	Extrusion	O
4	cooking	O
5	is	O
6	effective	O
7	for	O
8	the	O
9	inactivation	O
10	of	O
11	DON	O
12	but	O
13	is	O
14	of	O
15	limited	O
16	value	O
17	for	O
18	AFB1	O
19	,	O
20	even	O
21	if	O
22	metabisulphite	O
23	is	O
24	added	O
25	.	O

1	Also	O
2	,	O
3	the	O
4	EWS	B
5	protein	I
6	stimulates	O
7	transcription	O
8	mediated	O
9	by	O
10	the	O
11	COOH	O
12	-	O
13	terminal	O
14	transactivation	O
15	domain	O
16	of	O
17	the	O
18	cofactor	O
19	CREB	B
20	-	I
21	binding	I
22	protein	I
23	(	O
24	CBP	B
25	).	O

1	HSF	B
2	binds	O
3	DNA	O
4	as	O
5	a	O
6	trimer	O
7	,	O
8	and	O
9	additional	O
10	trimers	O
11	can	O
12	bind	O
13	DNA	O
14	co	O
15	-	O
16	operatively	O
17	.	O

1	Two	O
2	cases	O
3	with	O
4	marked	O
5	chronic	O
6	arm	O
7	lymphoedema	O
8	reported	O
9	major	O
10	and	O
11	persistent	O
12	improvements	O
13	in	O
14	arm	O
15	volume	O
16	for	O
17	at	O
18	least	O
19	12	O
20	months	O
21	after	O
22	treatment	O
23	with	O
24	HBO2	O
25	.	O

1	Growth	B
2	hormone	I
3	and	O
4	insulin	B
5	-	I
6	like	I
7	growth	I
8	factor	I
9	I	I
10	receptors	I
11	in	O
12	the	O
13	temporomandibular	O
14	joint	O
15	of	O
16	the	O
17	rat	O
18	.	O

1	Folate	O
2	metabolism	O
3	in	O
4	the	O
5	human	O
6	malaria	O
7	parasite	O
8	Plasmodium	O
9	falciparum	O
10	is	O
11	an	O
12	essential	O
13	activity	O
14	for	O
15	cell	O
16	growth	O
17	and	O
18	replication	O
19	,	O
20	and	O
21	the	O
22	target	O
23	of	O
24	an	O
25	important	O
26	class	O
27	of	O
28	therapeutic	O
29	agents	O
30	in	O
31	widespread	O
32	use	O
33	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	BACM	B
6	has	O
7	antiplaque	O
8	and	O
9	stronger	O
10	antidegradation	O
11	effects	O
12	than	O
13	GLCM	O
14	.	O

1	A	O
2	mutation	O
3	in	O
4	the	O
5	C	O
6	domain	O
7	of	O
8	Rb	B
9	,	O
10	L901Q	B
11	,	O
12	has	O
13	been	O
14	identified	O
15	that	O
16	completely	O
17	abolishes	O
18	cdk4	B
19	/	O
20	D1	B
21	phosphorylation	O
22	of	O
23	the	O
24	isolated	O
25	C	O
26	domain	O
27	.	O

1	Homo	O
2	-	O
3	oligomerisation	O
4	and	O
5	nuclear	O
6	localisation	O
7	of	O
8	mouse	B
9	histone	I
10	deacetylase	I
11	1	I
12	.	O

1	Energy	O
2	expenditure	O
3	was	O
4	obtained	O
5	using	O
6	a	O
7	primed	O
8	,	O
9	3	O
10	-	O
11	hour	O
12	infusion	O
13	of	O
14	NaH	O
15	(	O
16	13	O
17	)	O
18	CO	O
19	(	O
20	3	O
21	'),	O
22	breath	O
23	(	O
24	13	O
25	)	O
26	CO	O
27	(	O
28	2	O
29	)	O
30	enrichment	O
31	determination	O
32	by	O
33	isotope	O
34	ratio	O
35	mass	O
36	spectroscopy	O
37	,	O
38	and	O
39	the	O
40	application	O
41	of	O
42	a	O
43	standard	O
44	regression	O
45	equation	O
46	.	O

1	Fasting	O
2	gastrin	O
3	levels	O
4	(	O
5	normal	O
6	range	O
7	:	O
8	25	O
9	-	O
10	110	O
11	mU	O
12	/	O
13	L	O
14	)	O
15	varied	O
16	from	O
17	48	O
18	.	O
19	78	O
20	mU	O
21	/	O
22	L	O
23	-	O
24	168	O
25	.	O
26	20	O
27	(	O
28	mean	O
29	:	O
30	85	O
31	.	O
32	23	O
33	mU	O
34	/	O
35	L	O
36	).	O

1	Identification	O
2	of	O
3	pulmonary	O
4	vein	O
5	stenosis	O
6	after	O
7	radiofrequency	O
8	ablation	O
9	for	O
10	atrial	O
11	fibrillation	O
12	using	O
13	MRI	O
14	.	O

1	The	O
2	continuing	O
3	development	O
4	of	O
5	ligands	O
6	that	O
7	function	O
8	as	O
9	selective	O
10	estrogens	O
11	or	O
12	antiestrogens	O
13	for	O
14	ERalpha	O
15	or	O
16	ERbeta	O
17	should	O
18	allow	O
19	optimized	O
20	tissue	O
21	selectivity	O
22	of	O
23	these	O
24	agents	O
25	for	O
26	menopausal	O
27	hormone	O
28	replacement	O
29	therapy	O
30	and	O
31	the	O
32	treatment	O
33	and	O
34	prevention	O
35	of	O
36	breast	O
37	cancer	O
38	.	O

1	Baseline	O
2	variables	O
3	associated	O
4	with	O
5	CD	O
6	included	O
7	a	O
8	less	O
9	frequent	O
10	use	O
11	of	O
12	prestroke	O
13	aspirin	O
14	and	O
15	a	O
16	higher	O
17	incidence	O
18	of	O
19	early	O
20	CT	O
21	changes	O
22	of	O
23	edema	O
24	or	O
25	mass	O
26	effect	O
27	or	O
28	dense	O
29	middle	O
30	cerebral	O
31	artery	O
32	sign	O
33	.	O

1	A	O
2	peculiar	O
3	people	O
4	:	O
5	"	O
6	the	O
7	physiological	O
8	aspects	O
9	of	O
10	Mormonism	O
11	1850	B
12	-	I
13	1975	I
14	."	O

1	SH2D1A	B
2	protein	I
3	levels	O
4	are	O
5	up	O
6	-	O
7	regulated	O
8	by	O
9	CD40	O
10	cross	O
11	-	O
12	linking	O
13	and	O
14	down	O
15	-	O
16	regulated	O
17	by	O
18	B	O
19	cell	O
20	receptor	O
21	ligation	O
22	.	O

1	The	O
2	Genescan	O
3	program	O
4	predicted	O
5	an	O
6	open	O
7	reading	O
8	frame	O
9	of	O
10	a	O
11	novel	O
12	,	O
13	intron	O
14	-	O
15	less	O
16	gene	O
17	adjacent	O
18	to	O
19	the	O
20	B236	O
21	spot	O
22	that	O
23	encodes	O
24	a	O
25	putative	O
26	493	O
27	-	O
28	amino	O
29	acid	O
30	protein	O
31	containing	O
32	the	O
33	SNAG	O
34	repressor	O
35	motif	O
36	in	O
37	the	O
38	NH2	O
39	-	O
40	terminal	O
41	region	O
42	and	O
43	five	O
44	C2H2	O
45	-	O
46	type	O
47	zinc	O
48	finger	O
49	motifs	O
50	in	O
51	the	O
52	COOH	O
53	-	O
54	terminal	O
55	half	O
56	.	O

1	Under	O
2	our	O
3	conditions	O
4	,	O
5	the	O
6	combination	O
7	O3	O
8	/	O
9	UV	O
10	did	O
11	not	O
12	improve	O
13	the	O
14	degradation	O
15	rate	O
16	obtained	O
17	by	O
18	ozonation	O
19	.	O

1	The	O
2	metabolic	O
3	events	O
4	occurring	O
5	at	O
6	or	O
7	near	O
8	that	O
9	structure	O
10	and	O
11	involving	O
12	cyclin	B
13	D3	I
14	cause	O
15	the	O
16	translocation	O
17	of	O
18	ICP0	B
19	to	O
20	the	O
21	cytoplasm	O
22	.	O

1	In	O
2	the	O
3	single	O
4	case	O
5	the	O
6	restoration	O
7	of	O
8	a	O
9	structured	O
10	daily	O
11	routine	O
12	represents	O
13	the	O
14	presupposition	O
15	for	O
16	a	O
17	cognitive	O
18	therapy	O
19	.	O

1	Immunofluorescence	O
2	studies	O
3	in	O
4	C2C12	O
5	myotubes	O
6	show	O
7	that	O
8	Smad2	O
9	and	O
10	MEF2A	O
11	co	O
12	-	O
13	localise	O
14	in	O
15	the	O
16	nucleus	O
17	of	O
18	multinuclear	O
19	myotubes	O
20	during	O
21	differentiation	O
22	.	O

1	In	O
2	35	O
3	of	O
4	those	O
5	patients	O
6	DD	O
7	was	O
8	measured	O
9	also	O
10	with	O
11	microlatex	O
12	tests	O
13	--	O
14	Tinaquant	O
15	and	O
16	BC	O
17	d	O
18	-	O
19	dimer	O
20	.	O

1	Simulating	O
2	the	O
3	impact	O
4	during	O
5	human	O
6	jumping	O
7	by	O
8	means	O
9	of	O
10	a	O
11	4	O
12	-	O
13	degrees	O
14	-	O
15	of	O
16	-	O
17	freedom	O
18	model	O
19	with	O
20	time	O
21	-	O
22	dependent	O
23	properties	O
24	.	O

1	A	O
2	novel	O
3	approach	O
4	was	O
5	developed	O
6	for	O
7	identifying	O
8	transcription	O
9	factor	O
10	activities	O
11	associated	O
12	with	O
13	NGF	B
14	-	O
15	activated	O
16	,	O
17	but	O
18	not	O
19	EGF	B
20	-	O
21	activated	O
22	,	O
23	signaling	O
24	,	O
25	using	O
26	random	O
27	oligonucleotide	O
28	clones	O
29	from	O
30	a	O
31	DNA	O
32	recognition	O
33	library	O
34	to	O
35	isolate	O
36	specific	O
37	DNA	O
38	binding	O
39	proteins	O
40	from	O
41	PC12	O
42	nuclear	O
43	extracts	O
44	.	O

1	Atheroma	O
2	appears	O
3	as	O
4	a	O
5	very	O
6	low	O
7	signal	O
8	intensity	O
9	area	O
10	on	O
11	2	O
12	-	O
13	dimensional	O
14	time	O
15	-	O
16	of	O
17	-	O
18	flight	O
19	(	O
20	TOF	O
21	)	O
22	magnetic	O
23	resonance	O
24	(	O
25	MR	O
26	)	O
27	images	O
28	,	O
29	and	O
30	its	O
31	components	O
32	have	O
33	various	O
34	signal	O
35	intensities	O
36	on	O
37	spin	O
38	-	O
39	echo	O
40	(	O
41	SE	O
42	)	O
43	images	O
44	.	O

1	Finally	O
2	a	O
3	10	O
4	-	O
5	nucleotide	O
6	region	O
7	flanking	O
8	the	O
9	exon	B
10	4	I
11	protein	I
12	-	I
13	binding	I
14	site	I
15	is	O
16	homologous	O
17	to	O
18	instability	O
19	elements	O
20	within	O
21	five	O
22	other	O
23	transcripts	O
24	,	O
25	suggesting	O
26	that	O
27	a	O
28	common	O
29	coding	O
30	region	O
31	determinant	O
32	may	O
33	exist	O
34	.	O

1	Chronic	O
2	nutritional	O
3	diseases	O
4	of	O
5	infectious	O
6	origin	O
7	:	O
8	an	O
9	assessment	O
10	of	O
11	a	O
12	nascent	O
13	field	O
14	.	O

1	The	O
2	cut	O
3	-	O
4	off	O
5	percentage	O
6	positivity	O
7	value	O
8	was	O
9	established	O
10	using	O
11	500	O
12	brucellosis	O
13	-	O
14	positive	O
15	and	O
16	500	O
17	brucellosis	O
18	-	O
19	negative	O
20	serum	O
21	samples	O
22	,	O
23	confirmed	O
24	with	O
25	reference	O
26	to	O
27	the	O
28	sample	O
29	data	O
30	using	O
31	the	O
32	indirect	O
33	ELISA	O
34	kit	O
35	.	O

1	PROCEDURE	O
2	:	O
3	Cannulas	O
4	were	O
5	surgically	O
6	positioned	O
7	in	O
8	the	O
9	abomasal	O
10	body	O
11	and	O
12	pyloric	O
13	antrum	O
14	of	O
15	each	O
16	calf	O
17	.	O

1	The	O
2	utilities	O
3	measured	O
4	in	O
5	our	O
6	study	O
7	can	O
8	be	O
9	applied	O
10	directly	O
11	to	O
12	quality	O
13	-	O
14	of	O
15	-	O
16	life	O
17	determinations	O
18	in	O
19	clinical	O
20	trials	O
21	of	O
22	adjuvant	O
23	IFN	B
24	alpha	I
25	-	I
26	2b	I
27	to	O
28	measure	O
29	the	O
30	net	O
31	benefit	O
32	of	O
33	therapy	O
34	.	O

1	Cells	O
2	lacking	O
3	p116	B
4	exhibit	O
5	a	O
6	striking	O
7	defect	O
8	in	O
9	the	O
10	formation	O
11	of	O
12	these	O
13	macropinocytic	O
14	structures	O
15	,	O
16	a	O
17	concomitant	O
18	reduction	O
19	in	O
20	the	O
21	rate	O
22	of	O
23	fluid	O
24	phase	O
25	pinocytosis	O
26	,	O
27	a	O
28	significant	O
29	decrease	O
30	in	O
31	the	O
32	efficiency	O
33	of	O
34	chemotactic	O
35	aggregation	O
36	,	O
37	and	O
38	a	O
39	decrease	O
40	in	O
41	cellular	O
42	F	O
43	-	O
44	actin	B
45	content	O
46	.	O

1	Ectopic	O
2	expression	O
3	of	O
4	the	O
5	dominant	B
6	mutant	I
7	Lg3	I
8	allele	I
9	is	O
10	believed	O
11	to	O
12	cause	O
13	the	O
14	phenotype	O
15	.	O

1	Specimen	O
2	mass	O
3	reduction	O
4	increased	O
5	with	O
6	irradiance	O
7	from	O
8	19	O
9	to	O
10	72	O
11	%	O
12	of	O
13	the	O
14	initial	O
15	mass	O
16	for	O
17	9	O
18	--	O
19	31	O
20	W	O
21	/	O
22	cm	O
23	(	O
24	2	O
25	),	O
26	respectively	O
27	.	O

1	Analysis	O
2	of	O
3	the	O
4	genome	O
5	sequence	O
6	revealed	O
7	26	O
8	,	O
9	588	O
10	protein	O
11	-	O
12	encoding	O
13	transcripts	O
14	for	O
15	which	O
16	there	O
17	was	O
18	strong	O
19	corroborating	O
20	evidence	O
21	and	O
22	an	O
23	additional	O
24	approximately	O
25	12	O
26	,	O
27	000	O
28	computationally	O
29	derived	O
30	genes	O
31	with	O
32	mouse	O
33	matches	O
34	or	O
35	other	O
36	weak	O
37	supporting	O
38	evidence	O
39	.	O

1	The	O
2	other	O
3	inhibitor	O
4	was	O
5	a	O
6	single	O
7	TAR	O
8	decoy	O
9	,	O
10	driven	O
11	by	O
12	the	O
13	U6	B
14	small	I
15	nuclear	I
16	RNA	I
17	promoter	I
18	(	O
19	U6	B
20	-	I
21	P	I
22	).	O

1	By	O
2	comparison	O
3	,	O
4	in	O
5	nontumorigenic	O
6	Ad5	O
7	cells	O
8	,	O
9	class	O
10	I	O
11	expression	O
12	is	O
13	high	O
14	due	O
15	to	O
16	negligible	O
17	binding	O
18	of	O
19	COUP	B
20	-	I
21	TF	I
22	and	O
23	strong	O
24	binding	O
25	of	O
26	NF	B
27	-	I
28	kappaB	I
29	.	O

1	Moreover	O
2	,	O
3	a	O
4	complex	O
5	containing	O
6	PTP	B
7	phi	I
8	,	O
9	paxillin	O
10	,	O
11	and	O
12	a	O
13	paxillin	B
14	-	I
15	associated	I
16	tyrosine	I
17	kinase	I
18	,	O
19	Pyk2	B
20	,	O
21	can	O
22	be	O
23	immunoprecipitated	O
24	from	O
25	macrophage	O
26	lysates	O
27	,	O
28	and	O
29	the	O
30	catalytic	O
31	domain	O
32	of	O
33	PTP	B
34	phi	I
35	selectively	I
36	binds	O
37	paxillin	B
38	and	O
39	Pyk2	B
40	in	O
41	vitro	O
42	.	O

1	Our	O
2	previous	O
3	studies	O
4	have	O
5	shown	O
6	that	O
7	SHP	B
8	-	I
9	1	I
10	,	O
11	a	O
12	SH2	B
13	domain	I
14	-	I
15	containing	I
16	protein	I
17	-	I
18	tyrosine	I
19	phosphatase	I
20	,	O
21	is	O
22	expressed	O
23	not	O
24	only	O
25	in	O
26	cells	O
27	of	O
28	hematopoietic	O
29	lineages	O
30	,	O
31	but	O
32	also	O
33	in	O
34	many	O
35	non	O
36	-	O
37	hematopoietic	O
38	cells	O
39	under	O
40	the	O
41	control	O
42	of	O
43	an	O
44	alternative	O
45	tissue	O
46	-	O
47	specific	O
48	promoter	O
49	,	O
50	P1	O
51	.	O

1	Whereas	O
2	Smad2	O
3	was	O
4	rapidly	O
5	phosphorylated	O
6	by	O
7	TGF	B
8	-	I
9	beta	I
10	and	O
11	involved	O
12	in	O
13	the	O
14	initial	O
15	activation	O
16	of	O
17	Agc	B
18	expression	O
19	in	O
20	confluent	O
21	cells	O
22	,	O
23	Smad2	B
24	activation	O
25	was	O
26	not	O
27	required	O
28	for	O
29	maintaining	O
30	the	O
31	high	O
32	level	O
33	of	O
34	Agc	O
35	expression	O
36	.	O

1	The	O
2	astronaut	O
3	crew	O
4	operates	O
5	the	O
6	payload	O
7	and	O
8	documents	O
9	its	O
10	operation	O
11	.	O

1	This	O
2	molecule	O
3	,	O
4	wH22xeGFP	O
5	,	O
6	consists	O
7	of	O
8	the	O
9	entire	O
10	humanized	O
11	anti	O
12	-	O
13	FcgammaRI	O
14	mAb	O
15	H22	O
16	with	O
17	eGFP	O
18	genetically	O
19	fused	O
20	to	O
21	the	O
22	C	O
23	-	O
24	terminal	O
25	end	O
26	of	O
27	each	O
28	CH3	O
29	domain	O
30	.	O
31	wH22xeGFP	O
32	binds	O
33	within	O
34	the	O
35	ligand	O
36	-	O
37	binding	O
38	region	O
39	by	O
40	its	O
41	Fc	O
42	end	O
43	,	O
44	as	O
45	well	O
46	as	O
47	outside	O
48	the	O
49	ligand	O
50	-	O
51	binding	O
52	region	O
53	by	O
54	its	O
55	Fab	O
56	ends	O
57	,	O
58	thereby	O
59	cross	O
60	-	O
61	linking	O
62	FcgammaRI	O
63	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	hepatic	O
7	arterial	O
8	infusion	O
9	therapy	O
10	prolongs	O
11	the	O
12	survival	O
13	of	O
14	H3	O
15	patients	O
16	only	O
17	.	O

1	Hepatitis	O
2	B	O
3	and	O
4	C	O
5	seroprevalence	O
6	rates	O
7	among	O
8	high	O
9	-	O
10	risk	O
11	adolescents	O
12	are	O
13	lower	O
14	in	O
15	El	O
16	Paso	O
17	than	O
18	in	O
19	other	O
20	similar	O
21	US	O
22	populations	O
23	,	O
24	presenting	O
25	an	O
26	ideal	O
27	climate	O
28	for	O
29	prevention	O
30	programs	O
31	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	SOCS	O
6	box	O
7	interacted	O
8	with	O
9	Cullin	O
10	-	O
11	2	O
12	and	O
13	promoted	O
14	ubiquitination	O
15	of	O
16	TEL	B
17	-	I
18	JAK2	I
19	.	O

1	A	O
2	patient	O
3	is	O
4	described	O
5	with	O
6	skin	O
7	lesions	O
8	resembling	O
9	Kaposi	O
10	'	O
11	s	O
12	sarcoma	O
13	(	O
14	KS	O
15	).	O

1	Special	O
2	issues	O
3	devoted	O
4	to	O
5	the	O
6	biosynthesis	O
7	of	O
8	woody	O
9	plant	O
10	biopolymers	O
11	and	O
12	related	O
13	substances	O
14	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	ADAM	O
6	-	O
7	TS12	O
8	may	O
9	play	O
10	roles	O
11	in	O
12	pulmonary	O
13	cells	O
14	during	O
15	fetal	O
16	development	O
17	or	O
18	in	O
19	tumor	O
20	processes	O
21	through	O
22	its	O
23	proteolytic	O
24	activity	O
25	or	O
26	as	O
27	a	O
28	molecule	O
29	potentially	O
30	involved	O
31	in	O
32	regulation	O
33	of	O
34	cell	O
35	adhesion	O
36	.	O

1	Progressive	O
2	study	O
3	and	O
4	robustness	O
5	test	O
6	of	O
7	QSAR	O
8	model	O
9	based	O
10	on	O
11	quantum	O
12	chemical	O
13	parameters	O
14	for	O
15	predicting	O
16	BCF	O
17	of	O
18	selected	O
19	polychlorinated	O
20	organic	O
21	compounds	O
22	(	O
23	PCOCs	O
24	).	O

1	Additional	O
2	deletion	O
3	mutations	O
4	revealed	O
5	a	O
6	new	O
7	,	O
8	67	O
9	-	O
10	amino	O
11	-	O
12	acid	O
13	functional	O
14	domain	O
15	within	O
16	the	O
17	proline	O
18	-	O
19	rich	O
20	region	O
21	of	O
22	SLP	B
23	-	I
24	76	I
25	,	O
26	which	O
27	we	O
28	have	O
29	termed	O
30	the	O
31	P	B
32	-	I
33	1	I
34	domain	I
35	.	O

1	Patients	O
2	with	O
3	type	O
4	III	O
5	SOD	O
6	may	O
7	have	O
8	visceral	O
9	hyperalgesia	O
10	;	O
11	a	O
12	trial	O
13	of	O
14	antidepressants	O
15	or	O
16	a	O
17	therapeutic	O
18	trial	O
19	with	O
20	botulinum	B
21	toxin	I
22	injection	O
23	into	O
24	the	O
25	ampulla	O
26	should	O
27	be	O
28	considered	O
29	prior	O
30	to	O
31	more	O
32	invasive	O
33	endoscopic	O
34	therapy	O
35	.	O

1	We	O
2	have	O
3	now	O
4	tested	O
5	all	O
6	known	O
7	mammalian	B
8	Groucho	I
9	family	I
10	members	O
11	for	O
12	their	O
13	ability	O
14	to	O
15	interact	O
16	specifically	O
17	with	O
18	individual	O
19	Tcf	B
20	/	O
21	Lef	B
22	family	O
23	members	O
24	.	O

1	Body	O
2	weight	O
3	reduction	O
4	increases	O
5	insulin	B
6	sensitivity	O
7	and	O
8	improves	O
9	both	O
10	blood	O
11	glucose	O
12	and	O
13	blood	O
14	pressure	O
15	control	O
16	.	O

1	Sequence	O
2	analysis	O
3	indicates	O
4	that	O
5	RBP21	B
6	shares	O
7	homology	O
8	with	O
9	other	O
10	retinoblastoma	B
11	-	I
12	binding	I
13	proteins	I
14	in	O
15	the	O
16	pRb	B
17	-	I
18	binding	I
19	motif	I
20	LxCxE	O
21	at	O
22	the	O
23	C	O
24	-	O
25	terminal	O
26	region	O
27	.	O

1	Tolerance	O
2	in	O
3	renal	O
4	transplantation	O
5	after	O
6	allogeneic	O
7	bone	O
8	marrow	O
9	transplantation	O
10	-	O
11	6	O
12	-	O
13	year	O
14	follow	O
15	-	O
16	up	O
17	.	O

1	By	O
2	analyzing	O
3	5	O
4	'-	O
5	deletion	O
6	insulin	B
7	promoter	O
8	-	O
9	reporter	O
10	constructs	O
11	in	O
12	transient	O
13	transfections	O
14	of	O
15	clonal	O
16	INS	O
17	-	O
18	1	O
19	beta	O
20	-	O
21	cells	O
22	,	O
23	we	O
24	located	O
25	activating	O
26	Hh	O
27	-	O
28	responsive	O
29	regions	O
30	within	O
31	the	O
32	rat	B
33	insulin	I
34	I	I
35	promoter	I
36	that	O
37	include	O
38	the	O
39	glucose	O
40	-	O
41	response	O
42	elements	O
43	Far	O
44	(	O
45	E2	O
46	)	O
47	and	O
48	Flat	O
49	(	O
50	A2	O
51	/	O
52	A3	O
53	).	O

1	However	O
2	,	O
3	when	O
4	directed	O
5	to	O
6	the	O
7	nucleosome	O
8	by	O
9	fusion	O
10	to	O
11	core	O
12	histone	B
13	H2A	I
14	or	O
15	H2B	B
16	,	O
17	the	O
18	non	O
19	-	O
20	histone	B
21	tail	O
22	forms	O
23	an	O
24	MCB	O
25	that	O
26	appears	O
27	identical	O
28	to	O
29	that	O
30	of	O
31	the	O
32	endogenous	O
33	protein	O
34	.	O

1	Data	O
2	were	O
3	obtained	O
4	from	O
5	2	O
6	undergraduate	O
7	student	O
8	samples	O
9	,	O
10	a	O
11	self	O
12	-	O
13	report	O
14	group	O
15	(	O
16	n	O
17	=	O
18	132	O
19	)	O
20	who	O
21	provided	O
22	NEO	O
23	-	O
24	PI	O
25	-	O
26	R	O
27	self	O
28	-	O
29	ratings	O
30	on	O
31	2	O
32	occasions	O
33	separated	O
34	by	O
35	a	O
36	7	O
37	-	O
38	to	O
39	14	O
40	-	O
41	day	O
42	interval	O
43	and	O
44	an	O
45	informant	O
46	group	O
47	(	O
48	n	O
49	=	O
50	109	O
51	)	O
52	who	O
53	provided	O
54	ratings	O
55	of	O
56	well	O
57	-	O
58	known	O
59	friends	O
60	or	O
61	relatives	O
62	on	O
63	2	O
64	occasions	O
65	separated	O
66	by	O
67	a	O
68	6	O
69	month	O
70	interval	O
71	.	O

1	Pulmonary	O
2	embolectomy	O
3	and	O
4	lung	O
5	transplantation	O
6	are	O
7	the	O
8	main	O
9	indications	O
10	for	O
11	the	O
12	use	O
13	of	O
14	heart	O
15	-	O
16	lung	O
17	-	O
18	machine	O
19	.	O

1	Comparison	O
2	of	O
3	German	O
4	language	O
5	versions	O
6	of	O
7	the	O
8	QWB	O
9	-	O
10	SA	O
11	and	O
12	SF	O
13	-	O
14	36	O
15	evaluating	O
16	outcomes	O
17	for	O
18	patients	O
19	with	O
20	prostate	O
21	disease	O
22	.	O

1	The	O
2	median	O
3	preoperative	O
4	best	O
5	-	O
6	corrected	O
7	visual	O
8	acuity	O
9	of	O
10	0	O
11	.	O
12	08	O
13	(	O
14	range	O
15	hand	O
16	motions	O
17	/	O
18	0	O
19	.	O
20	003	O
21	to	O
22	0	O
23	.	O
24	4	O
25	),	O
26	improved	O
27	by	O
28	5	O
29	lines	O
30	to	O
31	a	O
32	median	O
33	final	O
34	postoperative	O
35	best	O
36	-	O
37	corrected	O
38	visual	O
39	acuity	O
40	of	O
41	0	O
42	.	O
43	25	O
44	(	O
45	range	O
46	0	O
47	.	O
48	025	O
49	-	O
50	0	O
51	.	O
52	5	O
53	)	O
54	(	O
55	P	O
56	=	O
57	0	O
58	.	O
59	001	O
60	).	O

1	Angina	O
2	(	O
3	Q	O
4	)	O
5	persistence	O
6	showed	O
7	marked	O
8	associations	O
9	with	O
10	previous	O
11	myocardial	O
12	infarction	O
13	,	O
14	diagnosed	O
15	angina	O
16	,	O
17	electrocardiogram	O
18	ischemia	O
19	,	O
20	and	O
21	subsequent	O
22	major	O
23	ischemic	O
24	heart	O
25	disease	O
26	events	O
27	from	O
28	Q5	O
29	onward	O
30	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	CAR	O
7	revealed	O
8	that	O
9	CAR	O
10	residues	O
11	Leu73	O
12	and	O
13	Lys121	O
14	and	O
15	/	O
16	or	O
17	Lys123	O
18	are	O
19	critical	O
20	contact	O
21	residues	O
22	,	O
23	with	O
24	Tyr80	O
25	and	O
26	Tyr83	O
27	being	O
28	peripherally	O
29	involved	O
30	in	O
31	the	O
32	binding	O
33	interaction	O
34	with	O
35	the	O
36	Ad5	O
37	,	O
38	Ad9	O
39	,	O
40	Ad12	O
41	,	O
42	and	O
43	Ad41L	O
44	fiber	O
45	knobs	O
46	.	O

1	Transforming	B
2	growth	I
3	factor	I
4	-	I
5	beta	I
6	(	O
7	TGF	B
8	-	I
9	beta	I
10	)	O
11	induced	O
12	growth	O
13	arrest	O
14	of	O
15	cells	O
16	involves	O
17	regulation	O
18	of	O
19	the	O
20	activities	O
21	of	O
22	both	O
23	D	O
24	-	O
25	and	O
26	E	O
27	-	O
28	type	O
29	cyclin	B
30	kinase	I
31	complexes	O
32	thought	O
33	to	O
34	be	O
35	mediated	O
36	primarily	O
37	by	O
38	the	O
39	regulation	O
40	of	O
41	p15	B
42	(	O
43	Ink4b	O
44	)	O
45	and	O
46	p27	B
47	(	O
48	Kip1	B
49	)	O
50	cyclin	B
51	kinase	I
52	inhibitors	O
53	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	SmSmad2	O
7	responds	O
8	to	O
9	the	O
10	TGF	B
11	-	I
12	beta	I
13	signals	O
14	by	O
15	interaction	O
16	with	O
17	receptor	B
18	I	I
19	,	O
20	which	O
21	phosphorylates	O
22	it	O
23	,	O
24	whereupon	O
25	it	O
26	translocates	O
27	into	O
28	the	O
29	nucleus	O
30	presumably	O
31	to	O
32	regulate	O
33	target	O
34	gene	O
35	transcription	O
36	and	O
37	consequently	O
38	elicit	O
39	a	O
40	specific	O
41	TGF	B
42	-	I
43	beta	I
44	effect	O
45	.	O

1	We	O
2	propose	O
3	that	O
4	TFOs	O
5	represent	O
6	a	O
7	therapeutic	O
8	potential	O
9	to	O
10	specifically	O
11	diminish	O
12	the	O
13	expression	O
14	of	O
15	c	B
16	-	I
17	sis	I
18	/	I
19	PDGF	I
20	-	I
21	B	I
22	proto	I
23	-	I
24	oncogene	I
25	in	O
26	various	O
27	pathologic	O
28	settings	O
29	where	O
30	constitutive	O
31	expression	O
32	of	O
33	this	O
34	gene	O
35	has	O
36	been	O
37	observed	O
38	.	O

1	The	O
2	increased	O
3	clearance	O
4	observed	O
5	in	O
6	young	O
7	infants	O
8	is	O
9	in	O
10	contrast	O
11	to	O
12	other	O
13	opioids	O
14	.	O

1	Peripheral	O
2	metabolism	O
3	of	O
4	androgens	O
5	takes	O
6	place	O
7	in	O
8	various	O
9	areas	O
10	within	O
11	the	O
12	pilosebaceous	O
13	unit	O
14	,	O
15	as	O
16	indicated	O
17	by	O
18	local	O
19	differences	O
20	in	O
21	the	O
22	activities	O
23	of	O
24	aromatase	O
25	,	O
26	5alpha	B
27	-	I
28	reductase	I
29	as	O
30	well	O
31	as	O
32	of	O
33	the	O
34	presence	O
35	of	O
36	the	O
37	androgen	O
38	receptors	O
39	.	O

1	This	O
2	unique	O
3	location	O
4	of	O
5	cavernous	O
6	malformation	O
7	is	O
8	associated	O
9	with	O
10	a	O
11	risk	O
12	of	O
13	permanent	O
14	loss	O
15	of	O
16	the	O
17	vision	O
18	.	O

1	The	O
2	JHRLSS	O
3	has	O
4	been	O
5	used	O
6	in	O
7	prior	O
8	studies	O
9	to	O
10	assess	O
11	RLS	O
12	severity	O
13	,	O
14	but	O
15	has	O
16	not	O
17	previously	O
18	been	O
19	validated	O
20	in	O
21	relation	O
22	to	O
23	direct	O
24	measures	O
25	of	O
26	the	O
27	morbidity	O
28	associated	O
29	with	O
30	RLS	O
31	.	O

1	Consistent	O
2	effects	O
3	on	O
4	pVHL	O
5	function	O
6	were	O
7	observed	O
8	for	O
9	all	O
10	mutations	O
11	within	O
12	each	O
13	subclass	O
14	.	O

1	Interestingly	O
2	,	O
3	the	O
4	CYP71D20	O
5	-	O
6	encoded	O
7	enzyme	O
8	activity	O
9	was	O
10	capable	O
11	of	O
12	converting	O
13	both	O
14	5	O
15	-	O
16	epi	O
17	-	O
18	aristolochene	O
19	and	O
20	1	O
21	-	O
22	deoxycapsidiol	O
23	to	O
24	capsidiol	O
25	in	O
26	vitro	O
27	,	O
28	consistent	O
29	with	O
30	the	O
31	notion	O
32	that	O
33	this	O
34	P450	O
35	enzyme	O
36	catalyzes	O
37	both	O
38	hydroxylations	O
39	of	O
40	its	O
41	hydrocarbon	O
42	substrate	O
43	.	O

1	A	O
2	new	O
3	species	O
4	of	O
5	Euspondylus	O
6	is	O
7	described	O
8	based	O
9	on	O
10	a	O
11	female	O
12	(	O
13	taken	O
14	within	O
15	a	O
16	bromeliad	O
17	)	O
18	from	O
19	Cerro	O
20	El	O
21	Humo	O
22	,	O
23	Sucre	O
24	,	O
25	northeastern	O
26	Venezuela	O
27	.	O

1	The	O
2	most	O
3	important	O
4	finding	O
5	,	O
6	however	O
7	,	O
8	was	O
9	that	O
10	IMT	O
11	values	O
12	were	O
13	related	O
14	with	O
15	24	O
16	h	O
17	SBP	O
18	or	O
19	PP	O
20	standard	O
21	deviation	O
22	(	O
23	P	O
24	<	O
25	0	O
26	.	O
27	001	O
28	),	O
29	a	O
30	measure	O
31	of	O
32	overall	O
33	SBP	O
34	or	O
35	PP	O
36	variability	O
37	.	O

1	In	O
2	addition	O
3	,	O
4	severe	O
5	vision	O
6	loss	O
7	can	O
8	be	O
9	seen	O
10	with	O
11	interferon	B
12	alfa	I
13	-	I
14	2b	I
15	-	O
16	associated	O
17	retinopathy	O
18	.	O

1	FLP	O
2	and	O
3	Cre	O
4	recombinase	O
5	function	O
6	in	O
7	Xenopus	O
8	embryos	O
9	.	O

1	Keratoconjunctivitis	O
2	sicca	O
3	appears	O
4	to	O
5	be	O
6	a	O
7	common	O
8	ocular	O
9	complication	O
10	and	O
11	all	O
12	children	O
13	with	O
14	JRA	O
15	should	O
16	be	O
17	screened	O
18	for	O
19	it	O
20	with	O
21	a	O
22	comprehensive	O
23	battery	O
24	of	O
25	tests	O
26	.	O

1	Moreover	O
2	,	O
3	PTax	O
4	expressed	O
5	higher	O
6	background	O
7	activities	O
8	than	O
9	PTF	O
10	,	O
11	indicating	O
12	that	O
13	the	O
14	sequence	O
15	of	O
16	the	O
17	synthetic	O
18	regulatory	O
19	region	O
20	can	O
21	influence	O
22	background	O
23	levels	O
24	.	O

1	After	O
2	allowing	O
3	time	O
4	for	O
5	absorption	O
6	,	O
7	participants	O
8	completed	O
9	a	O
10	bridge	O
11	simulator	O
12	task	O
13	.	O

1	The	O
2	cleavage	O
3	site	O
4	between	O
5	VPg	B
6	and	O
7	RNA	B
8	dependent	I
9	RNA	I
10	polymerase	I
11	was	O
12	predicted	O
13	to	O
14	be	O
15	E445	O
16	-	O
17	T446	O
18	based	O
19	on	O
20	the	O
21	amino	O
22	acid	O
23	sequence	O
24	analysis	O
25	of	O
26	the	O
27	polyprotein	O
28	from	O
29	different	O
30	sobemoviruses	O
31	.	O

1	Conformational	O
2	changes	O
3	of	O
4	the	O
5	ferric	O
6	uptake	O
7	regulation	O
8	protein	O
9	upon	O
10	metal	O
11	activation	O
12	and	O
13	DNA	O
14	binding	O
15	;	O
16	first	O
17	evidence	O
18	of	O
19	structural	O
20	homologies	O
21	with	O
22	the	O
23	diphtheria	B
24	toxin	I
25	repressor	I
26	.	O

1	At	O
2	visit	O
3	5	O
4	,	O
5	the	O
6	isokinetic	O
7	test	O
8	showed	O
9	impaired	O
10	muscle	O
11	function	O
12	recovery	O
13	from	O
14	23	O
15	%	O
16	to	O
17	32	O
18	%,	O
19	while	O
20	the	O
21	manual	O
22	test	O
23	showed	O
24	almost	O
25	full	O
26	recovery	O
27	.	O

1	Constitutive	O
2	phosphorylation	O
3	and	O
4	nuclear	O
5	localization	O
6	of	O
7	Smad3	B
8	are	O
9	correlated	O
10	with	O
11	increased	O
12	collagen	B
13	gene	I
14	transcription	O
15	in	O
16	activated	O
17	hepatic	O
18	stellate	O
19	cells	O
20	.	O

1	Cholesteryl	O
2	ester	O
3	transfer	O
4	protein	O
5	and	O
6	atherosclerosis	O
7	in	O
8	Japanese	O
9	subjects	O
10	:	O
11	a	O
12	study	O
13	based	O
14	on	O
15	coronary	O
16	angiography	O
17	.	O

1	And	O
2	,	O
3	most	O
4	importantly	O
5	,	O
6	reconstitution	O
7	of	O
8	a	O
9	consensus	O
10	CRE	O
11	,	O
12	within	O
13	the	O
14	21	O
15	-	O
16	bp	O
17	enhancers	O
18	increases	O
19	binding	O
20	of	O
21	CREB	B
22	/	O
23	ATF	B
24	proteins	I
25	but	O
26	abrogates	O
27	basal	O
28	repression	O
29	of	O
30	LTR	O
31	-	O
32	directed	O
33	transcription	O
34	in	O
35	vitro	O
36	.	O

1	Stable	O
2	transfection	O
3	of	O
4	human	B
5	CHOP	I
6	cDNA	I
7	into	O
8	mammary	O
9	carcinoma	O
10	cells	O
11	demonstrated	O
12	that	O
13	CHOP	B
14	functioned	O
15	not	O
16	as	O
17	a	O
18	mediator	O
19	of	O
20	hGH	O
21	-	O
22	stimulated	O
23	mitogenesis	O
24	but	O
25	rather	O
26	enhanced	O
27	the	O
28	protection	O
29	from	O
30	apoptosis	O
31	afforded	O
32	by	O
33	hGH	O
34	in	O
35	a	O
36	p38	B
37	MAPK	O
38	-	O
39	dependent	O
40	manner	O
41	.	O

1	The	O
2	combination	O
3	of	O
4	ifosfamide	O
5	,	O
6	epirubicin	O
7	and	O
8	etoposide	O
9	(	O
10	IEV	O
11	)	O
12	is	O
13	an	O
14	effective	O
15	salvage	O
16	regimen	O
17	for	O
18	lymphoproliferative	O
19	disease	O
20	.	O

1	Interestingly	O
2	,	O
3	the	O
4	activity	O
5	of	O
6	IkappaB	B
7	kinase	I
8	(	O
9	IKK	B
10	-	I
11	beta	I
12	),	O
13	which	O
14	plays	O
15	an	O
16	essential	O
17	role	O
18	in	O
19	NF	B
20	-	I
21	kappaB	I
22	activation	O
23	through	O
24	IkappaB	O
25	phosphorylation	O
26	,	O
27	was	O
28	largely	O
29	enhanced	O
30	in	O
31	paclitaxel	O
32	-	O
33	treated	O
34	cells	O
35	,	O
36	detected	O
37	as	O
38	IkappaBalpha	O
39	phosphorylation	O
40	.	O

1	The	O
2	recessive	O
3	hos1	O
4	mutation	O
5	causes	O
6	enhanced	O
7	induction	O
8	of	O
9	the	O
10	CBF	B
11	transcription	I
12	factors	I
13	by	O
14	low	O
15	temperature	O
16	as	O
17	well	O
18	as	O
19	of	O
20	their	O
21	downstream	O
22	cold	O
23	-	O
24	responsive	O
25	genes	O
26	.	O

1	Apart	O
2	from	O
3	antimicrobial	O
4	properties	O
5	,	O
6	recent	O
7	data	O
8	indicate	O
9	that	O
10	PMN	O
11	also	O
12	exert	O
13	anti	O
14	-	O
15	inflammatory	O
16	effects	O
17	by	O
18	stimulation	O
19	and	O
20	release	O
21	of	O
22	cytokine	O
23	antagonists	O
24	such	O
25	as	O
26	interleukin	B
27	-	I
28	1	I
29	receptor	I
30	antagonist	O
31	(	O
32	IL	B
33	-	I
34	1ra	I
35	).	O

1	Early	O
2	indicators	O
3	of	O
4	the	O
5	effect	O
6	of	O
7	a	O
8	breast	O
9	cancer	O
10	screening	O
11	program	O
12	for	O
13	low	O
14	-	O
15	income	O
16	women	O
17	.	O

1	An	O
2	association	O
3	was	O
4	demonstrated	O
5	between	O
6	the	O
7	expression	O
8	of	O
9	aberrantly	O
10	and	O
11	/	O
12	or	O
13	alternatively	O
14	spliced	O
15	mdm2	O
16	mRNAs	O
17	and	O
18	a	O
19	lack	O
20	of	O
21	progesterone	B
22	receptor	I
23	.	O

1	BACKGROUND	O
2	:	O
3	Dermoscopy	O
4	is	O
5	a	O
6	noninvasive	O
7	technique	O
8	that	O
9	increases	O
10	the	O
11	diagnostic	O
12	accuracy	O
13	of	O
14	pigmented	O
15	skin	O
16	lesions	O
17	,	O
18	particularly	O
19	improving	O
20	the	O
21	diagnosis	O
22	of	O
23	patients	O
24	with	O
25	cutaneous	O
26	melanoma	O
27	in	O
28	situ	O
29	(	O
30	CMIS	O
31	)	O
32	and	O
33	early	O
34	invasive	O
35	melanoma	O
36	.	O

1	Increased	O
2	erythropoietin	O
3	synthesis	O
4	in	O
5	patients	O
6	with	O
7	COLD	O
8	or	O
9	left	O
10	heart	O
11	failure	O
12	is	O
13	related	O
14	to	O
15	alterations	O
16	in	O
17	renal	O
18	haemodynamics	O
19	.	O

1	The	O
2	(	O
3	two	O
4	-	O
5	motif	O
6	)	O
7	domain	O
8	fold	O
9	contains	O
10	a	O
11	pair	O
12	of	O
13	calcium	O
14	binding	O
15	sites	O
16	very	O
17	similar	O
18	to	O
19	those	O
20	found	O
21	in	O
22	a	O
23	two	O
24	-	O
25	domain	O
26	prokaryotic	O
27	betagamma	O
28	-	O
29	crystallin	O
30	fold	O
31	family	O
32	member	O
33	,	O
34	Protein	O
35	S	O
36	.	O

1	Twenty	O
2	-	O
3	five	O
4	patients	O
5	also	O
6	received	O
7	PET	O
8	examinations	O
9	during	O
10	the	O
11	staging	O
12	procedures	O
13	.	O

1	In	O
2	the	O
3	last	O
4	case	O
5	,	O
6	both	O
7	hydroxychloroquine	O
8	,	O
9	carbamazepine	O
10	and	O
11	fluvoxamine	O
12	had	O
13	a	O
14	common	O
15	imputability	O
16	which	O
17	was	O
18	plausible	O
19	.	O

1	In	O
2	all	O
3	of	O
4	these	O
5	cases	O
6	,	O
7	expression	O
8	of	O
9	the	O
10	implicated	O
11	genes	O
12	was	O
13	absent	O
14	.	O

1	A	O
2	subset	O
3	of	O
4	patients	O
5	(	O
6	n	O
7	=	O
8	30	O
9	)	O
10	underwent	O
11	multichannel	O
12	pressure	O
13	flow	O
14	studies	O
15	,	O
16	which	O
17	demonstrated	O
18	that	O
19	transrectal	O
20	HIFU	O
21	reduces	O
22	bladder	O
23	outflow	O
24	obstruction	O
25	.	O

1	Biochemical	O
2	experiments	O
3	have	O
4	shown	O
5	that	O
6	CopG	O
7	co	O
8	-	O
9	operatively	O
10	associates	O
11	to	O
12	its	O
13	target	O
14	DNA	O
15	at	O
16	low	O
17	protein	O
18	:	O
19	DNA	O
20	ratios	O
21	,	O
22	completely	O
23	protecting	O
24	four	O
25	helical	O
26	turns	O
27	on	O
28	the	O
29	same	O
30	face	O
31	of	O
32	the	O
33	double	O
34	helix	O
35	in	O
36	both	O
37	directions	O
38	from	O
39	the	O
40	inverted	O
41	repeat	O
42	that	O
43	constitutes	O
44	the	O
45	CopG	O
46	primary	O
47	target	O
48	.	O

1	The	O
2	mechanism	O
3	of	O
4	ligand	O
5	-	O
6	activated	O
7	estrogen	B
8	receptor	I
9	alpha	I
10	(	O
11	ERalpha	O
12	)-	O
13	dependent	O
14	activation	O
15	of	O
16	gene	B
17	expression	O
18	through	O
19	the	O
20	SRE	O
21	was	O
22	determined	O
23	by	O
24	mutational	O
25	analysis	O
26	of	O
27	the	O
28	promoter	O
29	,	O
30	analysis	O
31	of	O
32	mitogen	B
33	-	I
34	activated	I
35	protein	I
36	kinase	I
37	(	O
38	MAPK	B
39	)	O
40	pathway	O
41	activation	O
42	by	O
43	E2	B
44	,	O
45	and	O
46	transforming	B
47	growth	I
48	factor	I
49	alpha	I
50	(	O
51	TGF	B
52	-	I
53	alpha	I
54	)	O
55	as	O
56	a	O
57	positive	O
58	control	O
59	.	O

1	This	O
2	study	O
3	investigated	O
4	whether	O
5	boron	O
6	would	O
7	enhance	O
8	the	O
9	ability	O
10	of	O
11	17beta	O
12	-	O
13	estradiol	O
14	(	O
15	E2	O
16	)	O
17	or	O
18	parathyroid	B
19	hormone	I
20	(	O
21	PTH	B
22	)	O
23	to	O
24	improve	O
25	bone	O
26	quality	O
27	in	O
28	ovariectomized	O
29	OVX	O
30	rats	O
31	.	O

1	2001	O
2	.	O

1	The	O
2	Gap69C	O
3	is	O
4	a	O
5	single	O
6	-	O
7	copy	O
8	gene	O
9	producing	O
10	a	O
11	major	O
12	2	O
13	.	O
14	1	O
15	-	O
16	kb	O
17	mRNA	O
18	throughout	O
19	development	O
20	,	O
21	but	O
22	its	O
23	amount	O
24	is	O
25	decreased	O
26	in	O
27	larvae	O
28	.	O

1	In	O
2	the	O
3	long	O
4	term	O
5	,	O
6	questions	O
7	still	O
8	remain	O
9	about	O
10	whether	O
11	pre	O
12	-	O
13	dialysis	O
14	rHu	O
15	EPO	B
16	either	O
17	speeds	O
18	up	O
19	or	O
20	delays	O
21	the	O
22	onset	O
23	of	O
24	dialysis	O
25	.	O

1	The	O
2	validity	O
3	of	O
4	the	O
5	FPS	O
6	-	O
7	R	O
8	was	O
9	further	O
10	supported	O
11	by	O
12	strong	O
13	positive	O
14	correlations	O
15	with	O
16	the	O
17	VAS	O
18	(	O
19	r	O
20	=	O
21	0	O
22	.	O
23	92	O
24	,	O
25	N	O
26	=	O
27	45	O
28	)	O
29	and	O
30	the	O
31	CAS	O
32	(	O
33	r	O
34	=	O
35	0	O
36	.	O
37	84	O
38	,	O
39	N	O
40	=	O
41	45	O
42	)	O
43	in	O
44	this	O
45	clinical	O
46	sample	O
47	.	O

1	The	O
2	BFA	O
3	System	O
4	reads	O
5	a	O
6	text	O
7	file	O
8	with	O
9	flows	O
10	,	O
11	measured	O
12	with	O
13	fluorescent	O
14	microsphere	O
15	technique	O
16	,	O
17	and	O
18	constructs	O
19	the	O
20	lung	O
21	anatomy	O
22	with	O
23	volumetric	O
24	pixels	O
25	showing	O
26	the	O
27	flows	O
28	with	O
29	a	O
30	color	O
31	schema	O
32	.	O

1	Therefore	O
2	,	O
3	to	O
4	understand	O
5	how	O
6	ErbB1	B
7	/	O
8	ErbB2	B
9	signaling	O
10	contributes	O
11	to	O
12	this	O
13	process	O
14	,	O
15	we	O
16	used	O
17	the	O
18	ErbB	B
19	kinase	I
20	inhibitor	O
21	AG1478in	B
22	ErbB2	I
23	-	O
24	dependent	O
25	BT	O
26	-	O
27	474	O
28	and	O
29	SKBR	O
30	-	O
31	3	O
32	human	O
33	breast	O
34	cancer	O
35	cells	O
36	.	O

1	Deletion	O
2	analyses	O
3	implicate	O
4	the	O
5	N	O
6	-	O
7	terminal	O
8	110	O
9	amino	O
10	acids	O
11	of	O
12	Grb14	O
13	and	O
14	ankyrin	O
15	repeats	O
16	10	O
17	-	O
18	19	O
19	of	O
20	tankyrase	O
21	2	O
22	in	O
23	mediating	O
24	this	O
25	interaction	O
26	.	O

1	Hormonal	O
2	regulation	O
3	of	O
4	multiple	O
5	promoters	O
6	of	O
7	the	O
8	rat	B
9	mitochondrial	I
10	glycerol	I
11	-	I
12	3	I
13	-	I
14	phosphate	I
15	dehydrogenase	I
16	gene	I
17	:	O
18	identification	O
19	of	O
20	a	O
21	complex	O
22	hormone	O
23	-	O
24	response	O
25	element	O
26	in	O
27	the	O
28	ubiquitous	O
29	promoter	O
30	B	O
31	.	O

1	SAMPLE	O
2	POPULATION	O
3	:	O
4	MCB	O
5	from	O
6	7	O
7	racing	O
8	Greyhounds	O
9	euthanatized	O
10	for	O
11	reasons	O
12	unrelated	O
13	to	O
14	MCB	O
15	abnormalities	O
16	.	O

1	Structural	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	class	B
7	I	I
8	major	I
9	histocompatibility	I
10	complex	I
11	(	I
12	MHC	I
13	)-	O
14	restricted	O
15	peptide	O
16	-	O
17	specific	O
18	T	B
19	cell	I
20	receptor	I
21	(	O
22	TCR	B
23	)-	O
24	alpha	O
25	/	O
26	betas	O
27	make	O
28	multiple	O
29	contacts	O
30	with	O
31	the	O
32	alpha1	O
33	and	O
34	alpha2	O
35	helices	O
36	of	O
37	the	O
38	MHC	B
39	,	O
40	but	O
41	it	O
42	is	O
43	unclear	O
44	which	O
45	or	O
46	how	O
47	many	O
48	of	O
49	these	O
50	interactions	O
51	contribute	O
52	to	O
53	functional	O
54	binding	O
55	.	O

1	Fans	O
2	in	O
3	tunnels	O
4	and	O
5	open	O
6	windows	O
7	at	O
8	aboveground	O
9	locations	O
10	appeared	O
11	to	O
12	greatly	O
13	reduce	O
14	the	O
15	likelihood	O
16	of	O
17	high	O
18	PH3	O
19	concentrations	O
20	in	O
21	enclosed	O
22	areas	O
23	.	O

1	In	O
2	DNA	O
3	strand	O
4	exchange	O
5	reactions	O
6	using	O
7	oligonucleotides	O
8	,	O
9	we	O
10	found	O
11	that	O
12	Rec2	O
13	exhibited	O
14	a	O
15	pairing	O
16	bias	O
17	that	O
18	is	O
19	opposite	O
20	that	O
21	of	O
22	RecA	O
23	.	O

1	A	O
2	major	O
3	mechanism	O
4	by	O
5	which	O
6	estrogens	O
7	prevent	O
8	osteoporosis	O
9	seems	O
10	to	O
11	be	O
12	repression	O
13	of	O
14	transcription	O
15	of	O
16	NF	B
17	-	I
18	kappa	I
19	B	I
20	target	O
21	genes	O
22	,	O
23	such	O
24	as	O
25	the	O
26	osteoclast	O
27	-	O
28	activating	O
29	cytokines	O
30	interleukin	B
31	-	I
32	6	I
33	and	O
34	interleukin	B
35	-	I
36	1	I
37	.	O

1	Linear	O
2	eight	O
3	-	O
4	or	O
5	nine	O
6	-	O
7	residue	O
8	D	O
9	-	O
10	peptides	O
11	derived	O
12	from	O
13	the	O
14	pocket	O
15	-	O
16	binding	O
17	domain	O
18	of	O
19	the	O
20	cyclic	O
21	molecules	O
22	also	O
23	bind	O
24	specifically	O
25	.	O

1	As	O
2	expected	O
3	,	O
4	homologous	O
5	loxP	O
6	sequences	O
7	efficiently	O
8	underwent	O
9	Cre	O
10	-	O
11	mediated	O
12	recombination	O
13	.	O

1	Multistage	O
2	models	O
3	and	O
4	the	O
5	A	O
6	-	O
7	bomb	O
8	survivor	O
9	data	O
10	:	O
11	implications	O
12	for	O
13	carcinogenic	O
14	mechanisms	O
15	?	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	a	O
6	more	O
7	differentiated	O
8	diagnosis	O
9	of	O
10	the	O
11	molar	O
12	relationship	O
13	will	O
14	allow	O
15	for	O
16	a	O
17	more	O
18	causally	O
19	directed	O
20	correction	O
21	of	O
22	Class	O
23	II	O
24	molar	O
25	relationship	O
26	.	O

1	It	O
2	is	O
3	surprising	O
4	that	O
5	dnaE173	O
6	,	O
7	a	O
8	potent	O
9	mutator	O
10	mutation	O
11	specific	O
12	for	O
13	sequence	O
14	substitution	O
15	as	O
16	well	O
17	as	O
18	single	O
19	-	O
20	base	O
21	frameshift	O
22	,	O
23	did	O
24	not	O
25	enhance	O
26	the	O
27	frequency	O
28	of	O
29	the	O
30	hot	O
31	-	O
32	spot	O
33	frameshift	O
34	mutation	O
35	.	O

1	Hypercalcemia	O
2	associated	O
3	with	O
4	elevated	O
5	serum	O
6	PTH	B
7	concentration	O
8	indicating	O
9	primary	O
10	hyperparathyroidism	O
11	was	O
12	found	O
13	in	O
14	7	O
15	BC	O
16	patients	O
17	(	O
18	7	O
19	%)	O
20	and	O
21	in	O
22	none	O
23	of	O
24	healthy	O
25	women	O
26	or	O
27	patients	O
28	with	O
29	thyroid	O
30	cancer	O
31	.	O

1	[	O
2	figure	O
3	:	O
4	see	O
5	text	O
6	]	O
7	The	O
8	Stille	O
9	coupling	O
10	reaction	O
11	has	O
12	been	O
13	performed	O
14	in	O
15	1	O
16	-	O
17	butyl	O
18	-	O
19	3	O
20	-	O
21	methylimidazolium	O
22	tetrafluoroborate	O
23	(	O
24	BMIM	B
25	BF4	I
26	),	O
27	a	O
28	room	O
29	-	O
30	temperature	O
31	ionic	O
32	liquid	O
33	(	O
34	RTIL	O
35	).	O

1	Examination	O
2	of	O
3	various	O
4	promoter	O
5	deletion	O
6	mutants	O
7	indicated	O
8	that	O
9	SF	B
10	-	I
11	1	I
12	acts	O
13	through	O
14	the	O
15	proximal	O
16	promoter	O
17	region	O
18	and	O
19	upstream	O
20	promoter	O
21	sequences	O
22	.	O

1	ORF1	O
2	(	O
3	1029	O
4	bp	O
5	;	O
6	EMBL	O
7	databank	O
8	,	O
9	Accession	O
10	No	O
11	.	O

1	Vector	O
2	stocks	O
3	containing	O
4	envelope	O
5	proteins	O
6	from	O
7	three	O
8	different	O
9	SIVmac	O
10	clones	O
11	,	O
12	namely	O
13	,	O
14	SIVmac239	O
15	(	O
16	T	O
17	-	O
18	lymphocyte	O
19	tropic	O
20	[	O
21	T	O
22	-	O
23	tropic	O
24	]),	O
25	SIVmac316	O
26	(	O
27	macrophage	O
28	tropic	O
29	[	O
30	M	O
31	-	O
32	tropic	O
33	]),	O
34	and	O
35	SIVmac1A11	O
36	(	O
37	dualtropic	O
38	),	O
39	were	O
40	tested	O
41	.	O

1	ISS	O
2	and	O
3	the	O
4	acute	O
5	physiology	O
6	and	O
7	chronic	O
8	health	O
9	evaluation	O
10	(	O
11	APACHE	O
12	II	O
13	)	O
14	calculated	O
15	on	O
16	admission	O
17	.	O

1	Ga	O
2	-	O
3	67	O
4	and	O
5	Tl	O
6	-	O
7	201	O
8	scintigraphy	O
9	in	O
10	extramedullary	O
11	plasmacytoma	O
12	:	O
13	a	O
14	case	O
15	report	O
16	.	O

1	Finally	O
2	,	O
3	there	O
4	are	O
5	a	O
6	growing	O
7	number	O
8	of	O
9	arguments	O
10	favouring	O
11	the	O
12	use	O
13	of	O
14	ACE	B
15	inhibitors	O
16	very	O
17	early	O
18	in	O
19	patients	O
20	with	O
21	diabetes	O
22	mellitus	O
23	.	O

1	This	O
2	paper	O
3	describes	O
4	the	O
5	results	O
6	of	O
7	an	O
8	initial	O
9	study	O
10	on	O
11	the	O
12	application	O
13	of	O
14	linear	O
15	solvation	O
16	energy	O
17	relationships	O
18	(	O
19	LSERs	O
20	)	O
21	to	O
22	the	O
23	prediction	O
24	of	O
25	internal	O
26	standard	O
27	compounds	O
28	in	O
29	reversed	O
30	-	O
31	phase	O
32	liquid	O
33	chromatographic	O
34	(	O
35	RPLC	O
36	)	O
37	method	O
38	development	O
39	.	O

1	A	O
2	38	O
3	-	O
4	year	O
5	-	O
6	old	O
7	woman	O
8	with	O
9	ulcerative	O
10	colitis	O
11	subsequently	O
12	developed	O
13	sarcoidosis	O
14	.	O

1	Blood	O
2	from	O
3	dams	O
4	was	O
5	collected	O
6	prior	O
7	to	O
8	inoculation	O
9	and	O
10	at	O
11	time	O
12	of	O
13	necropsy	O
14	for	O
15	measurement	O
16	of	O
17	IgM	O
18	and	O
19	IgG	B
20	antibodies	O
21	to	O
22	M	O
23	.	O
24	pulmonis	O
25	.	O

1	She	O
2	has	O
3	since	O
4	developed	O
5	a	O
6	positive	O
7	anti	B
8	-	I
9	cardiolipin	I
10	antibody	I
11	but	O
12	does	O
13	not	O
14	meet	O
15	diagnostic	O
16	criteria	O
17	for	O
18	systemic	O
19	lupus	O
20	erythematosis	O
21	.	O
22	CONCLUSION	O
23	:	O
24	The	O
25	presence	O
26	of	O
27	known	O
28	autoimmune	O
29	disease	O
30	in	O
31	a	O
32	woman	O
33	with	O
34	POF	O
35	should	O
36	not	O
37	dissuade	O
38	the	O
39	clinician	O
40	from	O
41	evaluating	O
42	for	O
43	a	O
44	potential	O
45	genetic	O
46	cause	O
47	.	O

1	The	O
2	mutation	O
3	experiments	O
4	showed	O
5	that	O
6	the	O
7	most	O
8	critical	O
9	sequence	O
10	for	O
11	the	O
12	repression	O
13	of	O
14	PTH	O
15	was	O
16	5	O
17	'-	O
18	GGGGGAGGGGAG	O
19	-	O
20	3	O
21	'	O
22	(+	O
23	1	O
24	to	O
25	+	O
26	12	O
27	)	O
28	of	O
29	PTHSR	O
30	.	O

1	Thus	O
2	,	O
3	while	O
4	the	O
5	folds	O
6	of	O
7	all	O
8	Myb	B
9	domains	O
10	resemble	O
11	each	O
12	other	O
13	closely	O
14	,	O
15	the	O
16	function	O
17	of	O
18	each	B
19	Myb	I
20	domain	I
21	depends	O
22	on	O
23	the	O
24	amino	O
25	acid	O
26	residues	O
27	that	O
28	are	O
29	located	O
30	on	O
31	the	O
32	surface	O
33	of	O
34	each	O
35	protein	O
36	.	O

1	A	O
2	cDNA	O
3	clone	O
4	encoding	O
5	C2H2	B
6	-	I
7	type	I
8	zinc	I
9	finger	I
10	protein	I
11	,	O
12	SCOF	B
13	-	I
14	1	I
15	,	O
16	was	O
17	isolated	O
18	from	O
19	soybean	O
20	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	evaluate	O
9	simplified	O
10	methods	O
11	for	O
12	estimation	O
13	of	O
14	Technetium	O
15	Tc	O
16	99m	O
17	(	O
18	99mTc	O
19	)-	O
20	pentetate	O
21	and	O
22	orthoiodohippurate	O
23	I	O
24	131	O
25	(	O
26	131I	O
27	-	O
28	OIH	O
29	)	O
30	plasma	O
31	clearance	O
32	in	O
33	dogs	O
34	and	O
35	cats	O
36	with	O
37	1	O
38	and	O
39	2	O
40	blood	O
41	samples	O
42	.	O

1	Sevelamer	O
2	hydrochloride	O
3	(	O
4	Renagel	O
5	)	O
6	is	O
7	a	O
8	nonabsorbed	O
9	phosphate	O
10	-	O
11	binding	O
12	polymer	O
13	marketed	O
14	for	O
15	the	O
16	treatment	O
17	of	O
18	hyperphosphatemia	O
19	in	O
20	adult	O
21	patients	O
22	receiving	O
23	hemodialysis	O
24	.	O

1	Using	O
2	a	O
3	novel	O
4	method	O
5	combining	O
6	chromatin	O
7	immunoprecipitation	O
8	and	O
9	genomic	O
10	array	O
11	hybridization	O
12	,	O
13	we	O
14	have	O
15	identified	O
16	a	O
17	460	O
18	-	O
19	kb	O
20	CENP	O
21	-	O
22	A	O
23	-	O
24	binding	O
25	DNA	O
26	domain	O
27	of	O
28	a	O
29	neocentromere	O
30	derived	O
31	from	O
32	the	O
33	20p12	O
34	region	O
35	of	O
36	an	O
37	invdup	O
38	(	O
39	20p	B
40	)	O
41	human	O
42	marker	O
43	chromosome	O
44	.	O

1	Cases	O
2	of	O
3	lung	O
4	cancer	O
5	with	O
6	intramedullary	O
7	metastasis	O
8	are	O
9	rare	O
10	,	O
11	especially	O
12	those	O
13	diagnosed	O
14	before	O
15	death	O
16	.	O

1	Direct	O
2	current	O
3	polarography	O
4	and	O
5	differential	O
6	pulse	O
7	polarographic	O
8	methods	O
9	have	O
10	been	O
11	developed	O
12	for	O
13	the	O
14	qualitative	O
15	as	O
16	well	O
17	as	O
18	quantitative	O
19	analysis	O
20	of	O
21	vitamin	O
22	B1	O
23	,	O
24	B2	O
25	and	O
26	B6	O
27	.	O

1	Fluorimetric	O
2	determination	O
3	of	O
4	methylmercury	O
5	as	O
6	an	O
7	ion	O
8	-	O
9	association	O
10	complex	O
11	with	O
12	rhodamine	O
13	B	O
14	in	O
15	the	O
16	presence	O
17	of	O
18	iodide	O
19	.	O

1	The	O
2	corresponding	O
3	genotype	O
4	was	O
5	determined	O
6	with	O
7	a	O
8	restriction	O
9	enzyme	O
10	-	O
11	based	O
12	assay	O
13	.	O

1	Patients	O
2	were	O
3	divided	O
4	into	O
5	two	O
6	group	O
7	;	O
8	Control	O
9	group	O
10	A	O
11	in	O
12	which	O
13	a	O
14	hot	O
15	-	O
16	water	O
17	circulating	O
18	system	O
19	was	O
20	used	O
21	and	O
22	group	O
23	B	O
24	in	O
25	which	O
26	a	O
27	transtracheal	O
28	heating	O
29	and	O
30	humidification	O
31	system	O
32	by	O
33	ANAMED	O
34	HUMITUBE	O
35	was	O
36	used	O
37	,	O
38	during	O
39	gastric	O
40	cancer	O
41	operation	O
42	.	O

1	Mental	O
2	rotation	O
3	of	O
4	paired	O
5	figures	O
6	engendered	B
7	activation	O
8	in	O
9	the	O
10	left	O
11	superior	O
12	parietal	O
13	lobule	O
14	and	O
15	the	O
16	right	O
17	frontal	O
18	medial	O
19	gyrus	O
20	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	Ras	B
7	-	I
8	activated	I
9	Raf	I
10	-	I
11	MEK	I
12	-	I
13	extracellular	I
14	signal	I
15	-	I
16	regulated	I
17	kinase	I
18	(	O
19	ERK	B
20	)	O
21	signaling	O
22	pathway	O
23	can	O
24	specifically	O
25	control	O
26	the	O
27	expression	O
28	of	O
29	individual	B
30	integrin	I
31	subunits	I
32	in	O
33	a	O
34	variety	O
35	of	O
36	human	O
37	and	O
38	mouse	O
39	cell	O
40	lines	O
41	.	O

1	These	O
2	TxRE	O
3	contain	O
4	cyclic	O
5	AMP	O
6	-	O
7	responsive	O
8	elements	O
9	(	O
10	CRE	O
11	),	O
12	but	O
13	,	O
14	remarkably	O
15	,	O
16	the	O
17	"	O
18	TGACGTCA	O
19	"	O
20	consensus	O
21	is	O
22	never	O
23	strictly	O
24	conserved	O
25	in	O
26	any	O
27	viral	O
28	strain	O
29	(	O
30	e	O
31	.	O
32	g	O
33	.,	O
34	AGACGTCA	O
35	,	O
36	TGACGGCA	O
37	,	O
38	TGACCTCA	O
39	).	O

1	The	O
2	hatcher	O
3	incubators	O
4	of	O
5	both	O
6	companies	O
7	were	O
8	also	O
9	persistently	O
10	contaminated	O
11	with	O
12	Salmonella	O
13	livingstone	O
14	and	O
15	Salmonella	O
16	thomasville	O
17	in	O
18	company	O
19	A	O
20	and	O
21	with	O
22	Salmonella	O
23	senftenberg	O
24	in	O
25	company	O
26	B	O
27	.	O

1	Binding	O
2	of	O
3	cell	O
4	type	O
5	-	O
6	specific	O
7	nuclear	O
8	proteins	O
9	to	O
10	the	O
11	5	O
12	'-	O
13	flanking	O
14	region	O
15	of	O
16	maize	B
17	C4	I
18	phosphoenolpyruvate	I
19	carboxylase	I
20	gene	I
21	confers	O
22	its	O
23	differential	O
24	transcription	O
25	in	O
26	mesophyll	O
27	cells	O
28	.	O

1	Susceptibility	O
2	to	O
3	ischemia	O
4	-	O
5	induced	O
6	arrhythmias	O
7	was	O
8	lower	O
9	in	O
10	1	O
11	-	O
12	week	O
13	diabetics	O
14	:	O
15	only	O
16	42	O
17	%	O
18	of	O
19	diabetic	O
20	hearts	O
21	exhibited	O
22	ventricular	O
23	tachycardia	O
24	(	O
25	VT	O
26	)	O
27	and	O
28	16	O
29	%	O
30	had	O
31	short	O
32	episodes	O
33	of	O
34	ventricular	O
35	fibrillation	O
36	(	O
37	VF	O
38	)	O
39	as	O
40	compared	O
41	to	O
42	VT	O
43	100	O
44	%	O
45	and	O
46	VF	O
47	70	O
48	%	O
49	(	O
50	including	O
51	sustained	O
52	VF	O
53	36	O
54	%)	O
55	in	O
56	the	O
57	non	O
58	-	O
59	diabetics	O
60	(	O
61	P	O
62	<	O
63	0	O
64	.	O
65	05	O
66	).	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	methodology	O
5	of	O
6	LHR	O
7	measurement	O
8	significantly	O
9	influences	O
10	the	O
11	clinical	O
12	contribution	O
13	of	O
14	Tl	O
15	-	O
16	201	O
17	lung	O
18	uptake	O
19	evaluation	O
20	.	O

1	The	O
2	authors	O
3	made	O
4	an	O
5	analysis	O
6	of	O
7	social	O
8	-	O
9	economical	O
10	conditions	O
11	limiting	O
12	the	O
13	possibilities	O
14	of	O
15	rendering	O
16	cardiosurgical	O
17	care	O
18	to	O
19	children	O
20	.	O

1	METHODS	O
2	:	O
3	Experiments	O
4	testing	O
5	the	O
6	new	O
7	catheter	O
8	and	O
9	comparing	O
10	it	O
11	to	O
12	the	O
13	existing	O
14	catheter	O
15	included	O
16	:	O
17	(	O
18	1	O
19	)	O
20	measurement	O
21	of	O
22	the	O
23	laser	O
24	output	O
25	beam	O
26	sizes	O
27	and	O
28	divergences	O
29	;	O
30	(	O
31	2	O
32	)	O
33	evaluation	O
34	of	O
35	particulate	O
36	matter	O
37	generation	O
38	during	O
39	ablation	O
40	of	O
41	atherosclerotic	O
42	tissue	O
43	;	O
44	(	O
45	3	O
46	)	O
47	measurement	O
48	of	O
49	ablation	O
50	hole	O
51	sizes	O
52	and	O
53	tissue	O
54	penetration	O
55	rates	O
56	;	O
57	(	O
58	4	O
59	)	O
60	histopathologic	O
61	examination	O
62	of	O
63	laser	O
64	-	O
65	induced	O
66	in	O
67	vivo	O
68	vessel	O
69	wall	O
70	injury	O
71	.	O

1	The	O
2	reproductive	O
3	effects	O
4	of	O
5	the	O
6	administration	O
7	of	O
8	4	O
9	-	O
10	chloro	O
11	-	O
12	2	O
13	-	O
14	methylphenoxyacetic	O
15	acid	O
16	(	O
17	MCPA	O
18	)	O
19	to	O
20	rats	O
21	were	O
22	evaluated	O
23	through	O
24	two	O
25	generations	O
26	,	O
27	from	O
28	prior	O
29	to	O
30	mating	O
31	,	O
32	throughout	O
33	mating	O
34	,	O
35	to	O
36	gestation	O
37	and	O
38	lactation	O
39	.	O

1	Here	O
2	we	O
3	suggest	O
4	that	O
5	uvrA	O
6	and	O
7	the	O
8	nucleotide	O
9	excision	O
10	repair	O
11	pathway	O
12	are	O
13	involved	O
14	in	O
15	the	O
16	repair	O
17	of	O
18	acid	O
19	-	O
20	induced	O
21	DNA	O
22	damage	O
23	and	O
24	are	O
25	associated	O
26	with	O
27	successful	O
28	adaptation	O
29	of	O
30	S	O
31	.	O
32	mutans	O
33	to	O
34	low	O
35	pH	O
36	.	O

1	The	O
2	improved	O
3	CSF	O
4	outflow	O
5	conductance	O
6	may	O
7	increase	O
8	the	O
9	intracranial	O
10	compliance	O
11	and	O
12	thereby	O
13	dampen	O
14	a	O
15	pathological	O
16	ICP	O
17	waveform	O
18	.	O

1	These	O
2	studies	O
3	demonstrate	O
4	that	O
5	site	O
6	-	O
7	specific	O
8	recognition	O
9	of	O
10	the	O
11	bxd	O
12	PRE	O
13	by	O
14	d	O
15	(	O
16	GA	O
17	)(	O
18	n	O
19	)	O
20	repeat	O
21	binding	O
22	activities	O
23	mediates	O
24	PcG	O
25	-	O
26	dependent	O
27	silencing	O
28	.	O

1	The	O
2	gonadotrope	O
3	-	O
4	specific	O
5	and	O
6	regulated	O
7	expression	O
8	of	O
9	the	O
10	GnRH	B
11	receptor	I
12	(	O
13	GnRH	B
14	-	I
15	R	I
16	)	I
17	gene	I
18	is	O
19	dependent	O
20	on	O
21	multiple	O
22	transcription	O
23	factors	O
24	that	O
25	interact	O
26	with	O
27	the	O
28	noncanonical	O
29	GnRH	B
30	-	I
31	R	I
32	activating	I
33	sequence	I
34	(	O
35	GRAS	O
36	),	O
37	the	O
38	activator	B
39	protein	I
40	-	I
41	1	I
42	(	O
43	AP	B
44	-	I
45	1	I
46	)	O
47	element	O
48	,	O
49	and	O
50	the	O
51	steroidogenic	B
52	factor	I
53	-	I
54	1	I
55	(	O
56	SF	B
57	-	I
58	1	I
59	)	O
60	binding	O
61	site	O
62	.	O

1	Before	O
2	PO3	O
3	administration	O
4	,	O
5	more	O
6	than	O
7	half	O
8	(	O
9	57	O
10	.	O
11	4	O
12	%)	O
13	of	O
14	the	O
15	patients	O
16	received	O
17	only	O
18	1	O
19	or	O
20	2	O
21	antituberculous	O
22	drugs	O
23	(	O
24	ethambutole	O
25	and	O
26	ethionamide	O
27	or	O
28	ethambutole	O
29	and	O
30	oprofloxacin	O
31	).	O

1	Using	O
2	the	O
3	presented	O
4	categorical	O
5	structure	O
6	as	O
7	domain	O
8	model	O
9	a	O
10	prototype	O
11	DSS	O
12	for	O
13	dipslide	O
14	urine	O
15	cultures	O
16	has	O
17	been	O
18	developed	O
19	.	O

1	Conclusion	O
2	:	O
3	The	O
4	Lp	O
5	(	O
6	a	O
7	)	O
8	levels	O
9	in	O
10	these	O
11	children	O
12	were	O
13	the	O
14	lower	O
15	ever	O
16	reported	O
17	.	O

1	Foxp1	O
2	and	O
3	Foxp2	B
4	are	O
5	expressed	O
6	at	O
7	high	O
8	levels	O
9	in	O
10	the	O
11	lung	O
12	as	O
13	early	O
14	as	O
15	E12	B
16	.	O
17	5	O
18	of	O
19	mouse	O
20	development	O
21	with	O
22	Foxp2	O
23	expression	O
24	restricted	O
25	to	O
26	the	O
27	airway	O
28	epithelium	O
29	.	O

1	Audiological	O
2	findings	O
3	in	O
4	pregnancy	O
5	.	O

1	Children	O
2	who	O
3	developed	O
4	lower	O
5	respiratory	O
6	tract	O
7	infections	O
8	or	O
9	PCP	O
10	had	O
11	increased	O
12	rates	O
13	of	O
14	decline	O
15	of	O
16	CD4	B
17	cell	O
18	counts	O
19	during	O
20	the	O
21	first	O
22	6	O
23	months	O
24	of	O
25	life	O
26	.	O

1	A	O
2	randomized	O
3	mix	O
4	of	O
5	180	O
6	sections	O
7	(	O
8	10	O
9	samples	O
10	x	O
11	3	O
12	tissues	O
13	x	O
14	3	O
15	stains	O
16	x	O
17	2	O
18	)	O
19	gave	O
20	90	O
21	matched	O
22	pairs	O
23	.	O

1	Sural	O
2	nerve	O
3	biopsy	O
4	showed	O
5	mild	O
6	thickening	O
7	of	O
8	the	O
9	perineurium	O
10	,	O
11	vascular	O
12	alterations	O
13	with	O
14	inflammatory	O
15	cell	O
16	infiltration	O
17	in	O
18	the	O
19	perineurium	O
20	,	O
21	and	O
22	remarkable	O
23	loss	O
24	of	O
25	large	O
26	and	O
27	small	O
28	myelinated	O
29	fibers	O
30	.	O

1	OBJECTIVES	O
2	:	O
3	The	O
4	objective	O
5	of	O
6	this	O
7	review	O
8	was	O
9	to	O
10	assess	O
11	the	O
12	effects	O
13	of	O
14	prophylactic	O
15	prostaglandin	O
16	use	O
17	in	O
18	the	O
19	third	O
20	stage	O
21	of	O
22	labour	B
23	.	O

1	Testing	O
2	was	O
3	associated	O
4	with	O
5	a	O
6	history	O
7	of	O
8	nonsexual	O
9	risk	O
10	behavior	O
11	,	O
12	increased	O
13	knowledge	O
14	of	O
15	the	O
16	hepatitis	O
17	C	O
18	virus	O
19	,	O
20	and	O
21	healthcare	O
22	provider	O
23	communication	O
24	.	O

1	Cytomegalovirus	O
2	,	O
3	Chlamydia	O
4	pneumoniae	O
5	,	O
6	and	O
7	Helicobacter	O
8	pylori	O
9	IgG	B
10	antibodies	I
11	and	O
12	restenosis	O
13	after	O
14	stent	O
15	implantation	O
16	:	O
17	an	O
18	angiographic	O
19	and	O
20	intravascular	O
21	ultrasound	O
22	study	O
23	.	O

1	A	O
2	5	O
3	-	O
4	month	O
5	-	O
6	old	O
7	infant	O
8	with	O
9	persistent	O
10	congenital	O
11	stridor	O
12	and	O
13	acute	O
14	respiratory	O
15	distress	O
16	is	O
17	presented	O
18	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	whether	O
6	RSTD	O
7	predicts	O
8	coronary	O
9	anatomy	O
10	during	O
11	acute	O
12	coronary	O
13	occlusion	O
14	.	O

1	Even	O
2	if	O
3	the	O
4	electrocardiographic	O
5	signs	O
6	are	O
7	subdued	O
8	,	O
9	the	O
10	underlying	O
11	blockade	O
12	of	O
13	I	O
14	(	O
15	Kr	O
16	)	O
17	current	O
18	may	O
19	precipitate	O
20	the	O
21	occurrence	O
22	of	O
23	arrhythmia	O
24	.	O

1	Acetoin	O
2	can	O
3	be	O
4	reused	O
5	by	O
6	the	O
7	bacteria	O
8	during	O
9	stationary	O
10	phase	O
11	when	O
12	other	O
13	carbon	O
14	sources	O
15	have	O
16	been	O
17	depleted	O
18	.	O

1	Analysis	O
2	of	O
3	the	O
4	promoter	O
5	sequence	O
6	revealed	O
7	the	O
8	presence	O
9	of	O
10	a	O
11	major	O
12	transcriptional	O
13	start	O
14	site	O
15	,	O
16	a	O
17	canonical	O
18	TATA	O
19	box	O
20	and	O
21	putative	O
22	cis	O
23	regulatory	O
24	elements	O
25	for	O
26	pituitary	O
27	specific	O
28	expression	O
29	as	O
30	well	O
31	as	O
32	an	O
33	E	O
34	-	O
35	responsive	O
36	element	O
37	.	O

1	IL	B
2	-	I
3	1beta	I
4	was	O
5	significantly	O
6	higher	O
7	in	O
8	endometrioma	O
9	than	O
10	in	O
11	lesions	O
12	of	O
13	other	O
14	localizations	O
15	.	O

1	An	O
2	economic	O
3	analysis	O
4	using	O
5	West	O
6	of	O
7	Scotland	O
8	Coronary	O
9	Prevention	O
10	Study	O
11	(	O
12	WOSCOPS	O
13	)	O
14	findings	O
15	indicates	O
16	that	O
17	statin	O
18	treatment	O
19	would	O
20	have	O
21	prevented	O
22	318	O
23	events	O
24	per	O
25	10	O
26	,	O
27	000	O
28	patients	O
29	in	O
30	a	O
31	population	O
32	similar	O
33	to	O
34	that	O
35	in	O
36	WOSCOPS	O
37	(	O
38	average	O
39	1	O
40	.	O
41	5	O
42	%	O
43	annual	O
44	risk	O
45	of	O
46	a	O
47	cardiovascular	O
48	event	O
49	)	O
50	at	O
51	a	O
52	discounted	O
53	cost	O
54	per	O
55	life	O
56	-	O
57	year	O
58	gained	O
59	of	O
60	20	O
61	,	O
62	375	O
63	pounds	O
64	($	O
65	31	O
66	,	O
67	818	O
68	).	O

1	Hydrogels	O
2	for	O
3	tissue	O
4	engineering	O
5	.	O

1	No	O
2	mutation	O
3	of	O
4	the	O
5	NRL	B
6	gene	I
7	was	O
8	found	O
9	in	O
10	any	O
11	of	O
12	the	O
13	two	O
14	families	O
15	.	O

1	However	O
2	,	O
3	most	O
4	produced	O
5	significant	O
6	alteration	O
7	of	O
8	small	O
9	intestinal	O
10	permeability	O
11	.	O

1	Our	O
2	results	O
3	show	O
4	that	O
5	CVN	O
6	specifically	O
7	recognizes	O
8	with	O
9	nanomolar	O
10	affinity	O
11	Man	O
12	(	O
13	9	O
14	)	O
15	GlcNAc	O
16	(	O
17	2	O
18	)	O
19	and	O
20	the	O
21	D1D3	O
22	isomer	O
23	of	O
24	Man	O
25	(	O
26	8	O
27	)	O
28	GlcNAc	O
29	(	O
30	2	O
31	).	O

1	Saccharomyces	O
2	cerevisiae	O
3	activates	O
4	a	O
5	regulatory	O
6	network	O
7	called	O
8	"	O
9	general	O
10	control	O
11	"	O
12	that	O
13	provides	O
14	the	O
15	cell	O
16	with	O
17	sufficient	O
18	amounts	O
19	of	O
20	protein	O
21	precursors	O
22	during	O
23	amino	O
24	acid	O
25	starvation	O
26	.	O

1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	,	O
5	entry	O
6	into	O
7	mitosis	O
8	requires	O
9	activation	O
10	of	O
11	the	O
12	cyclin	B
13	-	I
14	dependent	I
15	kinase	I
16	Cdc28	I
17	in	O
18	its	O
19	cyclin	B
20	B	I
21	(	O
22	Clb	O
23	)-	O
24	associated	O
25	form	O
26	.	O

1	Data	O
2	from	O
3	in	O
4	vitro	O
5	splicing	O
6	assays	O
7	,	O
8	UV	O
9	crosslinking	O
10	and	O
11	RNA	O
12	-	O
13	binding	O
14	competition	O
15	experiments	O
16	indicates	O
17	a	O
18	strong	O
19	correlation	O
20	between	O
21	the	O
22	binding	O
23	affinities	O
24	of	O
25	PSI	O
26	for	O
27	the	O
28	SELEX	O
29	sequences	O
30	and	O
31	their	O
32	ability	O
33	to	O
34	modulate	O
35	splicing	O
36	of	O
37	P	B
38	element	I
39	IVS3	I
40	in	O
41	vitro	O
42	.	O

1	The	O
2	sensitivity	O
3	of	O
4	human	O
5	neuroblastoma	O
6	cells	O
7	SK	O
8	-	O
9	N	O
10	-	O
11	SH	O
12	to	O
13	undergo	O
14	apoptosis	O
15	induced	O
16	by	O
17	thapsigargin	O
18	was	O
19	examined	O
20	.	O

1	A	O
2	.,	O
3	Slatkin	O
4	,	O
5	D	O
6	.	O

1	Multiparous	O
2	women	O
3	presented	O
4	higher	O
5	BMI	O
6	(	O
7	P	O
8	=	O
9	0	O
10	.	O
11	01	O
12	)	O
13	and	O
14	PBF	O
15	(	O
16	P	O
17	=	O
18	0	O
19	.	O
20	03	O
21	)	O
22	compared	O
23	with	O
24	primi	O
25	-	O
26	and	O
27	nulliparous	O
28	groups	O
29	.	O

1	CONCLUSIONS	O
2	AND	O
3	CLINICAL	O
4	RELEVANCE	O
5	:	O
6	Increased	O
7	cortical	O
8	thickness	O
9	and	O
10	geometric	O
11	properties	O
12	of	O
13	left	O
14	MCB	O
15	-	O
16	IV	O
17	and	O
18	-	O
19	V	O
20	of	O
21	Greyhounds	O
22	,	O
23	together	O
24	with	O
25	altered	O
26	turnover	O
27	and	O
28	orientation	O
29	of	O
30	osteons	O
31	in	O
32	the	O
33	dorsal	O
34	quadrants	O
35	of	O
36	left	O
37	MCB	O
38	,	O
39	are	O
40	site	O
41	-	O
42	specific	O
43	adaptive	O
44	responses	O
45	associated	O
46	with	O
47	asymmetric	O
48	cyclic	O
49	loading	O
50	as	O
51	a	O
52	result	O
53	of	O
54	racing	O
55	on	O
56	circular	O
57	tracks	O
58	.	O

1	To	O
2	examine	O
3	transcriptional	O
4	regulation	O
5	of	O
6	the	O
7	rat	B
8	eIF4E	I
9	gene	I
10	,	O
11	2	O
12	.	O
13	1	O
14	kB	O
15	of	O
16	the	O
17	rat	B
18	eIF4E	I
19	promoter	I
20	region	O
21	was	O
22	cloned	O
23	and	O
24	the	O
25	contribution	O
26	of	O
27	specific	O
28	elements	O
29	in	O
30	regulating	O
31	transcription	O
32	was	O
33	determined	O
34	in	O
35	primary	O
36	cultures	O
37	of	O
38	rat	O
39	cardiocytes	O
40	and	O
41	in	O
42	a	O
43	murine	O
44	C	O
45	(	O
46	2	O
47	)	O
48	C	O
49	(	O
50	12	O
51	)	O
52	myoblast	O
53	cell	O
54	line	O
55	.	O

1	The	O
2	prevalence	O
3	of	O
4	tobacco	O
5	dependence	O
6	diagnosed	O
7	according	O
8	to	O
9	the	O
10	ICD	O
11	-	O
12	10	O
13	criteria	O
14	was	O
15	higher	O
16	in	O
17	alcohol	O
18	-	O
19	dependent	O
20	individuals	O
21	(	O
22	58	O
23	.	O
24	1	O
25	%)	O
26	than	O
27	in	O
28	nondrinkers	O
29	or	O
30	social	O
31	drinkers	O
32	(	O
33	12	O
34	.	O
35	8	O
36	%).	O

1	Management	O
2	of	O
3	postvitrectomy	O
4	diabetic	O
5	vitreous	O
6	hemorrhage	O
7	with	O
8	tissue	B
9	plasminogen	I
10	activator	I
11	(	O
12	t	B
13	-	I
14	PA	I
15	)	O
16	and	O
17	volume	O
18	homeostatic	O
19	fluid	O
20	-	O
21	fluid	O
22	exchanger	O
23	.	O

1	Transactivation	O
2	of	O
3	oIFNtau	B
4	enhancer	O
5	-	O
6	reporter	O
7	constructs	O
8	was	O
9	primarily	O
10	regulated	O
11	by	O
12	three	O
13	regions	O
14	containing	O
15	AP	B
16	-	I
17	1	I
18	site	I
19	,	O
20	GATA	B
21	like	I
22	sequence	I
23	and	O
24	site	O
25	(	O
26	s	O
27	)	O
28	unidentified	O
29	.	O

1	SELECTION	O
2	CRITERIA	O
3	:	O
4	Randomised	O
5	controlled	O
6	trials	O
7	of	O
8	cabergoline	O
9	versus	O
10	placebo	O
11	in	O
12	patients	O
13	with	O
14	a	O
15	clinical	O
16	diagnosis	O
17	of	O
18	idiopathic	O
19	Parkinson	O
20	'	O
21	s	O
22	disease	O
23	and	O
24	long	O
25	-	O
26	term	O
27	complications	O
28	of	O
29	levodopa	O
30	therapy	O
31	.	O

1	0	O
2	%)	O
3	and	O
4	IL	B
5	-	I
6	12	I
7	(	O
8	42	O
9	.	O
10	6	O
11	%	O
12	vs	O
13	.	O

1	Copyright	O
2	2000	O
3	John	O
4	Wiley	O
5	&	O
6	Sons	O
7	,	O
8	Ltd	O
9	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	native	O
6	MRCK	O
7	exists	O
8	in	O
9	high	O
10	-	O
11	molecular	O
12	-	O
13	weight	O
14	complexes	O
15	.	O

1	METHODS	O
2	:	O
3	This	O
4	retrospective	O
5	review	O
6	comprised	O
7	2711	O
8	eyes	O
9	that	O
10	had	O
11	LASIK	O
12	between	O
13	September	O
14	1996	O
15	and	O
16	September	O
17	1999	O
18	.	O

1	Sixty	O
2	-	O
3	one	O
4	cases	O
5	of	O
6	cholera	O
7	,	O
8	all	O
9	caused	O
10	by	O
11	V	O
12	.	O
13	cholerae	O
14	O1	O
15	,	O
16	were	O
17	reported	O
18	.	O

1	This	O
2	could	O
3	lead	O
4	to	O
5	subsequent	O
6	outbreaks	O
7	if	O
8	Babesia	O
9	carrier	O
10	animals	O
11	were	O
12	to	O
13	be	O
14	introduced	O
15	into	O
16	the	O
17	herd	O
18	.	O

1	Instead	O
2	,	O
3	TRPS1	O
4	potently	O
5	and	O
6	specifically	O
7	represses	O
8	transcriptional	O
9	activation	O
10	mediated	O
11	by	O
12	other	O
13	GATA	B
14	factors	I
15	.	O

1	Eliminating	O
2	any	O
3	subset	O
4	of	O
5	ASCUS	O
6	reduces	O
7	the	O
8	ASCUS	O
9	/	O
10	SIL	O
11	ratio	O
12	but	O
13	also	O
14	significantly	O
15	diminishes	O
16	the	O
17	sensitivity	O
18	of	O
19	the	O
20	Papanicolaou	O
21	test	O
22	.	O

1	In	O
2	order	O
3	to	O
4	overcome	O
5	the	O
6	false	O
7	positive	O
8	readings	O
9	that	O
10	are	O
11	possible	O
12	in	O
13	sphincter	O
14	manometry	O
15	,	O
16	we	O
17	proposed	O
18	to	O
19	use	O
20	secretin	O
21	stimulated	O
22	endoscopic	O
23	ultrasound	O
24	(	O
25	SSEUS	O
26	)	O
27	to	O
28	measure	O
29	pancreatic	O
30	ductal	O
31	response	O
32	as	O
33	an	O
34	adjunctive	O
35	method	O
36	to	O
37	aid	O
38	and	O
39	supplement	O
40	the	O
41	diagnosis	O
42	.	O

1	Endovascular	O
2	aneurysm	O
3	repair	O
4	with	O
5	the	O
6	AneuRx	O
7	stent	O
8	-	O
9	graft	O
10	is	O
11	safe	O
12	,	O
13	but	O
14	is	O
15	it	O
16	effective	O
17	?	O

1	The	O
2	difference	O
3	of	O
4	hardness	O
5	over	O
6	time	O
7	of	O
8	composite	O
9	specimens	O
10	was	O
11	measured	O
12	using	O
13	Knoop	O
14	hardness	O
15	measurements	O
16	taken	O
17	at	O
18	the	O
19	top	O
20	and	O
21	bottom	O
22	surfaces	O
23	of	O
24	resin	O
25	specimens	O
26	made	O
27	in	O
28	a	O
29	Teflon	O
30	mold	O
31	the	O
32	same	O
33	dimensions	O
34	as	O
35	the	O
36	cavity	O
37	prepared	O
38	in	O
39	dentin	O
40	.	O

1	Implications	O
2	in	O
3	biomonitoring	O
4	of	O
5	the	O
6	observed	O
7	accumulation	O
8	patterns	O
9	,	O
10	especially	O
11	in	O
12	the	O
13	different	O
14	tissues	O
15	of	O
16	Posidonia	O
17	oceanica	O
18	,	O
19	are	O
20	discussed	O
21	.	O

1	Based	O
2	on	O
3	mutational	O
4	data	O
5	and	O
6	possible	O
7	mRNA	O
8	structure	O
9	,	O
10	we	O
11	hypothesized	O
12	about	O
13	the	O
14	effect	O
15	of	O
16	mRNA	O
17	structure	O
18	on	O
19	translation	O
20	of	O
21	the	O
22	two	O
23	major	O
24	C	O
25	/	O
26	EBPepsilon	O
27	isoforms	O
28	:	O
29	p32	B
30	and	O
31	p30	B
32	.	O

1	Retinoids	O
2	participate	O
3	in	O
4	the	O
5	onset	O
6	of	O
7	differentiation	O
8	,	O
9	apoptosis	O
10	and	O
11	the	O
12	inhibition	O
13	of	O
14	growth	O
15	in	O
16	a	O
17	wide	O
18	variety	O
19	of	O
20	normal	O
21	and	O
22	cancerous	O
23	cells	O
24	.	O

1	We	O
2	conclude	O
3	that	O
4	RPMS	O
5	acts	O
6	as	O
7	a	O
8	negative	O
9	regulator	O
10	of	O
11	EBNA2	B
12	and	O
13	Notch	B
14	activity	O
15	through	O
16	its	O
17	interactions	O
18	with	O
19	the	O
20	CBF1	B
21	-	O
22	associated	O
23	corepressor	O
24	complex	O
25	.	O

1	Isolated	O
2	Systolic	O
3	Hypertension	O
4	:	O
5	An	O
6	Update	O
7	.	O

1	Transfection	O
2	of	O
3	EGFP	O
4	-	O
5	tagged	O
6	DENTT	O
7	NLS	O
8	deletion	O
9	constructs	O
10	lacking	O
11	the	O
12	bipartite	O
13	NLS	O
14	-	O
15	1	O
16	were	O
17	excluded	O
18	from	O
19	the	O
20	nucleolus	O
21	.	O

1	VE	O
2	-	O
3	DEF	O
4	animals	O
5	had	O
6	significantly	O
7	higher	O
8	(	O
9	p	O
10	<	O
11	0	O
12	.	O
13	05	O
14	)	O
15	levels	O
16	of	O
17	myocardial	O
18	lipid	O
19	peroxidation	O
20	and	O
21	lower	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	)	O
29	protein	O
30	thiols	O
31	following	O
32	I	O
33	-	O
34	R	O
35	compared	O
36	to	O
37	the	O
38	CON	O
39	animals	O
40	.	O

1	The	O
2	position	O
3	of	O
4	the	O
5	analyst	O
6	as	O
7	expert	O
8	:	O
9	yesterday	O
10	and	O
11	today	O
12	.	O

1	Furthermore	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	ERSF	O
7	including	O
8	NF	B
9	-	I
10	Y	I
11	and	O
12	ATF6alpha	O
13	and	O
14	/	O
15	or	O
16	beta	O
17	and	O
18	capable	O
19	of	O
20	binding	O
21	to	O
22	ERSE	O
23	is	O
24	indeed	O
25	formed	O
26	when	O
27	the	O
28	cellular	O
29	UPR	O
30	is	O
31	activated	O
32	.	O

1	We	O
2	performed	O
3	the	O
4	present	O
5	study	O
6	to	O
7	clarify	O
8	the	O
9	relationship	O
10	between	O
11	the	O
12	DOX	O
13	binding	O
14	ability	O
15	(%	O
16	DB	O
17	)	O
18	and	O
19	the	O
20	histologic	O
21	response	O
22	,	O
23	rate	O
24	of	O
25	decrease	O
26	in	O
27	tumor	O
28	volume	O
29	of	O
30	malignant	O
31	soft	O
32	tissue	O
33	tumors	O
34	after	O
35	preoperative	O
36	chemotherapy	O
37	and	O
38	prognosis	O
39	.	O

1	We	O
2	have	O
3	also	O
4	isolated	O
5	and	O
6	analyzed	O
7	the	O
8	5	O
9	'	O
10	flanking	O
11	region	O
12	of	O
13	the	O
14	pea	B
15	33RNP	I
16	gene	I
17	.	O

1	We	O
2	have	O
3	previously	O
4	shown	O
5	that	O
6	the	O
7	adenoviral	B
8	12S	I
9	E1A	I
10	protein	I
11	modulates	O
12	the	O
13	phosphorylation	O
14	status	O
15	of	O
16	p130	B
17	and	O
18	p107	B
19	without	O
20	apparent	O
21	changes	O
22	in	O
23	the	O
24	cell	O
25	cycle	O
26	dependent	O
27	phosphorylation	O
28	of	O
29	the	O
30	retinoblastoma	B
31	protein	I
32	.	O

1	Baseline	O
2	MBF	O
3	in	O
4	females	O
5	was	O
6	significantly	O
7	(	O
8	P	O
9	<	O
10	0	O
11	.	O
12	001	O
13	)	O
14	higher	O
15	than	O
16	in	O
17	males	O
18	.	O

1	Only	O
2	nine	O
3	patients	O
4	were	O
5	offered	O
6	surgery	O
7	(	O
8	six	O
9	were	O
10	resected	O
11	and	O
12	three	O
13	were	O
14	found	O
15	inoperable	O
16	).	O

1	The	O
2	deubiquitinating	O
3	enzyme	O
4	DUB	O
5	-	O
6	2	O
7	is	O
8	induced	O
9	in	O
10	response	O
11	to	O
12	IL	B
13	-	I
14	2	I
15	but	O
16	as	O
17	yet	O
18	its	O
19	function	O
20	has	O
21	not	O
22	been	O
23	determined	O
24	.	O

1	A	O
2	split	O
3	motor	O
4	domain	O
5	in	O
6	a	O
7	cytoplasmic	O
8	dynein	O
9	.	O

1	Immunological	O
2	and	O
3	biochemical	O
4	characterization	O
5	of	O
6	streptococcal	O
7	pyrogenic	O
8	exotoxins	O
9	I	O
10	and	O
11	J	O
12	(	O
13	SPE	O
14	-	O
15	I	O
16	and	O
17	SPE	O
18	-	O
19	J	O
20	)	O
21	from	O
22	Streptococcus	O
23	pyogenes	O
24	.	O

1	Five	O
2	modalities	O
3	of	O
4	nonpharmacologic	O
5	approaches	O
6	are	O
7	recommended	O
8	at	O
9	present	O
10	for	O
11	lifestyle	O
12	modification	O
13	and	O
14	control	O
15	of	O
16	arterial	O
17	blood	O
18	pressure	O
19	elevation	O
20	:	O
21	1	O
22	)	O
23	weight	O
24	reduction	O
25	to	O
26	ideal	O
27	body	O
28	weight	O
29	,	O
30	since	O
31	it	O
32	reduces	O
33	risk	O
34	of	O
35	hypertension	O
36	as	O
37	well	O
38	as	O
39	overall	O
40	cardiovascular	O
41	morbidity	O
42	and	O
43	mortality	O
44	;	O
45	2	O
46	)	O
47	dietary	O
48	sodium	O
49	restriction	O
50	to	O
51	less	O
52	than	O
53	2	O
54	g	O
55	a	O
56	day	O
57	,	O
58	without	O
59	assurance	O
60	that	O
61	it	O
62	will	O
63	normalize	O
64	arterial	O
65	pressure	O
66	although	O
67	it	O
68	may	O
69	help	O
70	reduce	O
71	dosage	O
72	and	O
73	numbers	O
74	of	O
75	prescribed	O
76	antihypertensive	O
77	drugs	O
78	;	O
79	3	O
80	)	O
81	moderation	O
82	of	O
83	alcohol	O
84	consumption	O
85	to	O
86	less	O
87	than	O
88	1	O
89	ounce	O
90	a	O
91	day	O
92	;	O
93	4	O
94	)	O
95	a	O
96	regular	O
97	isotonic	O
98	exercise	O
99	program	O
100	;	O
101	and	O
102	5	O
103	)	O
104	cessation	O
105	of	O
106	tobacco	O
107	consumption	O
108	.	O

1	Descriptions	O
2	of	O
3	this	O
4	locus	O
5	would	O
6	allow	O
7	comparison	O
8	with	O
9	functionally	O
10	relevant	O
11	molecular	O
12	genetic	O
13	features	O
14	of	O
15	other	O
16	species	O
17	'	O
18	homologous	O
19	loci	O
20	including	O
21	the	O
22	single	O
23	-	O
24	copy	O
25	equid	O
26	LH	B
27	/	I
28	CGbeta	I
29	gene	I
30	and	O
31	the	O
32	primate	O
33	LHbeta	B
34	-	I
35	CGbeta	I
36	gene	I
37	cluster	I
38	locus	I
39	.	O

1	METHODS	O
2	:	O
3	One	O
4	hundred	O
5	fourteen	O
6	consecutive	O
7	patients	O
8	(	O
9	mean	O
10	age	O
11	61	O
12	years	O
13	)	O
14	with	O
15	focal	O
16	pancreatic	O
17	masses	O
18	,	O
19	detected	O
20	on	O
21	CT	O
22	,	O
23	underwent	O
24	EUS	O
25	-	O
26	FNA	O
27	by	O
28	using	O
29	a	O
30	linear	O
31	-	O
32	array	O
33	echoendoscope	O
34	and	O
35	22	O
36	-	O
37	gauge	O
38	needles	O
39	.	O

1	The	O
2	effects	O
3	of	O
4	chlordiazepoxide	O
5	(	O
6	2	O
7	.	O
8	5	O
9	-	O
10	15	O
11	.	O
12	0mg	O
13	/	O
14	kg	O
15	),	O
16	a	O
17	full	O
18	benzodiazepine	O
19	receptor	O
20	agonist	O
21	,	O
22	and	O
23	bretazenil	O
24	(	O
25	5	O
26	.	O
27	0	O
28	-	O
29	30	O
30	.	O
31	0mg	O
32	/	O
33	kg	O
34	),	O
35	a	O
36	partial	O
37	benzodiazepine	O
38	receptor	O
39	agonist	O
40	,	O
41	were	O
42	examined	O
43	in	O
44	the	O
45	murine	O
46	elevated	O
47	plus	O
48	-	O
49	maze	O
50	paradigm	O
51	.	O

1	Acute	O
2	effects	O
3	of	O
4	LI	O
5	160	O
6	(	O
7	extract	O
8	of	O
9	Hypericum	O
10	perforatum	O
11	,	O
12	St	O
13	John	O
14	'	O
15	s	O
16	wort	O
17	)	O
18	and	O
19	two	O
20	of	O
21	its	O
22	constituents	O
23	on	O
24	neuroendocrine	O
25	responses	O
26	in	O
27	the	O
28	rat	O
29	.	O

1	Guidelines	O
2	for	O
3	performing	O
4	a	O
5	routine	O
6	spiral	O
7	assay	O
8	are	O
9	presented	O
10	,	O
11	and	O
12	alternative	O
13	test	O
14	methods	O
15	intended	O
16	to	O
17	overcome	O
18	a	O
19	variety	O
20	of	O
21	technical	O
22	difficulties	O
23	(	O
24	such	O
25	as	O
26	restricted	O
27	sample	O
28	availability	O
29	,	O
30	sample	O
31	viscosity	O
32	or	O
33	volatility	O
34	,	O
35	etc	O
36	.)	O
37	are	O
38	recommended	O
39	.	O

1	An	O
2	additional	O
3	9	O
4	patients	O
5	achieved	O
6	normal	O
7	levels	O
8	with	O
9	adjunctive	O
10	drug	O
11	therapy	O
12	.	O

1	Anti	O
2	-	O
3	nucleolin	O
4	mAb	O
5	was	O
6	used	O
7	to	O
8	confirm	O
9	the	O
10	antigenic	O
11	properties	O
12	of	O
13	this	O
14	p95	O
15	component	O
16	.	O

1	Eliminating	O
2	any	O
3	subset	O
4	of	O
5	ASCUS	O
6	reduces	O
7	the	O
8	ASCUS	O
9	/	O
10	SIL	O
11	ratio	O
12	but	O
13	also	O
14	significantly	O
15	diminishes	O
16	the	O
17	sensitivity	O
18	of	O
19	the	O
20	Papanicolaou	O
21	test	O
22	.	O

1	Prrp	B
2	can	O
3	also	O
4	associate	O
5	with	O
6	the	O
7	EVH1	O
8	domain	O
9	of	O
10	Mena	B
11	,	O
12	another	O
13	microfilament	O
14	-	O
15	associated	O
16	protein	O
17	.	O

1	Experience	O
2	with	O
3	xylene	O
4	-	O
5	free	O
6	sections	O
7	since	O
8	1995	O
9	at	O
10	the	O
11	Vrinnevi	O
12	Hospital	O
13	is	O
14	favorable	O
15	.	O

1	Acquired	O
2	antithrombin	B
3	deficiency	O
4	in	O
5	sepsis	O
6	.	O

1	SIP1	B
2	(	O
3	Smad	B
4	interacting	I
5	protein	I
6	1	I
7	)	O
8	and	O
9	deltaEF1	O
10	(	O
11	delta	B
12	-	I
13	crystallin	I
14	enhancer	I
15	binding	I
16	factor	I
17	)	O
18	are	O
19	structurally	O
20	similar	O
21	transcriptional	O
22	repressors	O
23	.	O

1	SERS	O
2	spectra	O
3	were	O
4	obtained	O
5	by	O
6	vacuum	O
7	evaporation	O
8	and	O
9	casting	O
10	of	O
11	p	O
12	-	O
13	NTP	O
14	onto	O
15	silver	O
16	island	O
17	films	O
18	,	O
19	and	O
20	also	O
21	from	O
22	colloidal	O
23	silver	O
24	solutions	O
25	.	O

1	The	O
2	moduli	O
3	of	O
4	elasticity	O
5	of	O
6	the	O
7	gray	O
8	and	O
9	white	O
10	matter	O
11	were	O
12	3	O
13	.	O
14	4	O
15	+/-	O
16	1	O
17	.	O
18	4	O
19	kPa	O
20	(	O
21	mean	O
22	+/-	O
23	standard	O
24	deviation	O
25	)	O
26	and	O
27	3	O
28	.	O
29	4	O
30	+/-	O
31	0	O
32	.	O
33	9	O
34	kPa	O
35	in	O
36	the	O
37	axial	O
38	section	O
39	,	O
40	3	O
41	+/-	O
42	0	O
43	.	O
44	3	O
45	kPa	O
46	and	O
47	3	O
48	.	O
49	5	O
50	+/-	O
51	0	O
52	.	O
53	5	O
54	kPa	O
55	in	O
56	the	O
57	frontal	O
58	section	O
59	,	O
60	and	O
61	3	O
62	.	O
63	5	O
64	+/-	O
65	0	O
66	.	O
67	9	O
68	kPa	O
69	and	O
70	2	O
71	.	O
72	8	O
73	+/-	O
74	0	O
75	.	O
76	4	O
77	kPa	O
78	in	O
79	the	O
80	sagittal	O
81	section	O
82	,	O
83	respectively	O
84	.	O

1	[	O
2	Clinical	O
3	and	O
4	epidemiological	O
5	characteristics	O
6	of	O
7	squamous	O
8	cell	O
9	carcinoma	O
10	of	O
11	the	O
12	oral	O
13	cavity	O
14	in	O
15	women	O
16	]	O
17	BACKGROUND	O
18	:	O
19	Squamous	O
20	cell	O
21	carcinoma	O
22	(	O
23	SCC	O
24	)	O
25	of	O
26	the	O
27	oral	O
28	cavity	O
29	occurs	O
30	mainly	O
31	in	O
32	the	O
33	male	O
34	population	O
35	.	O

1	The	O
2	core	O
3	promoter	O
4	of	O
5	human	B
6	thioredoxin	I
7	reductase	I
8	1	I
9	:	O
10	cloning	O
11	,	O
12	transcriptional	O
13	activity	O
14	,	O
15	and	O
16	Oct	B
17	-	I
18	1	I
19	,	O
20	Sp1	B
21	,	O
22	and	O
23	Sp3	B
24	binding	O
25	reveal	O
26	a	O
27	housekeeping	O
28	-	O
29	type	O
30	promoter	O
31	for	O
32	the	O
33	AU	O
34	-	O
35	rich	O
36	element	O
37	-	O
38	regulated	O
39	gene	O
40	.	O

1	Phase	O
2	II	O
3	trial	O
4	of	O
5	the	O
6	anti	B
7	-	I
8	G	I
9	(	O
10	D2	O
11	)	O
12	monoclonal	O
13	antibody	O
14	3F8	O
15	and	O
16	granulocyte	B
17	-	I
18	macrophage	I
19	colony	I
20	-	I
21	stimulating	I
22	factor	I
23	for	O
24	neuroblastoma	O
25	.	O

1	A	O
2	log	O
3	-	O
4	linear	O
5	dose	O
6	-	O
7	response	O
8	was	O
9	obtained	O
10	for	O
11	the	O
12	average	O
13	increase	O
14	in	O
15	FEV1	O
16	up	O
17	to	O
18	6	O
19	h	O
20	(	O
21	AUC0	O
22	-	O
23	6	O
24	h	O
25	)	O
26	and	O
27	peak	O
28	FEV1	O
29	across	O
30	the	O
31	dose	O
32	range	O
33	administered	O
34	by	O
35	Respimat	O
36	.	O

1	Plasma	O
2	DHE	O
3	concentration	O
4	rose	O
5	promptly	O
6	above	O
7	5	O
8	ng	O
9	/	O
10	ml	O
11	after	O
12	the	O
13	application	O
14	of	O
15	the	O
16	PSA	O
17	tape	O
18	onto	O
19	the	O
20	damaged	O
21	skin	O
22	in	O
23	hairless	O
24	rat	O
25	.	O

1	A	O
2	complete	O
3	drug	O
4	history	O
5	was	O
6	compiled	O
7	,	O
8	specifying	O
9	the	O
10	amount	O
11	and	O
12	duration	O
13	of	O
14	VGB	O
15	medication	O
16	.	O

1	Epithelial	O
2	cytotoxicity	O
3	of	O
4	combined	O
5	antibiotics	O
6	was	O
7	additive	O
8	,	O
9	with	O
10	no	O
11	evidence	O
12	of	O
13	competition	O
14	or	O
15	synergism	O
16	.	O

1	In	O
2	Cd	O
3	-	O
4	spiked	O
5	OECD	O
6	soil	O
7	,	O
8	internal	O
9	Cd	O
10	levels	O
11	were	O
12	linearly	O
13	related	O
14	to	O
15	external	O
16	Cd	O
17	concentrations	O
18	,	O
19	whereas	O
20	the	O
21	springtails	O
22	maintained	O
23	fixed	O
24	internal	O
25	levels	O
26	of	O
27	Cu	O
28	and	O
29	Zn	O
30	regardless	O
31	of	O
32	spiked	O
33	concentrations	O
34	.	O

1	Interestingly	O
2	,	O
3	the	O
4	similarities	O
5	with	O
6	the	O
7	endophilin	O
8	proteins	O
9	cover	O
10	the	O
11	entire	O
12	sequence	O
13	of	O
14	the	O
15	SH3GLB	B
16	family	I
17	,	O
18	suggesting	O
19	a	O
20	common	O
21	fold	O
22	and	O
23	presumably	O
24	a	O
25	common	O
26	mode	O
27	of	O
28	action	O
29	.	O

1	Reovirus	O
2	mRNAs	O
3	are	O
4	efficiently	O
5	translated	O
6	within	O
7	host	O
8	cells	O
9	despite	O
10	the	O
11	absence	O
12	of	O
13	3	O
14	'	O
15	polyadenylated	O
16	tails	O
17	.	O

1	Grippers	O
2	with	O
3	integrated	O
4	piezoresistive	O
5	force	O
6	sensors	O
7	and	O
8	with	O
9	attached	O
10	strain	O
11	gauges	O
12	have	O
13	been	O
14	reported	O
15	.	O

1	Both	O
2	Z	O
3	and	O
4	R	O
5	expression	O
6	resulted	O
7	in	O
8	PML	O
9	dispersion	O
10	in	O
11	EBV	O
12	-	O
13	positive	O
14	cells	O
15	.	O

1	The	O
2	small	O
3	copepod	O
4	Pseudonychocamptus	O
5	proximus	O
6	progressively	O
7	replaced	O
8	the	O
9	large	O
10	Tisbe	O
11	furcata	O
12	in	O
13	sand	O
14	filters	O
15	during	O
16	the	O
17	fall	O
18	of	O
19	1995	O
20	and	O
21	was	O
22	responsible	O
23	for	O
24	the	O
25	large	O
26	increase	O
27	in	O
28	meiofaunal	O
29	biomass	O
30	observed	O
31	after	O
32	spring	O
33	1996	O
34	.	O

1	Evidence	O
2	-	O
3	based	O
4	care	O
5	:	O
6	a	O
7	new	O
8	formula	O
9	for	O
10	an	O
11	old	O
12	problem	O
13	?	O

1	Nrf2	O
2	regulates	O
3	expression	O
4	of	O
5	genes	O
6	encoding	O
7	enzymes	O
8	with	O
9	antioxidant	O
10	(	O
11	e	O
12	.	O
13	g	O
14	.	O
15	heme	O
16	oxygenase	O
17	-	O
18	1	O
19	(	O
20	HO	O
21	-	O
22	1	O
23	))	O
24	or	O
25	xenobiotic	O
26	detoxification	O
27	(	O
28	e	O
29	.	O
30	g	O
31	.	O

1	Workload	O
2	,	O
3	UAPs	O
4	,	O
5	and	O
6	you	O
7	.	O

1	RESULTS	O
2	:	O
3	At	O
4	latest	O
5	examination	O
6	,	O
7	mean	O
8	UPDRS	O
9	II	O
10	and	O
11	III	O
12	scores	O
13	had	O
14	improved	O
15	by	O
16	30	O
17	%	O
18	(	O
19	on	O
20	stimulation	O
21	,	O
22	off	O
23	therapy	O
24	)	O
25	with	O
26	mean	O
27	50	O
28	%	O
29	reduction	O
30	in	O
31	daily	O
32	off	O
33	time	O
34	.	O

1	Perfusion	O
2	technique	O
3	for	O
4	perfusion	O
5	-	O
6	assisted	O
7	direct	O
8	coronary	O
9	artery	O
10	bypass	O
11	(	O
12	PADCAB	O
13	).	O

1	Copyright	O
2	2001	O
3	Academic	O
4	Press	O
5	.	O

1	The	O
2	amount	O
3	of	O
4	drained	O
5	effusion	O
6	was	O
7	measured	O
8	,	O
9	and	O
10	fluid	O
11	was	O
12	sent	O
13	for	O
14	diagnostic	O
15	assessment	O
16	.	O